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Transmissible spongiform encephalopathies (TSEs) are a group of sub-acute
infectious neurodegenerative diseases that are characterized by the accumulation in
affected tissues of PrPSc, an abnormal isoform of the host prion protein (PrPc). After
peripheral exposure, TSE infectivity and PrPSc usually accumulate in lymphoid
tissues prior to neuroinvasion. Following either oral or intra-peritoneal inoculation
follicular dendritic cells (FDCs) are critical for the accumulation of TSE agents
within lymphoid tissues and their subsequent neuroinvasion. Studies in mice have
shown that exposure through scarified skin is an effective means of transmitting the
scrapie agent. Following inoculation via the skin a functional immune system is
critical for the transmission of the scrapie agent to the brain as severe combined
immunodeficiency (SCID) mice are refractory to infection. However, until now it
was not known what components of the immune system are important for scrapie
after transmission via the skin. Experiments in this thesis were designed to answer
the following questions: firstly does the scrapie agent accumulate within lymphoid
tissues after transmission via the skin; secondly what cells are critical for the
accumulation and replication of the scrapie agent within lymphoid tissues; and
finally how does the scrapie agent reach lymphoid tissues. To answer the first
question lymphoid tissues were collected at serial time points after inoculation with
the scrapie agent and infectivity titres measured by incubation period assays in
indicator mice. Experiments demonstrated that scrapie infectivity first accumulates
in the draining lymph node after inoculation via the skin and subsequently spreads to
other lymphoid tissues. To address the second aim of this thesis two separate
approaches were taken; firstly, a chimeric mouse model was used which had a
mismatch in PrP status between FDCs and other bone-marrow derived cells within
the lymphoid tissues. This experiment demonstrated that PrPc-expressing FDCs are
required for the accumulation of the scrapie agent within the spleen and that the PrP
status of bone-marrow derived cells has no effect on scrapie pathogenesis. Secondly,
mice were treated with a reagent to dedifferentiate FDCs either prior to or shortly
after challenge to determine the role of FDCs in scrapie neuroinvasion. Data
presented in this thesis shows that in the absence of FDCs prior to inoculation,
disease susceptibility is reduced. Finally it is not known how the scrapie agent is
transported from the site of exposure (e.g. the skin) to the draining lymphoid tissue.
Previous studies have suggested that dendritic cells are capable of acquiring and
transporting PrPSc from the gut lumen to the gut associated lymphoid tissues.
Langerhans cells (LCs) are a sub-population ofmigratory dendritic cells which reside
in the epidermis and migrate to the draining lymph node following antigen
encounter. Thus, LCs were considered a potential candidate for the transportation of
the scrapie agent from the skin to the draining lymphoid tissues. To investigate the
role of LCs in the active transportation of the scrapie agent from the skin, mouse
models were utilised in which active LC migration was blocked. Experiments
demonstrated that the early accumulation of the scrapie agent within the draining
lymph node and its subsequent neuroinvasion was not impaired in mice with blocked
LC migration, however these experiments did not address steady state LC migration,
thus a role for this can not be excluded. Although, in vitro studies in thesis have
suggested that LCs have the potential to acquire and degrade the scrapie agent,
suggesting that LCs might be involved in impeding the spread of the scrapie agent
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1.1 Transmissible spongiform encephalopathies
1.1.1 Historical Background
The transmissible spongiform encephalopathies (TSEs) or "prion diseases" are a
group of infectious, fatal neurodegenerative diseases, which affect both animals and
humans (Table 1.1). TSEs have previously been described as sub-acute spongiform
encephalopathies, slow virus diseases and transmissible dementias. The prototypic
TSE disease is scrapie, a naturally occurring disease of sheep and goats, which has
been recognized in Europe for over 300 years (McGowan, 1922). Other animal TSE
diseases include transmissible mink encephalopathy (TME) (Hartsough and Burger,
1965), chronic wasting diseases (CWD) of mule deer (Odocoileus hemionus
hemionus) and elk (Cervus elaphus nelsoni) (Williams and Young, 1980), and bovine
spongiform encephalopathy (BSE) (Wells et al., 1987). Following the discovery of
BSE in 1987, feline spongiform encephalopathy of domestic and exotic cats (Wyatt
et al., 1991) and spongiform encephalopathies of a number of exotic animals such as
kudu and oryx (Jeffrey and Wells, 1988; Kirkwood et al., 1990) were also identified.
These TSE diseases are considered to be derived from BSE and transmitted to these
species via contaminated feed (Jeffrey and Wells, 1988; Kirkwood et al., 1990;
Wyatt et al., 1991). Creutzfeldt Jakob diseases (CJD), Gerstmann-Strausler-
Scheinker syndrome (GSS), fatal familial insomnia (FFI) and kuru constitute the
major human TSE diseases. These human diseases can be further classified into
three etiological categories: sporadic, iatrogenic and familial (Table. 1.1.).
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Table 1.1- Transmissible spongiform encephalopathies of animals
and humans
TSE Species Comments Reference
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The BSE epidemic, which began in the United Kingdom (UK) in 1985 (Wells et al.,
1987), is believed to have arisen from the consumption by cattle of TSE-
contaminated protein supplements derived from the carcasses of ruminants
(Anderson et al., 1996). The original source of the BSE-agent or the conditions that
permitted its emergence in the UK remains unclear (Collee and Bradley, 1997a;
Collee and Bradley, 1997b). However, the subsequent appearance of vCJD in 1996
(Will et al., 1996) is considered to be caused by the same TSE strain that caused BSE
in cattle (Bruce et al., 1997; Hill et al., 1997), demonstrating that animal TSEs were
capable of crossing the species barrier to humans. To date (29th October 2004) there
have been 140 deaths from vCJD in the UK (figures from; http://www.cjd.ed.ac.uk/).
The epidemic of BSE and the subsequent emergence of vCJD has resulted in intense
scientific interest in TSE diseases with the aim of developing both diagnostic and
therapeutic strategies against these fatal neurological diseases.
1.1.2 The nature of the TSE agent
The precise nature of the TSE agent is still the subject of debate but currently there
are at least three main theories. One theory suggests that the infectious agent is a
small conventional virus, with genetic material encoding for its own survival and
replication. This hypothesis was proposed on the basis that TSEs are transmissible,
display strain specific pathogenesis and the reported presence of viral particles in
terminally scrapie-affected brain (Cho, 1976; Cho and Greig, 1975). However, this
hypothesis is refuted as experimental evidence demonstrated that the scrapie agent
was resistant to viral inactivation treatments such as ultraviolet light, ionizing
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radiation, dry heat and chemical treatments (Alper et al., 1966; Brown et ah, 1986;
Kimberlin et ah, 1983c; Somerville et ah, 2002; Taylor et ah, 1996b).
It was then suggested that it would be thermodynamically feasible for a protein to be
the sole component of the infectious agent (Griffith, 1967). Subsequent experiments
identified a protease-resistant sialoglycoprotein, which co-purified with infectivity
from TSE-affected brains (Bolton et ah, 1982; Prusiner, 1982). These data led to the
second theory proposed by Stanley Prusiner referred to as the "prion hypothesis"
(Prusiner, 1982). The prion hypothesis (derived from the first letters of
proteinaceous infectious particle) suggests that PrPSc, an abnormal, detergent-
insoluble, relatively proteinase-resistant isoform of a host glycoprotein PrP (Meyer
et ah, 1986) may constitute the major, or sole component of the infectious agent
(Prusiner, 1982), replicating in the absence of nucleic acid (Griffith, 1967; Prusiner,
1982). This hypothesis is further supported by recent experimental data, which
demonstrated that an abnormally folded fragment of recombinant mouse prion
protein causes neurological dysfunction when transmitted to mice, demonstrating for
the first time that prions might be infectious (Legname et ah, 2004). However, the
existence of many different TSE strains is not readily explained by the "prion
hypothesis", as it implies that the incoming PrPSc strain can convert host PrPc
regardless of its origin (Bruce, 1993; Bruce and Fraser, 1991). Furthermore, the
ability to separate PrPSc from TSE infectivity is also seen as an argument against the
"prion hypothesis" (Somerville and Dunn, 1996; Somerville et ah, 2002)
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The third theory to be proposed is termed the "virino hypothesis". This hypothesis
proposes that agent consists of infection specific informational components that
interact with host PrPc (Dickinson and Fraser, 1979; Dickinson and Outram, 1988)
and protects itself from degradation by converting PrPc to PrPSc (Farquhar et al.,
1998). Such an agent would have the genetic ability to confer different strain-
specific characteristics due to the presence of nucleic acid. However, as the agent
would not need to encode viral coat proteins the amount of nucleic acid present
would be very small and hence might explain why nucleic acid has not been detected
in TSE-affected tissues.
1.1.3 The cellular prion protein PrPc
The Prnp gene {PRNP in humans, Prnp in mice and PrP gene in other species)
comprises of a single gene in the genomes of rodents, man and ruminants (Oesch et
al., 1985; Westway and Prusiner, 1986). Prnp encodes a 33-35 kDa
P
sialoglycoprotein consisting of approximately 210 amino acid residues. The PrP
protein is highly conserved amongst mammals and expressed early during
P •
embryogenesis (Manson et al., 1992). The highest level of PrP expression is found
within the central (CNS) and peripheral (PNS) nervous systems (Oesch et al., 1985)
but it is also expressed to varying degrees in the tissues of the periphery (Caughey et
al., 1988; Dodelet and Cashmann, 1998; McBride et al., 1992). PrPc consists of
several distinct domains including a N-terminal signal peptide, a series of at least
four Cu2+ binding octapeptide repeats and a glycophosphatidylinositol (GPI) moiety
that attaches the protein to the plasma membrane (Fig. 1.1). PrPc contains two sites














Figure 1.1- A schematic representation of the normal host cellular protein PrPc. The
PrPc protein consists of a glycosyl-phosphatidyl-inositol (GPI) anchor which attaches
it to the cellular membrane of the cell, a series of copper binding octapeptide repeats
and two glycosylation sites at residues 181 and 197 (Oesch et al., 1985). Figure
originally created by Wilfred Goldmann (NPU, Edinburgh).
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these sites results in three cellular glycoforms; unglycosylated, monoglycosylated
and diglycosylated (Oesch et al., 1985). The function of PrP is unknown, as mice
deficient in the Prnp gene (Prnpmice) display no gross phenotypic changes
(Bueler et al., 1992; Manson et al., 1994a). However, there have been reports of
subtle abnormalities such as; disturbed circadian rhythms (Tobler et al., 1996) and
reduced T-lymphocyte responses (Cashman et al., 1990; Kubosaki et al., 2003;
Lewicki et al., 2003; Mabbott et al., 1997). Due to the high expression of PrPc in the
CNS, experimental research has focused on this tissue to try to determine the
function of PrPc. It has been suggested that a major function of PrPc might be to
promote neuronal survival by protecting against apoptosis, as Prnp'A cells are more
susceptible to apoptosis following serum deprivation (Bounhar et al., 2001; Kim et
al., 2004; Kuwahara et al., 1999; Roucou et al., 2004). Similarly, recent research has
shown that cross-linking of PrPc in vivo by treatment with PrP-specific monoclonal
antibodies triggers extensive apoptosis of neurons (Solforosi et al., 2004).
Alternatively, the ability of PrPc to bind copper (Cu) and block Cu toxicity to
neurons (Brown, 2004; Brown et al., 1997a; Brown et al., 1997b; Millhauser, 2004)
coupled with increase in oxidative stress markers in the brains of Prnp'A mice
(Milhavet et al., 2000; Wong et al., 2001), suggests that PrPc might also play a role
in protecting neurons against physiological stress. Taken together these data suggest
that PrP is most likely to have a neuroprotective function within the CNS.
1.1.4 PrP and its role in TSE pathogenesis
/ c
Prnp'' mice are refractory to TSE disease demonstrating that expression of host PrP
is critical for TSE disease (Bueler et al., 1993; Manson et al., 1994a). Furthermore,
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experiments where brain tissue from PrP-expressing wild-type mice was grafted into
the brains ofPrnp' ' mice have shown that TSE infection developed and spread only
within the PrP-expressing graft tissue (Brandner et al., 1996). The development of
TSE diseases is also affected by PrP gene dosage (Manson et al., 1994b). PrP
heterozygote mice (Prnp+/~) with only one functioning Prnp allele have a longer
disease incubation period than wild-type mice (Prnp+/+) with two functioning Prnp
alleles (Manson et al., 1994b). However, the pattern and level of deposition of PrPSc
is the same for both mouse models at the terminal stage of the disease, demonstrating
that the accumulation of PrPSe is not limited by the expression of PrPc by the host
(Manson et al., 1994b).
One factor that influences survival time in TSE-affected mice is the Sine (scrapie
incubation) gene (Dickinson et al., 1968). Sine has two alleles s7 and p7 that result
in short or prolonged disease incubation periods with the ME7 strain of mouse-
passaged scrapie, respectively (Dickinson and MacKay, 1961; Dickinson and
Meikle, 1971; Dickinson et al., 1968). Sine also has a major influence on the
incubation period of other TSE strains but the direction and magnitude of the effect
differs between strains (Bruce and Fraser, 1991). Subsequent research has shown that
Sine gene is congruent to the mouse Prnp gene and the dimorphisms at codon 108
and codons 189 are now referred to as Prnp" (Leu-108, Thr-189; Sincs7) and Prnpb
(Phe-108, Val-189; Sincp7) (Moore et al., 1998). However, a recent study of inbred
mouse lines has identified a third allele termed Prnpc (Phe-108, Thr-189) that has
been shown to influence the disease incubation period (Lloyd et al., 2004).
Classically, Sip the ovine homolog ofSinc/Prnp performs the same function in sheep
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and was originally described as having two alleles sA and pA (Dickinson and
Outram, 1988; Hunter et al., 1992). However, several polymorphisms within the
ovine PrP gene have been identified that are related to disease pathogenesis, notably
at codons 136, 154 and 171. These polymorphisms occur in different allelic
combinations which can confer either susceptibility or resistances to scrapie infection
dependent on the combination of alleles and the bred of sheep (Goldmann et al.,
1991; Goldmann et al., 1994; Hunter, 1998). Similarly, polymorphisms in the PRNP
gene in humans are linked to disease susceptibility (Prusiner, 1998). For example, a
change at codon 129 is linked to sCJD (Goldfarb et al., 1992), vCJD (Ironside, 2000)
and kuru (Lee et al., 2001) susceptibility. Similarly, mutation at codon 102 is linked
to susceptibility to GSS (Hsiao et al., 1989). However, factors other than
polymorphisms of the Prnp gene can influence TSE pathogenesis such as the route of
inoculation, the dose of the inoculum and the strain of the agent (Farquhar et al.,
1994).
One of the most significant scientific discoveries within TSE research was the
identification of the protein termed PrPSc. Initial ultra-structural studies of scrapie
infected brains demonstrated the presence of abnormal scrapie associated fibrils
(SAF) (Mertz et al., 1981). It was subsequent research by Prusiner et al that
demonstrated that SAF contains an abnormal protein, termed PrPSc, which also co-
purifies with scrapie infectivity (Prusiner, 1982). The prion hypothesis (section
1.1.2) proposed that PrPSc is the sole component of the infectious agent (Prusiner,
1982), replicating in the absence of nucleic acid (Griffith, 1967; Prusiner, 1982) by
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structurally converting the host cellular protein PrPc into the pathogenic isoform,
PrPSc (Prusiner, 1991).
To date approximately 20 phenotypically distinct scrapie strains have been identified
through serial passage in lines of inbred mice. The finding that there are many
distinct strains of scrapie is not readily explained by the prion hypothesis as it
implies that the incoming PrPSc strain can convert host PrPc regardless of its origin
into the same abnormal conformation (Bruce, 1993; Bruce and Fraser, 1991). It has
been proposed that differing TSE strains are due to differing conforms of PrPSc
(Prusiner, 1991), or to differences in PrPSc glycosylation patterns (Ermonval et ah,
2003). Although PrPSc was initially shown to co-purify with scrapie infectivity
(Bolton et al., 1982; Prusiner, 1982) experimental data has shown that in some
murine TSE models the level of PrPSc accumulation does not always correlate with
the level of scrapie infectivity in the affected tissue (Barron et al., 2001; Lasmezas et
al., 1997; Manson et al., 1999; Somerville and Dunn, 1996). However, the murine
ME7 scrapie model used in this study has been well characterized at the
Neuropathogenesis Unit (NPU), Edinburgh, and in this model there is distinct
correlation between the increasing presence of PrPSc in affected-tissues and the
presence of scrapie infectivity (Brown et al., 1999; Farquhar et al., 1994; Mabbott et
al., 2002; Mabbott et al., 2003). Thus, PrPSc is considered a good disease-specific
marker for scrapie infection in this study.
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1.1.5 Distinguishing between PrPc and PrPSc
PrPSc contains a proteinase resistant core with a molecular weight of 27-30 kDa and
is distinguishable from the normal host cellular protein PrPc by proteinase K (PK)
digestion. Immunoblots of uninfected and TSE affected tissues have shown that
T-j ^ ri r\
while PrP ~ a from an uninfected animal is fully hydrolysised by PK digestion,
prp33-35kDa g.Qm 7sp.affec^e(i tissues is only partially degraded, leaving the
proteinase resistant core protein prp20"30kDa (Oesch et al., 1985). TSE-affected tissues
can be identified by PK digestion and immunoblotting. Following immunoblotting a
typical three-banded pattern between molecular mass values of 20-30 kDa,
representing the unglycosylated, monoglycosylated and diglycosylated isomers of
PrP (in order of increasing molecular mass) is seen demonstrating the presence of
disease-specific PrPSc. PrPSc is also distinguishable from PrPc based on its
conformation. Infrared and circular dichroism experiments have shown that PrPc
consists of approximately 43% a-helix and 3% p-sheets, while PrPSc consists of
approximately 34% a-helix and 43% P-sheets (Pan et ah, 1993). At present there are
no commercially available antibodies which can specifically distinguish between
PrPc and PrPSc, although Paramithiotis and colleagues have recently described an
antibody which specifically recognises PrPSc (Paramithiotis et ah, 2003). The
absence of antibodies that can specifically distinguish between PrPc and PrPSc can be
problematic for experimental techniques that do not allow for PK digestion.
However, analysis of the level of deposition and localisation of PrPSc in TSE affected
tissues (Beekes and McBride, 1998; Bruce et ah, 1989) and use of serial tissue
sections for PK negative and PK positive experimental protocols (Schulz-Schaeffer
et ah, 2000) allows this difficulty to be circumvented.
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1.1.6 Scrapie
Scrapie is a naturally occurring TSE disease of sheep and goats, which has also been
referred to as la tremblante (French for trembling), traberkrankheit (German for
trotting disease), and rida (Icelandic for ataxia or tremor) (Detwiler et al., 2000).
Scrapie is present in the UK and in most sheep producing regions worldwide, with
the notable exceptions of Australia and New Zealand, which have not reported the
presence of scrapie.
Initially scrapie was believed to be an autosomally recessive genetic disease which
was not naturally infectious (McGowan, 1922). However, this hypothesis was
challenged when scrapie was accidentally transmitted to sheep via a vaccination for
louping ill disease derived from a suspension of brain and spleen homogenate, which
was unknowingly contaminated with scrapie (Gordon, 1946). In 1936, scrapie was
experimentally demonstrated to be transmissible by inoculation between sheep and
goats (Cuille and Chelle, 1936). Subsequently, research highlighted the similarities
between scrapie and other TSEs at the neuropathological, clinical and
epidemiological levels (Hadlow, 1959). From the early 1960s scrapie has been
experimentally transmitted to laboratory rodent models (Chandler, 1961; Chandler,
1963; Marsh and Hanson, 1971) and has been shown to be transmissible both
horizontally among flocks of sheep and vertically from ewe to lamb (Brotherston et
al., 1968; Foster et al., 1996; Haralambiev et al., 1973). The route of natural scrapie
transmission is unknown, but 2-5 years after the animal is infected clinical signs of
scrapie infection appear which include tremors of the head and neck, scratching,
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rubbing, lip smacking and gait abnormalities, with death being inevitable
(McGowan, 1922).
1.1.7 TSE strain identification and neuropathological characterisation in rodent
models
To date over 20 different scrapie strains have been identified through serial passage,
mainly in lines of inbred mice. Strains are identified according to the duration of
their highly reproducible incubation periods and their characteristic neuropathlogy.
When a serially-passaged scrapie strain is injected intra-cerebrally at a high dose into
a group of inbred mice, the mean disease incubation period is highly reproducible,
generally giving a standard error of less than 2% of the mean (Dickinson and
Meikle, 1971; Dickinson et al., 1968). In tissue sections from the brain of a scrapie-
affected animal tiny holes in the neuropil of both the grey and white matter, referred
to as vacuolation are present (Fig 1.2). Vacuolation differs in severity and
distribution according to the strain of scrapie agent; however, host genotype and
route of challenge can also affect the vacuolation pattern (Fraser, 1979; Fraser and
Dickinson, 1973). If strain of agent, host genotype and route of challenge are kept
constant then scrapie strains can also be identified based on their quantitative pattern
of vacuolar pathology (Fraser, 1979; Fraser and Dickinson, 1973). More recently, a
technique called glycoform analysis has been used to distinguish TSE strains
(Collinge et al., 1996; Parchi et al., 1995; Somerville, 1999; Somerville et al.,
1997b). This technique distinguishes TSE strains based on the intensity and
migration of their PrP glycoform banding pattern obtained by gel electrophoresis.
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Figure 1.2- Classical hallmarks of TSE disease within the brain are vacuolation of
the neuropil (a), deposition of the disease-specific protein PrP as determined by
immunolabelling with the PrP-specific monoclonal antiserum 6H4 (b; brown) and
glial cell activation as determined by immunolabelling with the monoclonal
antiserum GFAP (c; red). All sections were counterstained with haematoxylin to
distinguish cell nuclei. Original magnification X200
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There are four neuropathological hallmarks of TSE infection in rodent models (Fig.
1.2), although the severity of each varies according to the strain. These features
include glial cell activation resulting in an increase in the number and size of
astrocytes (Bruce et al., 1994; Deidrich et ah, 1991) and microglial cells (Williams et
ah, 1997), neuronal loss (Fraser, 2002), characteristic vacuolar pathology (Fraser,
1979; Fraser and Dickinson, 1973) and PrPSc deposition (Bendheim et ah, 1984;
DeArmond et ah, 1985). Glial cell activation can occur as a result of many
neurological diseases, however, the presence of vacuolation and PrPSc deposition are
key to the identification ofTSE infection (Fig 1.2).
1.2 Peripheral pathogenesis of TSEs
1.2.1 Routes of exposure
Natural TSEs are usually acquired by peripheral exposure. The possibility of oral
acquisition was first highlighted during a study of the Fore people of Papua New
Guinea (Gajdusek, 1985). In this study, the transmission of kuru was most likely
associated with the ritualistic practice of cannibalizing brains of deceased relatives
(Gajdusek, 1985). Data also suggests the consumption of BSE-contaminated feed by
cattle and the subsequent consumption of BSE-contaminated meat by humans is
responsible for the emergence of BSE (Wilesmith et ah, 1991) and vCJD
respectively (Bruce et ah, 1997; Hill et ah, 1997). The natural acquisition route of
scrapie is unknown, however it is likely to be acquired orally as PrPSc was first
detected in the Peyer's patches and GALT of naturally infected sheep (Andreoletti et
ah, 2000; Heggebo et ah, 2000).
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Although oral acquisition is considered the main route of natural exposure to TSE
agents, other routes of peripheral exposure have been identified. Sporadic CJD in
humans has been transmitted iatrogenically through transplantation of CJD
contaminated tissues or pituitary-derived hormones (Duffy et al., 1974). Concerns
therefore also exist that vCJD might be transmitted in a similar manner (Brown et al.,
1992; Hilton et al., 2004). The BSE agent has recently been shown to be
transmissible by blood transfusions in sheep (Houston et al., 2000; Hunter, 2003;
Hunter and Houston, 2002), as has the vCJD agent in humans (Llewelyn et al., 2004;
Pincock, 2004). Studies in mice have shown that transmission via the skin is also an
effective means of establishing TSE infection (Taylor et al., 1996a), suggesting that
skin lesions might be a route of natural exposure.
1.2.2 The lymphoreticular system in TSE pathogenesis
Following peripheral exposure, infectivity and PrPSc usually accumulate within the
lymphoreticular system (LRS) prior to neuroinvasion (Eklund et al., 1967). The role
of the LRS was first demonstrated after subcutaneous (s.c.) inoculation ofmice with
the Chandler scrapie strain (Eklund et al., 1967). Assays of various tissues at
sequential time points post-inoculation demonstrated that scrapie infectivity was
detectable within the spleen and peripheral lymph nodes at 4 weeks post-inoculation,
where it accumulated to high levels prior to detection within the CNS (Eklund et al.,
1967).
The role of the spleen in peripheral scrapie pathogenesis was further demonstrated by
studies which showed that genetic asplenia or splenectomy either prior to or shortly
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after peripheral exposure to the scrapie agent significantly extended the survival time
of experimentally inoculated rodents (Clarke and Haig, 1971; Fraser and Dickinson,
1970; Fraser and Dickinson, 1978). However, the presence of the spleen is not
obligatory in the establishment of scrapie infection following peripheral exposure as
splenectomy does not affect disease susceptibility, suggesting that other tissues are
able to sustain replication in its absence. Furthermore, splenectomy of mice before
s.c inoculation with the scrapie agent has no affect on the disease incubation period,
suggesting that the role of the spleen in scrapie pathogenesis is dependent on the
route of exposure (Fraser et al., 1992; Kimberlin and Walker, 1989a).
The use of severe combined immunodeficiency (SCID) mice, which lack mature B
and T-lymphocytes (Bosma et ah, 1983 288), has further demonstrated the
importance of the LRS in scrapie pathogenesis. SCID mice are resistant to scrapie
infection following peripheral exposure to moderate or low doses of scrapie
inoculum (Fraser et ah, 1996; O'Rourke et ah, 1994). Grafting of SCID mice with
bone-marrow from immunocompetent donors restores susceptibility to scrapie
infection and replication within the spleen (Fraser et ah, 1996; Lasmezas et ah, 1996;
O'Rourke et ah, 1994). Furthermore, pre-treatment of mice with pharmacological
agents which either stimulate or depress the immune system prior to inoculation with
the scrapie agent, results in either a shortening or lengthening of the disease
incubation period, respectively (Dickinson et ah, 1978; Farquhar and Dickinson,
1986; Mabbott et ah, 2001; Outram et ah, 1974; Sethi et ah, 2002).
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The involvement of the LRS in TSE pathogenesis was believed to be dependent on
host-strain interactions as BSE in cattle (Somerville et al., 1997a) and sporadic CJD
in humans (Hill et ah, 1999) appear to be confined to the nervous tissues. However,
recent research has demonstrated the presence of PrPSc in the spleens of some Swiss
sporadic CJD patients at the terminal stage of the disease, although its relevance to
disease pathogenesis is not known (Glatzel et ah, 2003). At present the targeting of
the LRS prior to neuroinvasion has been demonstrated in vCJD patients (Hilton et
ah, 1998), CWD in deer and elk (Sigurdson et ah, 1999), sheep with natural scrapie
(van Keulen et ah, 1996) and rodents experimentally inoculated with scrapie
(McBride et ah, 1992).
Extensive studies have been conducted to determine the contribution of different cell
types within the LRS to peripheral scrapie pathogenesis (Mabbott and Bruce, 2001;
Mabbott et ah, 1998). The role of some of these cell types is reviewed below.
1.2.3 T-lymphocytes
T-lymphocytes are unlikely to be involved in peripheral scrapie pathogenesis as
depletion of this cell population either by thymectomy or sub-lethal whole body y-
irradiation has no affect on the disease incubation period following peripheral
inoculation (Fraser and Dickinson, 1978; Fraser and Farquhar, 1987). Similarly
studies using transgeneic or immunodeficient mice which lack functional T-
lymphocytes (CD47", CD87", TCRa7", perforin7", SCID, Rag-l'' or Rag-2'''
mice) have shown that deficiencies in T-lymphocytes alone have no affect on the
accumulation of infectivity within the LRS or its subsequent neuroinvasion(Fraser et
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al., 1996; Klein et al., 1997; Klein et al., 1998). In addition, the expression of PrPc
only on T-lymphocytes is insufficient to sustain the replication of the scrapie agent in
the LRS (Raeber et al., 1999a), suggesting that PrP expression is not the only
requirement for sustaining agent replication. Recent research has shown that a
combined deficiency of CD4+ and CD8+ cell populations prior to either i.e. or i.p.
inoculation with scrapie strain RML results in a significantly longer disease
incubation period (Lewicki et al., 2003). As the effects are observed after both i.e.
and i.p. inoculation this suggests that disease pathogenesis in the CNS, not the LRS
is affected in the absence of both CD4 and CD8 cell populations (Lewicki et al.,
2003). Furthermore, as no affect on disease susceptibility was observed in the study
this suggests that any role T-lymphocytes might play in scrapie pathogenesis in this
model is unlikely to be significant due to full susceptibility of the above model to
scrapie infection (Lewicki et al., 2003).
1.2.4 Natural killer cells
The role of natural killer (NK) cells in peripheral scrapie pathogenesis has not been
directly addressed. However, studies investigating the role of B and T-lymphocytes
have indirectly suggested that NK cells are unlikely to play a key role in scrapie
pathogenesis within the LRS (Klein et al., 1997). The role of NK cells in innate
immunity is to directly lyse virus-infected cells and tumour cells and to secrete
various cytokines such as interferon-y to initiate an immune response (Roitt, 1994).
Studies have shown that the absence of NK effector molecules such as perforin
(perforin"7" mice) involved in cell lysis and interferon receptors (Arg'A mice) have no
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effect on scrapie pathogenesis (Klein et al., 1997) suggesting NK cells are not
involved in the lysis of scrapie infected cells.
1.2.5 B-lymphocytes
Following peripheral inoculation of SCID (Bosma et al., 1983), Rag-1'A (Mombaerts
et al., 1992), Rag-2~'~ (Shinkai et al., 1992) Arg '~ (Huang, 1993), and pMT (Kitamura
et al., 1991) mice which all lack mature B and T-lymphocytes, accumulation of
infectivity in the spleen is blocked and subsequent neuroinvasion impaired (Brown et
al., 1997c; Fraser et al., 1996; Klein et al., 1997; O'Rourke et al., 1994). As the role
of T-lymphocytes had been previously determined (section 1.2.3) these data led to
the suggestion by Klein et al that B-lymphocytes might play a key role in scrapie
pathogenesis (Klein et al., 1997), as deficiencies in these lymphocytes impaired
scrapie neuroinvasion. However, research, which reconstituted immunodeficient
mice with foetal liver cells from either PrP_/" deficient or PrP+/+ expressing mice
(Brown et al., 1999; Klein et al., 1998), demonstrated, that susceptibility to scrapie
infection was restored in the presence of PrP-deficient B-lymphocytes so long as
PrPc was expressed by stromal derived cells (Brown et al., 1999; Klein et al., 1998).
These data suggest that a cell population whose maturation depends on B-
lymphocytes is critical to scrapie pathogenesis following peripheral exposure.
B-lymphocytes produce important cytokine signals that mature and maintain
follicular dendritic cells (FDCs) within the germinal centres (Chaplin and Fu, 1998;
Kosco-Vilbois et al., 1997). Therefore mice deficient in mature B-lymphocytes are
also indirectly deficient in mature FDCs. Subsequent studies were therefore required
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to determine whether B-lymphocytes or FDCs were the key cell type involved in
sustaining the replication of the scrapie agent within the LRS.
1.2.6 Follicular dendritic cells (FDCs)
FDCs are considered to be derived from undifferentiated stromal precursor cells
within lymphoid tissues (Tew et ah, 1999). They are restricted to the light zones of
the germinal centres within lymphoid follicles where they function to trap and retain
antigen on their surface in the form of immune complexes for long term presentation
to B-lymphocytes (Tew et ah, 1997). B-lymphocytes compete for and bind antigens
on FDCs and emerge as either antibody forming cells, producing high affinity
antibodies or as memory B-cells with high affinity receptors (Tew et ah, 1997).
A number of biological properties of FDCs correspond with the experimental
evidence indicating that this cell type is likely to be involved in peripheral scrapie
pathogenesis. Studies by Clarke & Kimberlin have shown that the level of scrapie
infectivity present in the stromal compartments of the LRS, in which FDCs are
located, was on average ten times higher than that in the white pulp where B-
lymphocytes are located (Clarke and Kimberlin, 1984). Sub-lethal whole body y-
irradiation depletes actively dividing lymphocytes and monocytes (Fulop and
Phillips, 1986; Phillips and Fulop, 1989). When this treatment was administered to
mice, prior to or shortly after peripheral inoculation, no affect on scrapie
pathogenesis was detected (Fraser and Farquhar, 1987). This suggests the cell type
involved in scrapie pathogenesis within the lymphoid tissues is a radioresistant,
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mitotically inactive cell, of stromal origin, criteria that FDCs fulfil (Tew et al., 1999;
Tew et al., 1990; Tew et al., 1997).
Subsequent studies have demonstrated that within weeks of peripheral infection with
the scrapie agent, disease-specific PrP immunolabelling is detectable on the surface
and within the extracellular spaces of FDC processes (Jeffrey et al., 2000b; Mabbott
et al., 2002). PrPSc has also been detected in association with FDCs in the LRS; of
mice infected with scrapie (Mabbott et al., 2000b) or CJD (Kitamoto et al., 1991),
sheep with natural scrapie (van Keulen et al., 1996), mule deer fawns with CWD
(Sigurdson et al., 1999) and patients with vCJD (Hill et al., 1999).
Immunohistochemical labelling has suggested that FDCs in uninfected mice express
high levels of PrPc (Brown et al., 1999; McBride et al., 1992). The expression of
p ..
PrP by FDCs has been shown to be critical for the accumulation of the scrapie agent
within the LRS (Brown et al., 1999; Klein et al., 1998; Raeber et al., 1999b). In the
study by Brown and colleagues two mouse lines were produced by crossing the scid
mutation into either PrP deficient mice (Prnp") or PrP expressing wild-type mice
(Prnp+/+) (Brown et al., 1999). These SCID mice were then reconstituted with either
bone-marrow from Prnp+/+ expressing or PrnpA deficient mice. As a consequence,
the lymphocytes with a PrP status of the graft origin would induce the maturation of
FDC precursor cells with a PrP status of recipient origin. Using these chimeric
models immunolabelling for PrP in the spleen could only been detected on FDCs
when the FDCs themselves were carrying a Prnp+/+ gene and was independent of the
PrP status of the surrounding lymphocyte populations. This study demonstrated that
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FDCs express PrP and do not acquire it from neighbouring lymphocytes (Brown et
al., 1999). Furthermore, when these models were peripherally inoculated with the
ME7 scrapie strain, infectivity was only detected within spleens which contained
PrPc-expressing FDCs (Brown et al., 1999). None was detectable within the spleens
of animals which expressed PrPc only on lymphocyte populations, demonstrating
c • •that PrP -expressing FDCs are critical for substaining scrapie infection within the
LRS (Brown et al., 1999). However, current evidence suggests that different TSE
strains might differ in their targeting of different cell populations within the immune
system. For example, efficient replication of the RML scrapie isolate, unlike ME7
scrapie strain might require both PrPc-expressing FDCs and lymphocytes (Kaeser et
al., 2001; Klein et al., 1998).
However, research has demonstrated that the expression of PrP is not the only
cellular requirement for TSE infection (Lotscher et al., 2003; Montrasio et al., 2001;
Raeber et al., 1999a). Studies using transgenic Prnp'A mice over-expressing PrPc on
either B or T-lymphocytes alone (Montrasio et al., 2001; Raeber et al., 1999a) have
shown that PrPSc does not accumulate within the LRS following peripheral
inoculation. Furthermore, high levels of PrPc are expressed by the capsule and
trabeculae of the spleen (Lotscher et al., 2003) in both wild-type and
immunodeficient Rag-V'' mice (Mombaerts et al., 1992). As Rag-1~'~ mice are
refractory to scrapie infection (Klein et al., 1997) expression of PrPc by the capsule
and trabeculae clearly are not critical for scrapie pathogenesis (Lotscher et al., 2003).
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cAs PrP expression is unlikely to be the only cellular requirement for sustaining the
replication of the scrapie agent, further studies were conducted to identify other
biological properties of FDCs which makes them suitable cellular targets for scrapie
infection (Klein et ah, 2001; Lotscher et ah, 2003; Mabbott et ah, 2001). The
function of FDCs is to trap and retain antigens in the form of immune complexes
(Nossal et ah, 1968a; Nossal et ah, 1968b). Deficiencies in either circulating
antibodies or Fc-receptors (FcyR, FcyRII or FcyRIII) have no effect on TSE
pathogenesis (Klein et ah, 2001). However, studies have suggested that complement
components and cellular complement receptors may play a role in the localization
and retention of PrPSc to FDCs (Klein et ah, 2001; Mabbott et ah, 2001). Genetic
deficiency in C3 (Klein et ah, 2001) or temporary depletion of C3 (Mabbott et ah,
2001) impairs PrPSc accumulation in the spleen and significantly prolongs the
incubation period after peripheral challenge with the scrapie agent. Furthermore,
mice lacking the complement components C3, C2 or factor B (Taylor, 1998) have
significantly prolonged incubation periods following peripheral exposure to the
scrapie agent (Klein et ah, 2001; Mabbott et ah, 2001). However, a greater extension
of the disease incubation period was observed in mice deficient in Clq (Clqa'\
(Botto, 1998)) suggesting a possible role for Clq alone (Klein et ah, 2001; Mabbott
et ah, 2001). In addition, recent research has suggested that Clq may induce the up-
regulation of PrPc by FDCs, which might enhance susceptibility to scrapie infection
(Lotscher et ah, 2003).
The contribution of FDCs to scrapie accumulation within the LRS and its subsequent
neuroinvasion was further investigated by altering the immunological relationship
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that exists between FDCs and B-lymphocytes. Two key cytokines produced by B-
lymphocytes, which maintain FDCs in their dedifferentiated state are tumour
necrosis factor a (TNF-a), which signals through TNF-receptor l/p55 (TNF-R1)
(Tkachuk et al., 1998), and membrane bound lymphotoxin (LTa/p), whose signal is
mediated through the LTp receptor (LTpR) (Endres et ah, 1999). Each of these
receptors is expressed on the surface of FDCs and/or their precursors (Tew et ah,
1997). In contrast a deficiency in interleukin-6 (IL-6"7"), a soluble cytokine produced
by FDCs which signals the maturation and differentiation of B-lymphocytes in
germinal centres, impairs B lymphocyte development and thus impairs germinal
centre formation, however, FDC networks are maintained.
Research has demonstrated that deficiencies in germinal centres alone does not affect
peripheral scrapie pathogenesis, as peripherally challenged IL-6'7" mice accumulate
infectivity and PrPSc within their spleens to the same extent as wild-type mice, and
no differences in incubation periods were observed (Mabbott et ah, 2000b). In
contrast mice deficient in either TNFa (Pasparakis et ah, 1996) or TNF-R1
(Matsumoto et ah, 1996b) lack mature FDCs within lymphoid tissues, although the
presence and function of lymphocytes are maintained. Studies have shown that
TNFa"7" knockout mice are less susceptible to peripheral challenge with the ME7
scrapie strain than wild-type mice and fail to accumulate infectivity or PrPSc in their
spleens (Mabbott et ah, 2002; Mabbott et ah, 2000b). Similarly previous research
has shown that LTa"7", LT(3"7" and LTf3R " mice, which all lack mature FDC networks
(Futterer et ah, 1998; Koni et ah, 1997; Matsumoto et ah, 1996a), fail to accumulate
scrapie in the LRS and are less susceptible to peripheral inoculation with the RML
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scrapie isolate (Prinz et al., 2002). Similarly the, temporary dedifferentiation of
FDCs by treatment with the LT(3R immunoglobulin-fusion protein (LT|3R-Ig; (Force
et al., 1995), which blocks the LT(3R-signaling pathway (Mackay and Browning,
1998), inhibits the early accumulation of PrPSc and scrapie infectivity in the LRS and
reduces disease susceptibility (Mabbott et al., 2000a; Mabbott et al., 2003; Montrasio
et al., 2000). Taken together the above studies demonstrated that mature FDCs are
critical for scrapie pathogenesis following peripheral exposure.
However, studies have demonstrated that neuroinvasion of the scrapie agent can
occur in the absence of FDCs. Studies using the RML scrapie isolate have shown
that TNFR-1" ", TNFR-2" " and TNF-amice are as susceptible as wild-type mice to
scrapie infection (Klein et al., 1997; Prinz et al., 2002). These data suggest that in
some circumstances neuroinvasion of the RML scrapie isolate might occur via a
FDC-independent route. However, in some studies large doses of inoculum were
used which might directly infect peripherally nerves and thus, bypass replication
within the LRS (Fraser et al., 1996; Klein et al., 1998; Mabbott et al., 2000b;
Oldstone et al., 2002). In addition TNFR and TNF-a play a key role in mediating
macrophage function (Ma, 2001) therefore, it is likely that in their absence
macrophages will be impaired in the clearance of the agent. Further studies are
required to determine whether different scrapie strains utilise different cell
population for accumulation and replication within the LRS.
35
1.2.7 Macrophages
Both in vitro and in vivo studies have demonstrated that macrophages are capable of
sequestering and degrading scrapie infectivity (Beringue et al., 2000b; Carp and
Callahan, 1981; Carp and Callahan, 1982). Depletion of this cell population, prior to
or shortly after, peripheral inoculation results in increased accumulation of infectivity
and PrPSc in the spleen and shortens the disease incubation period (Beringue et al.,
2000b). Furthermore, during scrapie infection intra-lysosomal PrPSc accumulations
have been detected within tingible body macrophages in the spleens of rodents
experimentally infected with scrapie (Jeffrey et al., 2000b), naturally scrapie infected
sheep (Hermann et al., 2003; Jeffrey et al., 2000a) and naturally CWD infected deer
(Sigurdson et al., 2002). Thus, tingible body macrophages might acquire PrPSc by
either phagocytosis of FDC processes or from within the extracellular spaces
between FDC processes (Hermann et al., 2003; Jeffrey et al., 2000a; Sigurdson et al.,
2002). Recent research by Prinz et al has suggested that in some circumstances, such
as in TNFa"" deficient mice, macrophages might also be involved in replication of
the scrapie agent within the LRS following exposure to a large dose of scrapie
inoculum (Prinz et al., 2002).
1.2.8 The immune response to TSE infection
Despite the accumulation of high titres of TSE infectivity within the LRS of infected
animals, TSE infection does not appear to induce an immune response in the host.
For example, no TSE-specific detectable humoral immune response has been
observed (Chandler, 1959; Clarke and Haig, 1966; Marsh et al., 1970; Pattison et al.,
1964; Porter et al., 1973). Furthermore, deficiencies in either circulating antibodies
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or Fc-receptors (FcyR, FcyRII or FcyRIII) have no effect on TSE pathogenesis (Klein
et al., 2001). Similarly, there is no induction of cell-mediated immunity during
scrapie infection (Kingsbury et al., 1981). In support of these data, studies using
transgenic or immunodeficient mice, which lack functional T-lymphocytes (CD4"~,
CD8"7", P2-p_/\ TCRa"7" or perforin"7"mice) (Klein et al., 1997; Klein et al., 1998) have
shown that the absence of functional T-lymphocytes has no effect on disease
pathogenesis. The lack of a immune response to the TSE agent is not due to
immunosuppression, as studies have demonstrated that TSE-affected animals are
immunologically responsive to other antigens following exposure to the TSE agent
(Clarke, 1968; Gardiner and Marucci, 1969; Garfin et al., 1978).
Although there is no classical immune response to TSE infection, studies of naturally
and experimentally scrapie-affected sheep have demonstrated elevated levels of
immunoglobulin production during the clinical phase of the disease (Collis and
Kimberlin, 1983; Collis et al., 1979). Furthermore, increases in serum amyloid P
component in scrapie-affected mice (Coe et al., 2000), and tumour necrosis factor-a,
interleukin-1P, and interleukin-6 in scrapie-affected cell lines (Bacot et al., 2003)
have been detected. Recent research has also shown that murine scrapie infection is
associated with the hypertrophy of FDC networks and increased numbers ofmature
B-lymphocytes within secondary lymphoid follicles (McGovern et al., 2004),
however the ability of FDCs to trap antigen is unaltered (McBride et al., 1992).
Taken together these data suggest that any alterations in the host's immune response
may be related to TSE-induced immune dysfunction rather than a direct immune
response to the TSE agent.
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1.2.9 Chemotherapy for TSE diseases
As the conversion of PrPc to PrPSc is believed by many to be the cause of TSE
infection this interaction has been targeted in the development of therapeutic
interventions (Aguzzi et al., 2001; Head et ah, 2001; Koster et ah, 2003). Many of
the therapeutic interventions used are sulphated polyanions (Koster et al., 2003).
PrPSt amyloid is known to contain sulphated glycosaminoglycans, it is therefore
suggested that this group of drugs might competitively block the interaction between
PrP and endogenous glycosaminoglycans (Caughey and Raymond, 1993). For
example, Congo red (CR) is a sulfonated azo dye commonly used in histopathology
to stain amyloid fibrils has been shown to inhibit the accumulation of PrPSc and
infectivity in scrapie-affected mouse neuroblastoma cells (Caughey et al., 1993;
Caughey and Race, 1992). In addition, administration of CR to scrapie-affected
hamsters at the time of inoculation can prolong the incubation period (Ingrosso et al.,
1995). However, the use of CR therapeutically is limited by its low blood-brain
barrier permeability and carcinogenicity (Rudyk et al., 2000). Furthermore, recent
research has now shown that CR renders PrPSc resistant to clearance by phagocytic
cells in vivo, but has no affect on the disease incubation period in mouse models
(Beringue et al., 2000a). A recent study using curcumin a non-toxic, natural
compound which is structurally related to CR has found that although it is capable of
inhibiting PrPSc accumulation in vitro it had no effect when given orally to scrapie-
affected hamsters (Caughey et al., 2003). Thus, the problems associated with CR
therapy are unlikely to be overcome in the immediate future.
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Other drug treatments which have been shown to bind amyloid or deregulate PrPc to
PrPSt conversion either in vivo or in vitro include: anthracycline 4-iodo-4-deoxy-
doxorubicin (IDX) (Tagliavini et ah, 1997), tetrapyrroles (Brown, 1984; Caughey et
al., 1998), amphotericin B (Adjou et al., 1996; Pocchiari et al., 1987), suramin (Gilch
et ah, 2001; Ladogana et ah, 1992), tetracycline (Tagliavini et ah, 2000) and P-sheet
breaker peptides (Soto, 1999; Soto et ah, 2000).
The anti-malarial drug quinacrine and the antipsychotic drug chlorpromazine both
inhibit PrPSc formation and can cross the blood-brain barrier (Korth et ah, 2001).
Studies of scrapie and CJD affected rodent models have shown that a quinacrine
derivative, termed quinoline, can prolong survival time (Murakami et ah, 2004).
However, other groups have reported no effect on survival time following quinacrine
administration to murine CJD models (Collins et ah, 2002). As these drugs have
been previously approved for use in humans it has been possible to test their clinical
application on vCJD patients. Administration of quinacrine to vCJD patients daily
for 3 months resulted in a clinical improvement in patient responsiveness (Nakajima
et ah, 2004). A larger study, termed the Prion-1 trial, is presently underway in the
UK to further investigate the use of quinacrine in human TSE diseases
(http://www.ctu.mrc.ac.uk/studies/cjd.asp). Similarly, pentosan polysulphate (PS), a
heparin analogue with anti-inflammatory and anti-thrombotic properties (MacGregor
et ah, 1984), has been shown to reduce disease susceptibility and extend survival
time in rodent models over a range of times both pre- and post-inoculation (Doh-ura
et ah, 2004; Farquhar et ah, 1999). PS has already been used in both clinical and
veterinary medicine. Its use was approved by the High Court (UK) for treatment of
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vCJD patients (Dyer, 2003; Mayor, 2003). Treatment with PS appeared to stabilise
both patients (Dyer, 2003; Mayor, 2003). Although, a large number ofpotential drug
candidates have been tested, currently no effective therapy exists to treat TSE
diseases in animals or humans.
1.2.10 Immunisation strategies for TSE diseases
The possibility of anti-TSE immunisation strategies was first highlighted by studies
which demonstrated that in vitro pre-incubation of anti-PrP antibodies with scrapie-
affected hamster brain homogenate reduced the scrapie titre (Gabizon et al., 1988).
The inhibitory effects of anti-PrP antibodies are considered to be due to the binding
of the antibodies to either PrPc or PrPSc molecules, blocking or modifying the
conversion of PrPc to PrPSc (Heppner et ah, 2001b; Peretz et ah, 2001; Sigurdsson et
ah, 2003; White et ah, 2003). Anti-PrP antibodies might also block PrPSc replication
by either accelerating PrPc degradation (Perrier et ah, 2004) or by altering PrPc
biogenesis (Gilch et ah, 2003).
To determine whether PrP-specific antibodies were effective in vivo, Heppner et al
generated mice which expressed an anti-prion protein antibody p chain in Prnp~/+
mice. These mice did not succumb to scrapie infection following peripheral
inoculation, suggesting that the PrP-specific immunity was responsible for their
protection (Heppner et ah, 2001b). Others have shown that administration of anti-
PrP antibodies to scrapie-affected mice can reduce levels of PrPSc and scrapie
infectivity within the periphery and prolong survival time (Sigurdsson et ah, 2003;
White et ah, 2003). Immunisation of scrapie-affected rodents with anti-PrP
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antibodies either conjugated to keyhole limpet hemocyanin (Schwarz et ah, 2003) or
emulsified in complete Freund's adjuvant (Tal et ah, 2003), both known stimuli of
the immune system, have also been shown to prolong survival time. At present no
immunisation strategies have been approved for use in TSE-affected animals or
humans.
1.3 Transportation of TSE Agents
1.3.1 How are TSEs agents transported to the LRS?
Although extensive research has been conducted to define the role of the LRS in TSE
pathogenesis following peripheral exposure, little is known of how TSE agents are
transported from the site of challenge to the LRS. As FDCs are non-mobile cells
situated in secondary lymphoid tissues often distant from the site of initial exposure,
the TSE agent would need to be transported to FDCs either via the lymphatics to the
draining lymph nodes or via the bloodstream to the spleen. A number of possible
cellular candidates exist for the transportation of the TSE agent from the site of
challenge to the LRS, some ofwhich are discussed below.
1.3.2 M-cells
After oral TSE exposure immunolabelling for PrP is detected in the follicle
associated epithelium (FAE) (Beekes and McBride, 2000; Heggebo et al., 2002),
suggesting that the uptake of the TSE agent from the gut lumen occurs via the FAE.
Membranous cells (M-cells) situated in the FAE acquire luminal material and
transport it directly to the subepithelial lymphoid tissues (Neutra et al., 2001). It has
been demonstrated that M-cells are able to perform transepithelial transport of
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infectivity in vitro (Heppner et al., 2001a). Taken together these data suggest that M-
cells might be an important transport mechanism for TSE agents following oral
exposure.
1.3.3 Dendritic cells
Dendritic cells (DCs) are bone-marrow derived migratory cells which reside in
peripheral tissues and the T-lymphocyte areas of lymphoid organs (Banchereau et al.,
2000; Steinman et al., 1974). The main function ofDCs is to acquire antigen with in
the periphery and then transport it to the draining lymphoid tissues to be presented in
a MHC class restricted manner primarily to T-lymphocytes (Banchereau et al., 2000;
Banchereau and Steinman, 1998; Steinman et al., 1974). Studies have shown that the
prion protein fragment PrPio6-i26 is a chemoattractant for immature monocyte-derived
DC (Kaneider et al., 2003), suggesting that DC might traffic to TSE affected tissues.
Furthermore, studies by Huang et al demonstrated that DC can acquire PrPSc in vitro
and transport intestinally administered PrPSc directly to lymphoid tissues in vivo
(Huang et al., 2002). Thus, it is highly likely that following oral exposure DCs
would be involved in the transportation of the TSE agent from the gut lumen to the
gut-associated lymphoid tissues. DCs might also be likely candidates for the
transportation of the TSE agent to lymphoid tissues following inoculation via other
routes of peripheral exposure.
1.3.4 Macrophages
Macrophages are mobile phagocytic cells present within the majority of tissues and
the blood (Roitt, 1994). Their natural function is to clear apoptotic cells and
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pathogens and subsequently present antigens in a MHC class restricted manner
(Roitt, 1994). However, as studies suggest that macrophages are involved in the
degradation of scrapie (Beringue et al., 2000b; Carp and Callahan, 1981; Carp and
Callahan, 1982) it is unlikely this cell type is critical to the transportation of the TSE
agent.
1.3.5 Lymphocytes
T-lymphocyte are unlikely candidates for transportation of TSE agents from the
periphery to the LRS deficiencies in T-lymphocytes alone (CD4"/_, CD8 ", /?2/fA ,
TCRoC or perforinmice) has no effect on disease susceptibility or the
accumulation of infectivity within lymphoid tissues (Klein et al., 1997; Klein et al.,
1998). Taken together these data suggest that it is unlikely that T-lymphocytes are
involved in transportations of the agent.
The presence of B-lymphocytes is required for peripheral scrapie infection, as mice
deficient in B-lymphocytes alone (pMT mice; (Klein et al., 1997) or jointly deficient
in both mature B and T-lymphocytes (SCID, Rag-1''', Rag-2~'~ and Arg" mice) have
impaired accumulation of scrapie infectivity within the spleen as well as impaired
neuroinvasion (Brown et al., 1997c; Fraser et al., 1996; Klein et al., 1997; O'Rourke
et al., 1994). Although the role of B-lymphocytes in TSE pathogenesis is likely to be
due to their immunological relationship with FDCs (Chaplin and Fu, 1998; Kosco-
Vilbois et al., 1997) the possibility that B-lymphocytes might be involved in the
transport of TSE infectivity can not be excluded. However, no infectivity has been
detected on circulating blood lymphocytes in rodent models when high levels of
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infectivity are detected within lymphoid tissues (Raeber et ah, 1999b), suggesting
that B-lymphocytes are unlikely to be involved in the peripheral transport of the TSE
agent.
1.3.6 Peripheral nerves
The initial sites in which TSE agents might enter the host (gastro-intestinal tract and
the skin) (Beekes and McBride, 2000; Kimberlin and Walker, 1989a; Taylor et ah,
1996a) are highly innervated tissues and therefore TSE agents might be transported
directly to the CNS via peripheral nerves. Studies using transgenic mice that express
PrPc only on nervous tissue and not within their lymphoid organs have demonstrated
that after oral exposure scrapie infectivity successfully reaches the CNS and induces
disease (Race et al., 1995). Indeed, the relatively neurotropic TSE strain 263K is
considered to directly infect nerves at the site of inoculation (Beekes and McBride,
2000; Beekes et ah, 1998; McBride and Beekes, 1999; McBride et al., 2001).
Furthermore, peripheral exposure to a high dose of TSE inoculum can establish TSE
infection in the CNS without the requirement for replication of the agent within the
LRS (Klein et al., 1997; Klein et al., 1998; Prinz et al., 2002). However, the
relevance of high dose inoculum to natural TSE pathogenesis is not known. Studies
have also shown that highly immunodeficient SCID mice are refractory to scrapie
infection following exposure to moderate/low doses of inoculum (Fraser et al., 1996;
ORourke et al., 1994). Thus, the role of the peripheral nerves in transport of the
TSE agent may be dependent on the dose of inoculum, the strain of agent and route
of exposure used.
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1.3.7 TSE agent transport from the LRS to the CNS
Following accumulation and replication within the LRS it is not known how TSE
agents are transported from FDCs to the PNS/CNS. The role of peripheral nerves in
the transportation of the agent was first demonstrated by studies where injection of
scrapie directly into the sciatic nerve by-passed the need for prior replication within
the LRS and was sufficient to cause disease (Kimberlin et al., 1983a; Kimberlin et
al., 1983b; Kimberlin and Walker, 1980). Since these initial experiments, several
studies have demonstrated that TSE infectivity gains access to the CNS via particular
neural pathways and ganglia of the peripheral nervous system (Beekes and McBride,
2000; Beekes et al., 1998; Glatzel and Aguzzi, 2000; Glatzel et al., 2001; McBride
and Beekes, 1999; McBride et al., 2001). However, it is not known how scrapie
infectivity reaches the PNS from FDC networks on which it accumulates. It is
possible that the scrapie agent might be transported by a mobile cell type such as the
DCs (Aucouturier et al., 2001). Similarly, T-lymphocytes have been proposed as a
mode of transport for scrapie infectivity from the periphery to the CNS due to the
detection of infiltrates of T-lymphocytes within the brains of scrapie-affected rodent
models (Betmouni et al., 1996; Lewicki et al., 2003). However, this hypothesis
seems unlikely as removal of the thymus or deficiencies in T-lymphocytes have no
effect on disease pathogenesis (Fraser and Dickinson, 1978; Klein et al., 1997).
Alternatively, recent research has demonstrated that movement of FDCs closer to
peripheral nerves by disruption of chemokine gradients enhanced neuroinvasion of
the scrapie agent (Prinz et al., 2003b), suggesting that transport into the PNS could
occur directly from FDCs. Further research is required to determine the precise TSE
agent transport mechanism between FDCs and nerves.
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1.4 TSEs and the skin
1.4.1 TSE agent transmission via the skin
Studies in mice have shown that TSE exposure through scarified skin is an effective
means of scrapie transmission (Taylor et ah, 1996a); the skin might be a possible
route of natural exposure. The potential acquisition of TSE agents via the skin
highlights important health and safety issues, including whether scientists and health
workers are at risk from acquiring infectivity from handling infected tissues or
instruments. Previous studies have demonstrated that surgical instruments
contaminated with CJD infectivity are capable of transmitting infection (Flechsig et
ah, 2001; Ramasamy et ah, 2003) it is therefore conceivable that the skin may be the
route of exposure following any surgical procedure which breaches this barrier.
Furthermore, many biopharmaceutical and cosmetic products that are applied to the
skin contain material from sheep and cattle sources (Birmingham, 2000; Department
of Health, 2002; Lupi, 2002), which could potentially harbour TSE infectivity.
Scarified skin or skin lesions might also be potential routes of exposure for scrapie in
sheep (Brotherston et ah, 1968) or CWD of deer (Miller et ah, 2004). Understanding
the immunobiology of scrapie following transmission via the skin will be important
in the assessing the relative risk of exposure via this route and the development of
therapeutic strategies.
1.4.2 Structure and biology of the skin
The skin covers the entire surface of the body and forms a continuous layer with the
epithelial mucosa of the gastro-intestinal, respiratory and urogenital tracts. Human
skin forms approximately 8 % of the total body mass and it thickness can range from
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1.5 - 4 mm depending on its location and maturation (Champion et al., 1991). The
skin provides a continuous physical barrier that protects the internal systems from
mechanical, chemical, thermal, photic, osmotic and microbial damage. The skin is
responsible for many diverse functions including: biochemical synthesis of Vitamin
D, production of cytokines and growth factors, primary immunosurveillance and
sensory surveillance (Millington and Wilkinson, 1983).
The skin is comprised of two main layers, the epidermis and dermis, although some
texts may refer to a third layer termed the subcutaneous layer composed mainly of fat
(Fig. 1.4). The epidermis is divided into five strata from deep to superficial; stratum
basale, stratum spinosum, stratum granulosum, stratum lucidum and the stratum
comeum (Williams, 1995). The majority of the epidermis is comprised of
keratinocytes. Keratinocytes are terminally differentiated from mitotically active
basal cells within the stratum basale to non-viable cornified cells of the stratum
corneum (Kligman, 1964). As these cells migrate upwards from the stratum basale
to the corneum (approximately over a 28 day period) there is a progressive increase
in the synthesis of keratin proteins. Melanocytes are also present within the
epidermis, which are interspersed among keratinocytes within the stratum basale.
Melanosomes (pigment containing granules produced by melanocytes) are
transferred to surrounding keratinocytes providing them with protection from ultra¬
violet light as they progress upwards through the strata (Sagebiel and Odland, 1972).
Merkel cells are also present within the stratum basale in association with nerve
endings (Winkelmann, 1973). These neuroendocrine cells function as















Figure 1.3- A schematic representation of the layers of the skin.
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cells (LCs) are present within the basal and spinosum strata (Langerhans, 1868).
Langerhans cells are responsible for immunosurvelliance and immunological
responses within the skin. Occasionally a very small number of lymphocytes are
found within the deepest layers of the epidermis but they are not considered a
resident cell population.
The dermal layer of the skin is separated from the epidermal layers by a basement
membrane comprised of the membranes of basal cells, collagen and lamina
filaments. The dermis consists of two layers, the papillary dermis and the reticular
dermis, although transition between the two is gradual (Williams, 1995). Both layers
consist of dense networks of collagen fibres and elastin fibres and proteoglycans
(Hay, 1981) interwoven by blood vessels and nerve fibres. The dermis contains two
major categories of cells: fixed cells and free cells. Fixed cells include, fibroblasts,
endothelial cells, nerve cells and muscle cells. Whereas, free cells whose
percentages can vary according to anatomical location and immune status include,
macrophages, dermal dendritic cells, eosinophils, neutrophils, mast cells and B and
T-lymphocytes. The skin also can contains pilosebaceous units which contain the
hair shaft and its follicle and its associated arrector pili muscle and sebaceous gland
which are all located within the dermis although the hair shaft extends out through
the epidermis.
1.4.3 Antigen transport from the skin
After a pathogen has entered the skin there are several mechanisms by which it may
be transported out with this microenvironment. Pathogen invasion of the skin leads
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to the release of pro-inflammatory cytokines such as TNF-a and interleukins (IL) by
keratinocytes and LCs within the epidermis and mast cells, dendritic cells and
macrophages within the dermis (Kupper and Fuhlbrigge, 2004). The subsequent
sequence of events and relative proportion of cell types involved can vary depending
on the type of antigen present. In general, LCs and dermal DCs acquire antigens
present at the site of exposure and are stimulated to mature by the cytokine and
chemokine signals released by surrounding cells. They then emigrate from the skin to
the draining lymph node where they present antigen in a MHC-class restricted
manner to nai've T-lymphocytes to initiate a primary immune response (Lappin et al.,
1996). The release of pro-inflammatory cytokines and chemokines by cells within
the skin also attracts macrophages, NK cells and neutrophils from the dermal post¬
capillary venule to the site of injury. The main function of neutrophils and
macrophages is the phagocytosis and enzymatic digestion of pathogenic bacteria.
Macrophages also possess the ability to present antigen in a MHC-class restricted
manner to memory T-lymphocytes either at the site of injury or by migrating to the
draining lymphoid tissues. Antigens are also transported from the skin in a cell free-
dependent manner as oposonised components of the complement cascade (Pepys,
1976). Opsonised antigen is transported within the tissue fluids of the skin and
subsequently passes into the lymphatic vessels and drains to the nearest draining
lymph node. Antigens can also leave the skin via the blood vessels ultimately with
the potential to invade distant tissues from the site of exposure as is observed
following exposure to malaria (Pouniotis et al., 2004). The skin is also highly
innervated, and some pathogens such as rabies virus (Coulon et al., 1989) and the
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herpes simplex virus (Worrell and Cockerell, 1997) have been shown to directly
infect peripheral nerves.
1.4.4 Candidate mechanisms for the transport of the scrapie agent from the skin
The majority of cells that reside in the skin are non-mobile, in terms of movement
outwith the skin and therefore unlikely to be directly involved in the transport of
scrapie infectivity. However, both LCs and macrophages are highly mobile cells and
both possess the ability to acquire antigen (Ag) in the periphery and transport it to the
nearest draining lymph nodes (DLNs). It is therefore conceivable that either of these
cell types could transport scrapie infectivity from the skin to lymphoid tissues. Both
in vivo and in vitro studies have demonstrated the capacity of macrophages to reduce
scrapie infectivity rather than aid its transmission (Beringue et al., 2000b; Carp and
Callahan, 1982; Jeffrey et ah, 2000b), suggesting these cells would be an unlikely
transport mechanism from the skin.
The genetic or temporary depletion of complement components, prior to peripheral
inoculation of rodent models, with the scrapie agent, results in a significantly
prolonged incubation period (Klein et ah, 2001; Mabbott et ah, 2001). Furthermore,
these studies demonstrate that complement components are involved in the
localization of scrapie infectivity to FDCs (Klein et ah, 2001; Mabbott et ah, 2001),
suggesting that the transport of scrapie infectivity from the skin to the LRS might be
cell free. In addition, peripheral nerves could directly take up the scrapie agent
however, this seems unlikely, as SCID mice are refractory to scrapie infection
following inoculation via the skin (Taylor et ah, 1996).
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The most likely candidate for the transportation of the scrapie agent from the skin to
the LRS are LCs. Research by Huang et al demonstrated that migrating intestinal
DCs can acquire and transport PrPSc from the gut lumen through the lymphatics to
the LRS (Huang et al., 2002). As LCs are immature dendritic cells, it is conceivable
that LCs might perform the same function following exposure to the scrapie agent
via the skin. In addition, studies using the neurotoxic prion protein fragment PrPio6-
126 have shown that this peptide is a chemoattractant for immature DCs (Kaneider et
al., 2003) and can also induce up-regulation of pro-inflammatory cytokines such as
IL-1J3 and TNFa following exposure (Bacot et al., 2003). Taken together these data
suggest that LCs might have the potential to transport the scrapie agent from the skin
to the LRS.
1.4.5 Langerhans cells
LCs (Langerhans, 1868) are a population of immature DCs located above the basal
layer of epithelial cells in the skin, oral, nasal, esophageal, pulmonary, vaginal and
rectal mucosa. Within the skin, LCs constitute approximately 2-4% of all epithelial
cells and usually reside within the stratified spinosum epithelia (Prickle cell layer) of
the epidermis. LCs originate from bone-marrow progenitors (Elbe et al., 1989) and
circulate in the peripheral blood before residing within the skin (Strunk et al., 1997).
LCs can be identified within the epidermis according to their dendritic morphology
and the presence of the intracytoplasmic organell, termed the Birbeck granule
(Birbeck et al., 1961), although not all LCs have this structure (Mommaas et al.,
1994). LCs can also be identified based on their surface phenotype, as they are the
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only cell population within the normal epidermis that expresses MHC class II
(Klareskog et al., 1977 794).
LCs are the sentinels of the skin, consistently sampling their microenvironment for
both self and non-self Ag. Upon Ag-encounter immature LCs are induced to
undergo phenotypic and functional changes that culminate in the complete transition
from Ag-capturing cells to a mobile Ag-presenting cell (APC). During this
maturation, LCs leave their cutaneous compartment and migrate to the draining
lymph node where they present antigen in a MHC-class restricted manner to naive T-
lymphocytes initiating primary immune responses (Lappin et al., 1996).
1.4.6 Antigen acquisition and processing by LCs
LCs express a wide range of surface molecules that allow them to recognize and
acquire Ag (Banchereau and Steinman, 1998). For example, Toll-like receptors
(TLRs) 2 and TLR-4 have been recently shown to be expressed by LCs and are able
to directly bind LPS, whereas TLR-9 expressed by LCs binds unmethylated CpG
motifs (Mitsui et al., 2004). Simiarly, C-type lectins such as Langerin, Dectin-2 and
CD205 bind pathogen associated sugar residues via highly conserved carbohydrate
recognition domains (Figdor et al., 2002). Studies have also shown that LCs also
express complement receptors (ClqR and CR3; (Burke and Gigli, 1980)) and Fc-
receptors (FcyRII/III; (Esposito-Farese et al., 1995)) both of which facilitate the
uptake of Ag-coated in immune complexes. In addition, LCs are also able to bind
apoptotic cells via integrin components (Albert et al., 1998; Berman et al., 2003).
Once captured, Ag can be internalized via several different mechanisms such as
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phagocytosis (Reis e Sousa et al., 1993), macropinocytosis (Sallusto and
Lanzavecchia, 1995) and receptor mediated endocytosis (Jiang, 1995). The Ag then
enters the endocytic pathway of the cell and is directed towards late-endosomal
compartments for loading onto MHC molecules (Banchereau and Steinman, 1998).
Furthermore, previous studies have shown that DCs are capable of secreting
proteases to process extracellular Ag which is then directly loaded onto MHC
molecules at the cell surface (Santambrogio et al., 1999). However, not all Ags are
degraded by DCs as studies have shown that LCs are able to acquire and retain
unprocessed Ag and transfer them to naive B-lymphocytes to initiate an immune
response (Wykes et al., 1998).
1.4.7 LC activation and migration
The production of various cytokines by both LCs and keratinocytes plays a key role
in the induction of LC activation and migration to the DLN (Luger and Schwarz,
1990). In response to certain stimuli, such as application of contact allergens
(Silberberg-Sinakin et al., 1976), low-dose UVB radiation (Bergstresser et al., 1980),
invasion of pathogens or necrotic cells (Banchereau and Steinman, 1998) both cell
types produce a variety of cytokines such as IL-la, IL-ip, IL-18 GM-CSF, TNF-a
and macrophage inflammatory proteins (MIPs) (Lappin et al., 1996). The cytokines
produced first following stimulation and considered the most critical to LC migration
are TNF-a and IL-ip (Cumberbatch et al., 2001; Cumberbatch et al., 1997b;
Cumberbatch et al., 1999; Cumberbatch and Kimber, 1992). IL-ip, which is
primarily a product of LC, is delivered in an autocrin fashion via IL-1 receptor
(Cumberbatch et al., 1997a; Cumberbatch et al., 1997b; Cumberbatch et al., 1999).
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In contrast, TNF-a is derived from the surrounding keratinocytes and signals through
the TNF-R2 on the LC (Cumberbatch and Kimber, 1992; Wang et al., 1996; Wang et
al., 1997). In the absence of either of these two cytokines active LC migration is
impaired (Cumberbatch et al., 1997b).
LCs are attached to keratinocytes via E-cadherin (Jakob and Udey, 1997). Following
the production of the fore mentioned cytokines a decline in the expression ofmRNA
for E-cadherin occurs allowing LCs to dissociate (Jakob and Udey, 1997).
Furthermore, LCs up-regulate adhesion molecules such as intergrin proteins (Price et
al., 1997) and ICAM-1 (Cumberbatch et al., 1992), which guide LCs to the basement
membrane of the dermis. The secretion ofmetalloproteinases by LCs allows partial
digestion of the basement membrane to facilitate their passage to the afferent
lymphatics (Kobayashi, 1997).
Upon activation and migration LCs express the chemokine receptor CCR7 (Saeki et
al., 1999) which mediates their migration through the afferent lymphatics towards the
DLN through the coordinated actions of several chemokines such as 6Ckine and
macrophage inflammatory protein-3p (Kellermann et al., 1999). During this
migration, LCs develop a mature phenotype becoming potent APCs. Upon arrival at
the DLN mature APCs present Ag in a MHC-restricted manner to T-lymphocytes
and stimulate their proliferation and differention via the co-stimulatory molecules
CD40, CD80 and CD86 (Banchereau et al., 2000). The production of IL-12 by
APCs polarizes the differentiation of T-lymphocytes into cytotoxic Thl cells, which
are involved in cell-mediated immunity (Cella, 1996; Koch, 1996; Reis e Sousa,
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1997). Alternatively, IL-4 production by APCs polarizes T-lymphocytes to
proliferate and differentiate into Th2 cells, which aid humoral immunity (Hayashi et
al„ 2000).
1.4.8 LC and pathogen interactions
Following transmission via the skin, several pathogens are known to exploit LCs
either to gain transport to the lymphoid tissues or to avoid immune detection
(Rescigno and Borrow, 2001). Human immunodeficiency virus has been shown to
use CCR5 receptor expressed by LCs to infect these cells and then utilizes their
migration pathway to facilitate transport to T-lymphocyte regions of lymphoid
tissues where it preferential infects CD4+ T-lymphocytes (Kavanagh and Bhardwaj,
2002; Kawamura et al., 2003; Reece et al., 1998). Similarly, LCs have been shown
to be involved in the transport of cytomegalovirus (CMV) to lymphoid tissues
(Hertel et al., 2003). This virus also down-regulates MHC class II expression by LCs
by interfering with the transcription and trafficking of MHC (Hertel et al., 2003),
presumably to hinder the priming of virus specific T-lymphocytes. Other pathogens
which utilize LCs include, dengue virus (Wu et al., 2000), maedi-visna lentivirus
(Ryan et al., 2000), Venezuelan equine encephalitis virus (MacDonald and Johnston,
2000) and Leishmania major (von Stebut et al., 1998), demonstrating the variety of
pathogens which can exploit LC functions.
1.5 Aims
Studies by Taylor and colleagues have shown that skin scarification is an effective
means of scrapie agent transmission in mice (Taylor et al., 1996a). Understanding
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the immunobiology of the scrapie agent transmission via the skin will help to
determine the likelihood of transmission of natural TSEs via this route and aid the
development of therapeutic strategies. A functional immune system is critical for the
transmission of scrapie to the CNS following skin scarification, as SCID mice are
refractory to scrapie infection, (Taylor et al., 1996a). These data demonstrate that
infectivity is unable to reach the CNS directly via the blood or peripheral nerves.
Instead, it is likely that infectivity accumulates and replicates in the LRS prior to
neuroinvasion, as observed with other peripheral routes of exposure (Hilton et al.,
1998; Kimberlin and Walker, 1989a; McBride et al., 1992; Sigurdson et al., 1999;
van Keulen et al., 1996).
With this in mind the overall aim of this study was to utilize a mouse-passaged
scrapie model to investigate the immunobiology of TSEs following transmission via
the skin. Specifically this study addresses the following issues:
1) To determine whether the scrapie agent accumulates in the LRS following
transmission via the skin and if so, what cells are critical for the accumulation
of the agent in the LRS.
2) To determine how the scrapie agent is transported from the skin to the LRS
Aim 1:
Studies using SCID mice have suggested that there is a requirement for the LRS after
transmission of the scrapie agent via the skin (Taylor et al., 1996a). However, it is
not known whether the scrapie agent accumulates within lymphoid tissues prior to
neuroinvasion. To address this issue, tissue samples were collected at various time
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points after inoculation and infectivity levels measured (Chapter 3). Furthermore, it
is not known which cells within the LRS are critical for the accumulation of the
scrapie agent following transmission via the skin. The most likely candidate cells
involved in replication and accumulation of infectivity in the LRS are FDCs, which
are critical for the efficient transmission of the disease to the CNS following other
peripheral routes of inoculation (Brown et al., 1999; Mabbott et al., 2000b). In order
to address this issue two separate approaches were taken. Firstly, a chimeric mouse
model was used that had a mismatch in PrP status between FDCs and other bone-
marrow derived cells within the LRS (Brown et al., 1999) to determine the separate
roles FDCs and lymphocytes (Chapter 4). Secondly, FDCs were temporarily
dedifferentiated either prior to, or shortly after, inoculation to determine the role of
FDCs in neuroinvasion (Chapter 5).
Aim 2:
Previous research has suggested that DCs have the potential to transport the scrapie
agent (Huang et al., 2000). It is therefore conceivable that LCs, a sub-population of
DCs situated in the epidermis, could transport the agent from the skin to the LRS
after inoculation via the skin. LCs were exposed to scrapie-affected brain
homogenate in vitro to determine whether LCs have the potential to acquire PrPSc
and scrapie infectivity (Chapter 6). Secondly, mouse models were utilised which had
impaired LC migration to the DLN. Using these models the role of LCs in the
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2.1 Mouse strains
All mice used in these studies were housed under specific pathogen free conditions in
a conventional animal facility with a 12 hrs light and 12 hrs dark cycle. Mice were
used between 8-12 weeks of age and individual experiments were age-matched. All
experiments were conducted under the provisions of the Animals (Scientific
Procedures) Act 1986.
2.1.1 C57BL/Dk
This mouse strain has been extensively used at the Neuropathogenesis Unit (NPU),
Institute for Animal Health, Edinburgh in scrapie transmission studies and as
indicator mice in incubation period bioassays to determine scrapie infectivity titres.
2.1.2 129/Ola mice and Prnp+I+ mice
The 129/Ola mouse strain was used at the NPU as a background strain for the
generation of Prnpmice. The Prnp deficient mouse model (Prnpmice) was
generated on the 129/Ola mouse background by insertion of a neomycin resistance
cassette into exon 3 of the Prnp gene (Manson et al., 1994a).
2.1.3 SCIWPrnp+/+ mice
The SCID/EV«/?+/+ mouse line was originally produced as described by Brown et al
(Brown et al., 1999), by crossing Severe Combined Immunodeficicnt mice (SCID)
(C.B-17 scid/scid, MHC type H-2d) with Prnp deficient mice (129/Ola Prnp'A mice,
MHC type H-2b) (Manson et al., 1994a). At the F2 generation, mice were selected
for the SCID phenotype, MHC type H-2b and either the Prnp+/+ or Prnp~'~ genotype.
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2.1.4 CD40 ligand deficient mice
CD40 ligand (Tnfsf5) deficient (CD40L7") mice (Xu et al., 1994) were a kind gift
from Prof. David Gray, University ofEdinburgh, UK. These mice were generated by
the insertion of a neomycin resistance cassette into exons 3 and 4 of the Tnfsf5 gene.
Mice were backcrossed and maintained on a C57BL/6 background. Age-matched
C57BL/6 mice were used as wild-type controls for experiments using these
immunodeficient mice.
2.2 Mouse genotype and phenotype confirmation
2.2.1 Preparation of chromosomal DNA
Portions of tail tissue (approximately 10 mm long) or spleen tissue fragments
(approximately 5 mg) were incubated in 800 pi of lysis buffer (1.5 M sodium acetate,
1 M Tris-HCl, pH 8, 0.5 M EDTA, 10% SDS, 7 pg/ml Proteinase K: (Roche
Diagnostics, Lewis, UK)) and gently shaken for 16-18 hrs at 37°C. Following
incubation, 600 pi of phenol: chloroform: isoamyl alcohol (25:24:1, Sigma, Poole,
UK) was added to the lysate and vortexed thoroughly. The samples were then
centrifuged at 13,000 x g for 5 mins and supernatant fractions collected. To the
supernatant, 20 pi of 3 M sodium acetate and 600 pi of isopropanol were added. The
samples were then mixed by inversion several times before being left to stand for 10
min at room temperature. Samples were then centrifuged at 13,000 x g for 1 min and
the supernatant discarded. The resulting DNA pellet was washed in 70%
ethanol/water (vol/vol) and resuspended in 100 pi of sterile DNase and RNase free
water. DNA preparations were stored at 4°C prior to analysis.
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2.2.2 Determination ofPrnp genotype by the polymerase chain reaction
The Prnp genotypes of bone-marrow grafted animals were determined by PCR
analysis, through the amplification of the Prnp gene and a portion of the neomycin
resistance gene, to detect the presence of the Prnp'' genotype. The PCR mixture,
(total volume 60.7 pi) contained; 5 pi 1 OX PCR buffer, 5.0 pi 50mM MgCh, 1.0 pi
lOmM dNTP mix (Life Technologies, Paisley, UK), 1 pi chromosomal DNA, 0.5 pi
(100 pmol/pl) each of primers 1, 2, 3 and 4, 0.2 pi Taq polymerase (5U/pl) (Life
Technologies) and 50 pi sterile DNase and RNase free water. The sequences of the
oligonucleotide primers for Prnp gene were as follows:
Primer 1. Prnp Fwd- 5'- ATG GCG AAC CTT GGC TAC TGG CTG- 3'
Primer 2. Prnp Rev- 5'- TCA TCC CAG GAT CAG CAA GAT GAG- 3'
Sequence positions are taken from Entrez entry U29186 (Lee et al., 1998). Primer 1
anneals to position 28690-28713 and primer 2 to 29454-29431. The above forward
and reverse primers anneal to the start and stop codons of the Prnp gene open
reading frame, respectively. These primer pairs were designed to generate a
fragment of 750 bp.
The sequences of the oligonucleotide primers for the mouse neomycin resistance
gene were as follows:
Primer 3. Neo Fwd- 5'- TTG AGC CTG GCG AAC AGT TC - 3'
Primer 4. Neo Rev- 5' - GAT GGA TTG CAC GCA GGT TC - 3'
Sequence positions are taken from Entrez entry M77786 (unpublished). Primer 3
anneals to position 4860-4878 and primer 4 to 5371-5352. The above primers anneal
to the neomycin resistance gene within Prnp '' mice, which is located within exon 3
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of the Prnp gene (Manson et al., 1994a). These primer pairs were designed to
generate a fragment of 550 bp.
Following a hot start at 94°C for 3 mins an amplification cycle was carried out for
30 cycles at the following temperatures; 94°C 50 sec, 62°C 50 sec, 72°C 50 sec on a
thermal cycler (Genius PCR System, Techne, Cambridgeshire, UK). A final
extension period at 72°C for 10 mins was included at the end of the 30 cycles. PCR
products were resolved electrophoresis at 125V through a 1.5% agarose gel
containing 1 pg/ml ethidium bromide.
2.2.3 Determination of TnfsfS genotype by the polymerase chain reaction
The Tnfsf5 genotype of C57BL/6 (wild-type) and CD40L7" deficient mice was
determined by PCR analysis, through the amplification of a portion of the Tnfsf5
gene or a portion of the neomycin resistance gene inserted into exon 3 and 4 of the
Tnfsf5 gene. The PCR mixture, (total volume 60.7 pi) contained; 5 pi 10X PCR
buffer, 1.5 pi 50mM MgCh, 1.0 pi lOmM dNTP mix (Life Technologies), 1 pi
chromosomal DNA, 0.5 pi (100 pmol/pl) each of the primers 1, 2, 3 and 4, 0.2 pi
Taq polymerase (5U/pl) (Life Technologies) and 50 pi sterile DNase and RNase free
water. The sequences of the oligonucleotide primers for theTnfsf5 gene were as
follows;
Primer 1. Tnfsf5 Fwd-5'- CCC AAG TGT ATG AGC ATG TGT GT-3'
Primer 2. Tnfsf5 Rev-5'- GTT CCT CCA CCT AGT CAT TCA TC-3'
Sequence positions are taken from Entrez entry AL672128.8 (unpublished). Primer
1 anneals to position 146478-146500 and primer 2 anneals to position 146740-
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146718. The above forward and reverse primers anneal to introns 4 and 5 of
theTnfsf5 gene respectively. These primer pairs were designed to generate a of
fragment 250 bp.
The sequences of the oligonucleotide primers for the mouse neomycin resistance
gene were:
Primer 3. Neo Fwd-5'- GCC CTG AAT GAA CTG CAG GAC-3'
Primer 4. Neo Rev-5'- GGG TAG CCA ACG CTA TGT C-3'
Sequence positions are taken from Entrez entry M77786. Primer 3 anneals to
position 5218-5197 and primer 4 to 4708-4726. The above forward and reverse
primers anneal to exons 3 and 4 of the neomycin resistance gene respectively. These
primer pairs were designed to generate a of fragment 500 bp.
Following a hot start at 94°C for 1.5 mins an amplification cycle was carried out for
12 cycles at the following temperatures; 94°C 20 sec, 64°C 30 sees, 72°C 35 sees,
followed by a second amplification cycle carried out for 25 cycles at the following
temperatures; 94°C 20 sec, 58°C 30 sees, 72°C 35 sees. A final extension period at
72°C for 10 mins was included at the end of the second amplification cycle. All
PCR products were resolved by electrophoresis at 125 V through a 1.5% agarose gel
containing 1 pg/ml ethidium bromide.
2.2.4 Enzyme-linked immunoabsorbent assay (ELISA) for mouse
immunoglobulins (Ig)
For analysis of Ig content, sera was diluted (1/1000) in carbonate bicarbonate buffer
(0.5 M, pH 5) and absorbed to flat bottomed, medium binding microwell plates
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(Costar®, High Wycombe, UK) for 18-24 hrs at 4°C. Plates were then blocked with
0.01 M PBS (pH 7.5) containing 1% bovine serum albumin (BSA). Bound Ig was
detected using horseradish peroxidase conjugated rabbit anti-mouse Ig (DAKO,
Cambridgeshire, UK). Bound peroxidase activity was measured by incubation with
o-phenylenediamine as a substrate (Sigma). Optical density (OD) was measured at
490 nm using a V-max kinetic microplate reader (Molecular devices, CA, USA). A
standard curve was generated by serial dilutions of polyclonal mouse Ig (lmg/ml)
(Serotec, Oxford, UK) and was used to convert the OD values of experimental
samples to mg of Ig/ml of sera. Sera from wild-type immunocompetent mice and
SCID mice were used as reference controls.
2.3 Pre- inoculation manipulations/treatments
2.3.1 Bone-marrow grafting of SCID/Prnp+/+ mice
Bone-marrow from the femurs and tibias of adult 129/Ola mice or Prnp'~ mice
(section 2.1.2) (Manson et al., 1994a) was prepared as single-cell suspensions
(3xl07- 4xl07 viable cells/ml) in Hank's balanced salt solution (HBSS) (Life
Technologies). Recipient SC\D/Prnp+/+ mice (section 2.1.3) were reconstituted with
0.1 ml bone-marrow by injection into the tail vein.
2.3.2 Caspase-1 inhibitor treatment
Where indicated, before inoculation with the scrapie agent by skin scarification
groups of C57BL/Dk mice were pre-treated at the shaved inoculation site with 50 pi
of 0.4 mM caspase-1 inhibitor II (Ac-YVAD-cmk; Calbiochem, Beeston, UK), 0.4
mM caspase-3 inhibitor III (Ac-DEVD-cmk; Calbiochem) or vehicle alone Dimethyl
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sulfoxide (DMSO) using a previously established protocol (Antonopoulos et al.,
2001). One hour later mice were inoculated with the scrapie agent as described in
section 2.4.2. Care was taken to ensure that the scrapie agent was only applied to the
pre-treated area of skin.
2.3.3 LTpR-Ig treatment
Where indicated, either 3 days before, or 14 or 42 days after inoculation with the
scrapie agent by skin scarification, groups of C57BL/Dk mice were given a single
100 pg intra-peritoneal (i.p.) injection of a fusion protein containing the soluble
lymphotoxin P receptor (LTpR) domain linked to the Fc portion of human IgGl
(LTpR-Ig) (Force et al., 1995) or 100 pg of polyclonal human IgG (hu-Ig;
Sandoglobulin®). Both reagents were a kind gift from Jeff Browning (Biogene Inc,
Cambridge, MA, USA).
2.4 Inoculation with the scrapie agent
2.4.1 Scrapie strains
The ME7 scrapie strain was used for all inoculations conducted in this thesis. ME7
was originally isolated from the spleen of a Suffolk sheep affected with natural
scrapie (Zlotnik and Rennie, 1963). The strain was originally passaged into mice by
intragastric challenge of Moredun random bred mice. The agent was then passaged
intracerebrally (i.e.) into Moredun mice followed by 9 passages in inbred C57BL/Dk
mice at NPU.
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The mouse-passaged ME7 strain of scrapie has been well characterised and produces
prominent neuronal vacuolation. This scrapie strain has been used extensively at
NPU for the study of peripheral scrapie pathogenesis in mice. After peripheral
inoculation with moderate or low dose of ME7 (1.0% or 0.1% brain homogenate)
there is an obligate requirement for amplification of the agent in lymphoid tissues
prior to neuroinvasion (Brown et al., 1999; Fraser and Dickinson, 1970; Fraser and
Dickinson, 1978; Fraser and Farquhar, 1987; Mabbott et al., 2000a; Mabbott et al.,
2002; Mabbott et al., 2000b; Mabbott et al., 2003; Taylor et al., 1996a) This scrapie
strain is therefore the most appropriate strain to use to investigate peripheral
pathogenesis of scrapie infection after inoculation via the skin.
2.4.2 Inoculation with the scrapie agent
Mice were inoculated with the ME7 scrapie strain by skin scarification of the medial
• ... 9 •
surface of the right thigh. Prior to scarification approximately 1 cm area of hair
covering the site of scarification was trimmed using curved scissors and then
removed completely with an electric razor. Twenty-four hours later a 23-gauge
needle was then used to create a 1 cm long abrasion of the upper epidermal layers of
the skin at scarification site. Then using a 26-gauge needle one droplet (~6 pi) of
ME7 scrapie inoculum from either a 1% or 0.1% (wt/vol) dilute of terminally
scrapie-affected mouse brain homogenate in physiological saline, was applied to the
abrasion and worked into the site using sweeping strokes. The scarification site was
then sealed with OpSite (Smith & Nephew Medical Limited, Hull, UK) and allowed
to dry before returning the animals to their final holding cages. Where indicated
some mice were inoculated intra-cerebrally (i.e.) with 20 pi of a 1 % scrapie-affected
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mouse brain homogenate in physiological saline (a dose of approximately 1 x 104 5
intracerebral units, 50 % infectious dose {ID50 units}) as a titre control. Following
inoculation, animals were coded and assessed weekly for signs of clinical disease and
killed at a standard clinical end-point (as described in section 2.4.3) (Fraser and
Dickinson, 1973). Scrapie diagnosis was confirmed by histopathological assessment
of vacuolation in the brain (section 2.4.4).
2.4.3 Determination of scrapie incubation period
The scrapie incubation period is defined as the time elapsed (in days) between the
day of inoculation and the clinical endpoint of the disease (Dickinson et al., 1968;
Fraser and Dickinson, 1973). At NPU all mice are clinically monitored by
experienced animal technicians and scoring of clinical symptoms begins
approximately 120 days after inoculation dependent on the route of exposure.
Inoculated mice are assessed weekly on the same day and each mouse is given a
rating as follows; "unaffected", "possibly affected" or "definitely affected". The
clinical endpoint is defined in one of four ways: 1) the day on which the mouse
receives a second consecutive "definite" rating; 2) the day on which a mouse
receives a third "definite" rating within four consecutive weeks; 3) the day on which
the mouse is culled in extremis or 4) the mouse is found dead in its cage after
receiving a "definite" rating at the time of scoring the previous week. This system




Whole brains were cut into five defined areas (Fraser and Dickinson, 1968), fixed in
2% paraformaldehyde-periodate-lysine (0.1 M periodate; 0.075 M D-L Lysine; 2%
paraformaldehyde in 0.05 M phosphate buffer pH 7.4) and embedded in paraffin
wax. Sections (thickness, 6 pm) were stained with hematoxylin and eosin.
Vacuolation in the brain was scored on a scale of 0-5, by experienced histology staff,
in the following grey-matter (G1-G9) and white-matter (W1-W3) areas (Fraser and
Dickinson, 1973): Gl, dorsal medulla; G2, cerebellar cortex; G3, superior colliculus;
G4, hypothalamus; G5, thalamus; G6, hippocampus; G7, septum; G8, retrosplenial
and adjacent motor cortex; G9, cingulate and adjacent motor cortex; Wl, inferior and
middle cerebellar peduncles; W2, decoction of superior cerebellar peduncles; W3,
cerebral peduncles.
2.4.5 Bioassay of scrapie infectivity in tissues samples
At various time points after challenge mice were sacrificed and tissues taken to
determine the scrapie infectivity titre. For bioassay of scrapie infectivity in the
spleen, half spleens were pooled from 2-4 mice from each group and prepared as 10
% (wt/vol) homogenates in physiological saline and 20 pi injected i.e. into groups of
up to 12 C57BL/Dk indicator mice. Similarly, inguinal lymph nodes draining the
site of challenge were pooled from 2-4 mice from each group and prepared as 10%
(wt/vol) homogenates. The scrapie titre in each sample was determined from the
mean incubation period response curves for scrapie-infected spleen tissue (Dickinson
et al., 1969). To compare the levels of scrapie infectivity remaining at the site of
skin scarification, skin (approximately 1 cm2) from the inoculation site was
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homogenized in 200 pi of physiological saline in a Ribolyser (Hybaid, Middlesex,
UK). Samples were pooled from 4 mice and 20 pi injected i.c into groups of up to
12 C57BL/Dk indicator mice.
2.5 Ex vivo analysis of tissues
2.5.1 Immunohistochemical analysis of lymphoid tissues
To monitor follicular dendritic cell (FDC) status, spleen or inguinal lymph nodes
were snap-frozen at the temperature of liquid nitrogen. Serial frozen sections
(thickness, 10 pm) were cut on a cryostat and FDCs visualized by staining with one
or more of the following antibodies: FDC-specific rat monoclonal antibodies FDC-
M1 (BD Pharmingen, Oxford, UK), FDC-M2 (AMS Biotechnology, Oxon, UK),
8C12 monoclonal antiserum to detect complement receptor 1 (CD35) (BD
PharMingen).
B-lymphocytes were detected using either rat monoclonal antibody RA3-6B2
specific for CD45R (Caltag, Towcester, UK) or the lectin peanut agglutinin (PNA),
which preferentially binds to galactosyl (P 1-3) N-acetylgalactosamine residues (t-
Antigen) on blasting germinal centre B-lymphocyte glycoproteins (Rose, 1980)
(Vector Laboratories, Burlingame, CA, USA).
For the detection of PrP in spleen tissue or inguinal lymph nodes, tissues were fixed
in 2% paraformaldehyde-periodate-lysine (0.1 M periodate; 0.075 M D-L Lysine;
2% paraformaldehyde in 0.05 M phosphate buffer pFl 7.4) and embedded in paraffin
wax. Sections (thickness, 6 pm) were deparaffinized, and pre-treated to enhance PrP
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immunostaining by immersion in water (55°C for 30 mins), and subsequent
immersion in formic acid (98%) for 5 min (Tricia McBride personal
communication). Sections were then stained with the PrP-specific rabbit polyclonal
antiserum 1B3 (Appendix 1) (Farquhar et al., 1989)
All immunolabeling for the above antibodies was carried out using alkaline
phosphatase coupled to the avidin-biotin complex (Vector Laboratories). Vector Red
(Vector Laboratories) was used as a substrate. All sections were counterstained with
hematoxylin to distinguish cell nuclei.
2.5.2 Immunohistochemical analysis of brain tissue
For the detection of PrP in brain tissue, tissues were fixed in periodate-lysine-
paraformaldehyde (0.1 M periodate; 0.075 M D-L Lysine; 2% paraformaldehyde in
0.05 M phosphate buffer pH 7.4) and embedded in paraffin wax. Sections
(thickness, 6 pm) were deparaffinized, and pre-treated to enhance PrP
immunostaining by hydrated autoclaving (15 min, 121°C), and subsequent
immersion in formic acid (98%) for 5 min (Kitamoto et al., 1991). Sections were
then stained with the PrP-specific mouse monoclonal antibody 6H4 (Prionics,
Zurich, Switerland) (Appendix 1) and immunolabelling was carried out using the
DAKO EnVision™+ System (DAKO,). Diaminobenzidine (DAB) (Sigma) was used
as a substrate.
Glial fibrillary acid protein (GFAP) was detected on adjacent brain sections using
rabbit GFAP-specific antibody (DAKO) and immunolabelling carried out using
72
alkaline phosphatase coupled to the avidin-biotin complex (Vector Laboratories).
Vector Red was used as a substrate (Vector Laboratories). All sections were
counterstained with hematoxylin to distinguish cell nuclei.
Microglia were detected by staining with biotin-conjugated Lycopersicon
esculentum-agglutinin (LEA; Sigma), which preferentially binds to poly-N-acetyl
lactosamine residues on microglial cells (Acarin et ah, 1994). Immunolabelling was
carried out using hydrogen peroxidase coupled to the avidin-biotin complex with
DAB as a substrate.
2.5.3 Paraffin embedded tissue (PET) immunoblots.
For detection of PrPSc in spleen and inguinal lymph nodes, tissues were fixed in 2%
paraformaldehyde-periodate-lysine and embedded in paraffin wax. Serial sections
(thickness 6pm) were mounted on polyvinylidine difluoride membranes (PVDF,
0.45pm-pore; Bio-Rad, Hemel, Hempstead, UK) and fixed by incubation at 55°C
overnight. PET blotting was carried out as previously described (Schulz-Schaeffer et
ah, 2000). Briefly PVDF membranes were deparaffinised and digested with 20
pg/ml of proteinase K (10 mM Tris-HCl pH 7.8, 100 mM NaCl and 0.1% Brij) for
16 hrs at 55°C. Membranes were then washed in TBS/Tween (10 mM Tris-HCl pH
7.8, 100 mM NaCl, 0.5% Tween) before being denatured in 3 M guanidine
isothiocyanate (10 mM Tris-HCl pH 7.8) for 10 mins. Prior to immunodetection
membranes were blocked in 2% casein. PrP was detected with the PrP specific
rabbit polyclonal antiserum 1B3 (Farquhar et ah, 1989) (Appendix 1) in blocking
buffer for 2 hrs, followed by alkaline phosphatase-conjugated goat anti-rabbit
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Immunoresearch Laboratories Inc, West Grove, PA, USA), and bound alkaline
phosphatase activity detected with SigmaFast™ NBT/BCIP solution (Sigma). PET
blots were assessed using an Olympus dissecting microscope.
2.5.4 Immunoblot detection of PrPSc
Individual spleen fragments or pooled inguinal lymph nodes (two pooled from each
mouse assayed) were prepared as previously described by Farquhar (Farquhar et al.,
1994). Briefly, before immunoblot analysis, tissue homogenates were treated with
80 pg proteinase K (to confirm the presence of PrPSc) and subsequently partially
purified by treatment with 2% (wt/vol) N-lauroylsarcosine (in 0.1 M Tris pH 7.4)
allowing sedimentation only of the proteinase-K-resistant, detergent-insoluble
fraction of PrP (PrPSc). Samples were subjected to electrophoresis through sodium
dodecyl sulphate 10-20% polyacrylamide gels (Bio-Rad) and transferred to PVDF
membranes (Bio-Rad) by semi-dry blotting. PrP was detected with the PrP-specific
mouse monoclonal antibody 8H4 (Zanusso et al., 1998) (Appendix 1).
Immunolabelling was carried out using horseradish peroxidase conjugated rat anti-
mouse antibody (Jackson ImmunoResearch Laboratories Inc), and bound horseradish
peroxidase activity detected with Supersignal® West Dura Extended Duration
Substrate (Pierce, Chester, UK).
Where indicated PrP was also detected in earlier experiments (Chapter 4; Fig. 4.9)
with the PrP-specific rabbit polyclonal antiserum 1B3 (Farquhar et al.,
1989)(Appendix 1) followed by alkaline phosphatase-conjugated goat anti-rabbit
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antibody (Jackson ImmunoResearch Laboratories Inc), and bound alkaline
phosphatase activity detected with SigmaFast™ NBT/BCIP solution (Sigma).
2.6 Cell lines
2.6.1 Culture of cell lines
The XS106, XS52 and NS47 cell lines used in this research were a kind gift from
Akira Takashima (Dept. Dermatology, University of Texas, U.S.A). The XS52 and
XS106 cell lines are long term dendritic cell lines established from the epidermis of
newborn mice (Timares et al., 1998; Xu et al., 1995a). The XS52 and XS106 cell
lines were cultured in complete RPMI 1640 medium (cRPMI) (Gibco BRL, Paisley,
UK) containing 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES buffer,
0.25 pg/ml antibiotic-antimycotic solution, 50 pM 2-P-mercaptoethanol, 1% non¬
essential amino acids (Sigma) and 10% heat-inactivated fetal calf serum (Invitrogen,
Paisley, UK). NS47 cells belong to the fibroblast lineage and are cultured in cRPMI
as described above (Schuhmachers et ah, 1995). Culture media for the XS52 cell
lines was further supplemented with 2 ng/ml mouse recombinant granocyte
macrophage colony-stimulating factor (GM-CSF: R&D Systems, Abingdon, UK)
and 10% (v/v) culture supernatant derived from the NS47 cell line. The culture
media used to culture the XS106 cells was supplemented with 0.5 ng/ml mouse
recombinant GM-CSF (R&D Systems) and 5% culture supernatant derived from the
NS47 cell line. All cell lines were cultured at 37°C in 5% CCVair atmosphere.
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2.6.2 Passage and storage of cell lines
Upon receipt of the cell lines, cells were cultured and passaged 4 times to obtain a
large batch culture. Cells were then removed from the culture vessels using cell
dissociation solution (1% EDTA; Sigma). Cells were then washed in cRPMI and
resuspended at 2xl05 cells/ml of freezing media {10% dimethyl sulphoxide (Sigma)
and 90% heat-activated fetal calf serum (Invitrogen)}and stored in a Nalgene
cryogenic freezing container (Nalgene, Hertford, UK) at -80°C for 24 hrs. Aliquots
were then stored in liquid nitrogen until required. For each experiment a new vial of
cells was revived and seeded at the density appropriate for the culture vessel being
used (Table 2.1). Cells were grown for 10 days in culture prior to use in
experiments. All cells were grown and passaged in the same manner to ensure
homogeneity between cell populations in individual experiments.
Table 2.1 Seeding density of cell lines
Cell Culture Vessel Volume of Media (mis) Number of Cells
24 well plate 1 ml per well 5xl05
25 cm2 flasks 5 mis 6xl05
75 cm2 flasks (NS47 cells) 10 mis 3xl05
2.6.3 Cell viability and metabolic activity assay
Aliquots of cells were diluted 1/10 in trypan blue solution (Sigma). Viable cells
were identified by the exclusion of trypan blue and viable cell numbers determined
using a heamocytometer. The metabolic activity of cell lines was also determined by
76
the colorimetric AlamarBlue™ assay (Serotec) as per manufactures instructions.
The AlamarBlue system contains an oxidation-reduction (REDOX) indicator that
changes colour in response to the chemical reduction of growth medium resulting
from cellular metabolic activity. Colour change was measured by absorbance at 570
nm and 600 nm using a V-max kinetic microplate reader (Molecular devices).
2.7 Characterisation of cell lines
2.7.1 Flow cytometry analysis
Cells were harvested and viable cell numbers determined by trypan blue exclusion
(section 2.6.3). Cells were centrifuged at 1,400 rpm 4°C for 10 mins and resulting
pellets resuspended in FACS buffer (PBS pH 7.4 containing 0.1% BSA, 0.1%
sodium azide and 0.02% EDTA) to give lxlO6 cells per 100 pi of buffer. Cells were
blocked for 15 mins at room-temperature with 0.1 pg ofmouse monoclonal antibody
CT-17.2 (Caltag) which specifically reacts with CD16.2/CD32.2 allotypic variants of
the mouse FcyIII/II receptor. Cells were then incubated with one of the following
FITC-conjugated monoclonal antibodies specific for either: CD40 (clone 3/23),
CD80 (clone RMMP-1), CD86 (clone RMMP-2), MHC II-Ak (clone 14V. 18),
CD205 (clone NLDC-145) (all from Serotec), CDllc (clone HL3), CD54 (clone
3E2) (BD Biosciences) or 8H4 (PrP- Appendix 1; (Zanusso et al., 1998)) for 1 hour
at 4°C. Immunolabeling of 8H4 was carried out using goat anti-mouse FITC-
conjugated antibody for 45 mins at 4°C (Caltag). The appropriate FITC-conjugated
antibodies (Serotec) were used as non-specific Ig-isotype controls. All antibodies
were titrated prior to use to determine their saturation point. All samples were fixed
in 1% paraformaldehyde and flow cytometry conducted on a FACSCalibur™
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(Becton Dickinson, San Jose, CA, USA) and data analysed using CELLQuest™
(Becton Dickinson)
2.7.2 Reverse transcription polymerase chain reaction analysis of Prnp mRNA
expression
mRNA was isolated from cell lines using pMACS mRNA Isolation Kit (Miltenyi
Biotec Ltd, Bergisch Gladbach, Germany) as per the manufacturer's instructions.
cDNA was synthesised from 100 ng of mRNA. Briefly, lpl oligo (dT)i2-i8 primer
(25 pg: Life Technologies) and 12 pi DEPC-treated water was added to the mRNA
and incubated at 70°C for 10 mins. 4 pi 5X First strand buffer, 2 pi DTT (0.1M) and
lpl dNTP (lOmM) (Life Technologies) was then added and incubated at 42°C for 2
mins. Finally 1 pi of Superscript II (Life Technologies) was added and the mixture
incubated at 42°C for for 50 mins. The reaction was stopped by incubation at 70°C
for 15 mins. The expression ofPrnp was determined through PCR amplification of
the cDNA. The PCR mixture, (total volume 60.2 pi) contained; 5 pi 10X PCR
buffer, 1.5 pi 50 mM MgCl, 1 pi 10 mM dNTP mix (Life Technologies), 1 pi cDNA,
0.5 pi (lOOpmol/pl) each of specific primers, 0.2 pi Taq polymerase (Life
Technologies) and 50 pi sterile DNase and RNase free H20. The sequences of the
specific primers used were as follows;
Primer combination 1.
1.Prnp Fwd-5'- AGG TTA ACT GAA CCA TTT CAA CCG AGC-3':
2 Prnp Rev-5'- TCC CCC AGC CTA GAC CAC GAG A-3'
Primer combination 2
lPrnp Fwd-5'- AGG TTA ACT GAA CCA TTT CAA CCG AGC-3':
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3 Prnp Rev-5'- GCT TGT TCC ACT GAT TAT GG-3'
Sequence positions are taken from Entrez entry U29186 (Lee et al., 1998). Primer 1
anneals to position 10869-10890 in exon 2. Primer 2 anneals to position 29506-
29485 in the 3' untranslated region and primer 3 anneals to position 28990-28977 in
exon 3. Primers 1 and 2 are designed to generate a fragment of 1000 bp and primers
1 and 3 to generate a fragment of 400 bp.
Following a hot start at 94 °C for 3 mins an amplification cycle was carried out for
30 cycles at the following temperatures; 94 °C 30 sec, 63 °C 30 sec, 72 °C 60 sec on
a thermal cycler. A final extension period at 72 °C for 10 mins was included at the
end of the 30 cycles. PCR products were resolved by gel electrophoresis at 125V
through a 1.5% agarose gel containing 1 pg/ml ethidium bromide.
2.7.3 Reverse transcription polymerase chain reaction analysis of TLR-2 and
TLR-4 mRNA expression
mRNA was isolated from XS106 cells using the pMACS mRNA Isolation Kit
(Miltenyi Biotec, Germany) as per the manufacturer's instructions. cDNA was
synthesised from 100 ng of mRNA. Briefly, lpl oligo (dT)i2-i8 primer (25 pg: Life
Technologies) and 12 pi DEPC-treated water was added to the mRNA and incubated
at 70°C for 10 mins. 4 pi 5X First strand buffer, 2 pi DTT (0.1M) and lpl dNTP
(lOmM) (Life Technologies) was then added and incubated at 42°C for 2 mins.
Finally 1 pi of Superscript II (Life Technologies) was added and the mixture
incubated at 42°C for 50 mins. The reaction was stopped by incubation at 70°C for
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15 mins. The expression of TLR-2 and TLR-4 was determined through PCR
amplification of the cDNA. The PCR mixture, (total volume 60.2 pi) contained; 5 pi
10X PCR buffer, 1.5 pi 50 mM MgCl, 1 pi 10 mM dNTP mix (Life Technologies), 1
pi cDNA, 0.5 pi (100 pmol/pl) each of specific primers, 0.2 pi Taq polymerase (Life
Technologies) and 50 pi sterile DNase and RNase free H20. The sequences of the
specific primers used were as follows;
TLR-2 Fwd-5'- GTCTCTGCGACCTAGAAGTGGA-3'
TLR-2 Rev-5'- CGGAGGGAATAGAGGTGAAAGA-3'
TL- 4 Fwd-5'- GCAATGTCTCTGGCAGGTGTA-3'
TLR-4-Rev-5'- CAAGGGATAAGAACGCTGAGA-3'
Sequence positions for TLR-2 are taken from Entrez entry AF165189 (Lin et al.,
2000). The forward primer anneals to position 126-147 and the reverse primer
anneals to position 162-140. Sequence positions for TLR-4 are taken from Entrez
entry NM 021297 (Dissanayake et al., 2004). The forward primer anneals to
position 949-968 and the reverse primer anneals to position 1354-1334. Primers for
TLR-2 are designed to generate a fragment of 336 bp and primers fro TLR-4 are
designed to generate a fragment of 406 bp.
Following a hot start at 94 °C for 2.5 mins an amplification cycle was carried out for
32 cycles at the following temperatures; 94 °C 30 sec, 56 °C 30 sec, 72 °C 45 sec for
TLR-2. The optimum cycling conditions for TLR-4 were 95 °C 45 sec, 61 °C 45
sec, 72 °C for 45 sec, for 36 cycles. All reactions were carried out on a thermal
cycler and a final extension period at 72 °C for 10 mins was included at the end of
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the cycles. PCR products were resolved by gel electrophoresis at 125V through a
1.5% agarose gel containing 1 pg/ml ethidium bromide.
2.8 Analysis of cell lines after exposure to the scrapie agent
2.8.1 Preparation of brain homogenates for in vivo experiments
Brains used as inocula in cell culture experiments were removed aseptically from
terminally scrapie-affected C57BL/Dk mice. Age-matched, non-infected C57BL/Dk
mice were used as negative controls. Four whole brains were pooled from each
group and homogenised in a sterilised Griffith homogeniser in cRPMI (section 2.6.1)
to give a 10% (wt/vol) homogenate. Aliquots were stored at -80°C until required.
2.8.2 Exposure of cells to the scrapie agent and lipopolysaccaride
Sterile glass coverslips were placed into the wells of 24 well plate (Corning, Bucks,
UK) and cells were plated at lxlO5 cells per well. When cultures were confluent 10
pi of 10% brain homogenate (approximately 1 mg of brain homogenate) was added
to each well. Cells were then incubated for 16 hrs at 37°C in 5% CO2/ air
atmosphere. Residual homogenate was then removed by washing the cells with
cRPMI by pipetting and fresh media added. Cells were then maintained for, 24, 48,
72 or 96 hrs in culture with no further fresh media added. Where indicated cells
were also stimulated with 10 ng/ml of lipopolysaccharide (LPS serotype 055 :B5:
Sigma) one hour before exposure to the scrapie agent. Cells were maintained in
culture and treated in the same manner as stated above.
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2.8.3 Immunofluorescent confocal microscopy
XS106 cells were exposed to the scrapie agent as described in section 2.8.2 for the
times indicated. Cells were then washed and cytospin preparations prepared at a cell
density of approximately lxl 05 per slide. Cytospins were fixed in methanol at -20°C
for 20 mins and non-specific binding sites blocked with 3% BSA for 1 hour. Further
blocking of non-specific binding was achieved by addition 0.1 pg of mouse
monoclonal antibody CT-17.2 (Fcyll/III; Caltag). Avidin/biotin binding sites were
subsequently blocked with the avidin/biotin blocking kit (Vector Laboratories) as per
manufacture's instructions. PrP was detected using the PrP-specific mouse
monoclonal antibody 8H4 (Zanusso et al., 1998) (Appendix 1), followed by biotin
conjugated goat anti-mouse antibody (Jackson ImmunoResearch Laboratories).
Immunolabelling was carried out using Strepavidin Alexa 488 (Biosciences,
Cambridge, UK). Cell nuclei were distinguished using Dapi nucleic acid stain
(Biosciences).
2.8.4 Cell immunoblot detection of PrPSc
PVDF membranes (Biorad) were treated with 100% methanol and then soaked in
lysis buffer (0.5% deoxycholate, 0.5% Triton X-100, 150 mM NaCl, 150 mM Tris
HC1 pH 7.5). After exposure to the scrapie agent (section 2.8.2) for the allocated
time period coverslips were removed and placed cell-side down on PVDF
membranes (Biorad). Filter paper, which had been previously soaked in lysis buffer,
was used as a cassette for the transfer and a glass plate used to apply pressure. The
coverslips were removed and the membranes left to air dry for 1 hr. Blots were
stored at -20 °C prior to analysis.
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For detection of PrP, membranes were rehydrated in lysis buffer and treated with
proteinase-K (10 pg/ml in 0.1 M Tris-HCl pH 7.4) and then denatured with 3 M
guanidine isothiocyanate. To confirm the presence of PrPSc on membranes as
previously described (Bosque and Prusiner, 2000). After the above pre-treatments
membranes were probed with either PrP-specific mouse monoclonal antibody 8H4 or
7A12 (Zanusso et al., 1998) (Appendix 1), followed by horseradish peroxidase-
conjugated goat anti-mouse antibody (Jackson ImmunoResearch Laboratories).
Bound horseradish peroxidase activity was detected with Supersignal® West Dura
Extended Duration Substrate (Pierce). After exposure, membranes were stained with
0.5 pg/ml ethidium bromide and observed in UV light to confirm transfer of the cell
layer
2.8.5 Determination of scrapie infectivity in cell lysates
Cells were dislodged by a rubber policeman and cell suspensions collected. Viable
cell numbers were determined by trypan blue exclusion. Cells were washed twice in
HBSS. Cell pellets were resuspended in appropriate volume of sterile saline to give
2xl05 cells per 20 pi dose. Lysis of cells was achieved by 10 successive rapid
freeze-thaw cycles at the temperature of liquid nitrogen. Non-infected cells or cells
exposed to normal brain homogenate were used as reference controls. Samples were
stored at -80°C until use. Cell lysates were injected i.e. (20 pi) into groups of up to
12 C57BL/Dk indicator mice. The scrapie titre in each tissue was estimated from the




All data is presented as the mean ± S.E.M. The statistical significance of differences
in means between experimental groups was calculated using ANOVA one-way
analysis with Minitab software. A p-value < 0.05 was considered to be significantly
different.
Infectivity titres as determined by incubation period assay in indicator mice have a
standard deviation of ± 0.5 log i.e. ID5o/g, this margin of error was used as a
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After peripheral exposure, TSE infectivity and PrPSc usually accumulate in lymphoid
tissues prior to neuroinvasion. Studies in mice have shown that scrapie exposure
through scarified skin is an effective means of scrapie transmission. Following
inoculation via the skin a functional immune system is critical for the transmission of
the scrapie agent to the brain, as severe combined immunodeficiency mice are
refractory to infection. Until now, it has not been known whether scrapie infectivity
accumulated in the skin and the lymphoid tissues after inoculation via the skin. To
investigate this, mice were inoculated with the scrapie agent by skin scarification and
skin and lymphoid tissues were collected at various times after inoculation.
Infectivity titres in pooled tissues homogenates were then measured by incubation
period assay in groups of indicator mice. Data presented here demonstrates that
scrapie infectivity does not replicate in the skin following skin scarification but
instead accumulates and replicates in the draining lymph node (DLN). Trace levels
of infectivity were detected in the DLN after inoculation, which then steadily
increased from 7 days post-exposure, reaching plateau levels at approximately 42
days after inoculation. At 42 days after inoculation, infectivity had spread to the
non-draining lymph node and the spleen, most likely via the blood.
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3.2 Introduction
The involvement of the lymphoreticular tissues (LRT) in scrapie pathogenesis was
first demonstrated after subcutaneous inoculation of mice with the Chandler scrapie
strain (Eklund et al., 1967). Assays of various tissues at sequential time points after
inoculation with scrapie-affected brain homogenate demonstrated that infectivity was
first detectable in the spleen and peripheral lymph nodes 28 days after inoculation,
and accumulated to high levels within these tissues prior to detection within the
spinal cord or the brain (Eklund et al., 1967). Similarly, following intra-peritoneal or
oral transmission of the ME7 scrapie strain, infectivity accumulates in LRT before
spreading to the central nervous system (CNS) (Brown et al., 1999; Fraser, 1996;
Mabbott et al., 2000b). The accumulation of the scrapie agent in LRT is critical for
disease pathogenesis as survival time is significantly extended if the spleen is
removed before intra-peritoneal inoculation (Fraser and Dickinson, 1970; Fraser and
Dickinson, 1978).
The natural acquisition route of scrapie is unknown, however, studies of naturally
scrapie infected sheep have shown that PrPSc is first detected in the Peyer's patches
and gut-associated lymphoid tissues, prior to its detection within other lymphoid
tissues and the CNS (Andreoletti et al., 2000; Heggebo et al., 2002; Heggebo et al.,
2000; van Keulen et al., 1996). Thus, demonstrating the involvement of the LRT in
TSE pathogenesis in species other than rodents Subsequent studies, have
demonstrated the involvement of the LRT of vCJD patients (Hilton et al., 1998),
chronic wasting disease of deer and elk (Sigurdson et al., 1999) and transmissible
mink encephalopathy of mink (TME) (Hadlow et al., 1987). However, the LRT
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appears not to be involved in all TSE disease as BSE in cattle (Somerville et al.,
1997a) and sporadic CJD in humans (Hill et al., 1999) appear to be confined to the
nervous tissues. However PrPSc is detectable in the LRT of sCJD patients at the end
stage of the disease (Glatzel et al., 2003). Furthermore, PrPSc is detectable in the
LRT of rodents and sheep experimentally infected with BSE (Farquhar et al., 1996;
Foster et al., 2001). Thus, the involvement of the LRT appears to be strain and
species dependent (Farquhar et al., 1996; Foster et al., 2001; Hill et al., 1999;
Somerville et al., 1997a).
Studies in mice have shown that exposure to the scrapie agent through scarified skin
is an effective means of transmission (Taylor et al., 1996a). A functional immune
system is critical for the transmission of the scrapie agent from scarified skin to the
brain as severe combined immunodeficiency mice are refractory to infection via this
route (Taylor et al., 1996a). However, in their studies Taylor et al did not investigate
whether scrapie infectivity accumulated within the LRT after inoculation via the skin
(Taylor et al., 1996a). Determining the sequence of events following skin
scarification is important to the understanding of the immunobiology of scrapie
infection and will aid in the subsequent development of therapeutic strategies.
With these points in mind, experiments were undertaken to determine whether
scrapie infectivity accumulates in the LRT following inoculation via the skin and the
timing of targeting of infectivity to these tissues.
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3.3 Results
3.3.1 Inoculation of mice via skin scarification and tissue collection.
To determine whether scrapie infectivity accumulated within the skin and the LRT
following inoculation via skin scarification, C57BL/Dk mice were each inoculated
with a 1% dilution of brain homogenate from a terminally scrapie-affected mouse by
skin scarification of the right thigh (Chapter 2; section 2.4.2). At each of the times
indicated after inoculation, skin from the site of inoculation, draining right inguinal
lymph nodes (ILNs), non-draining left ILNs and the spleen were collected from 4
mice. As a control, a group of 12 mice was left to develop clinical scrapie. All these
mice succumbed to disease with a mean incubation period of 308 ± 4 days.
Infectivity titres in pooled tissue (n = 4) homogenates were determined by incubation
period assay by intra-cerebral injection into groups of up to nine C57BL/Dk indicator
mice (Chapter 2; section 2.4.5). Previous studies have suggested that the dose-
response curves used to estimate infectivity titres should be specific for the tissue
being assayed (Robinson et al., 1990). However, in this study infectivity titres were
estimated using a spleen dose-response curve (Chapter 2; section 2.4.5), as dose-
response curves were not available for ME7 scrapie infected skin and ILNs.
3.3.2 Scrapie infectivity in the skin at the site of challenge
As skin tissue had not been previously used in incubation period bioassay
experiments a homogenate of pooled sterile skin (n = 4) spiked with 24 pi of
terminally scrapie-affected brain homogenate was included as a control. All assay
mice inoculated with spike skin homogenate developed clinical signs of scrapie at
approximately 198 ± 6 days post-inoculation (dpi), representing an approximate
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scrapie infectivity titre of 6.5 log i.e. 50% infectious dose (ID50)/g (Table 3.1; Fig
3.1). In contrast, only low levels of infectivity were detected in the skin at 30 mins
after inoculation (Table 3.1; Fig 3.1). The majority of assay mice developed clinical
scrapie at approximately 251 ± 3 dpi, suggesting an infectivity titre of approximately
4.0 log i.e. ID50/g (Table 3.1; Fig 3.1). Similarly, at 24 hrs after inoculation all assay
mice developed clinical scrapie at approximately 238 ± 6 dpi, suggesting an
infectivity titre of approximately 4.5 log i.e. ID5o/g (Table 3.1; Fig 3.1. At 7 days
after inoculation only trace levels of infectivity were detected in the skin, as only 2/6
assay mice developed clinical signs of scrapie at 257 ± 5 dpi, suggesting an
infectivity titre of approximately < 3.9 log i.e. ID50/g (Table 3.1; Fig 3.1).
3.3.3 Accumulation of scrapie infectivity within the draining inguinal lymph
node
Scrapie infectivity was undetectable in the right ILN 30 mins after inoculation (Table
3.2; Fig 3.1). All assay mice remained free from the signs of clinical scrapie
infection up to 282 dpi, suggesting an infectivity titre if present, below < 3.7 log i.e.
ID50/g (Table 3.2; Fig 3.1). However, by 24 hrs after inoculation trace levels of
infectivity were detected as 1/5 assay mice developed clinical disease (Table 3.2; Fig
3.1). At 7 days after inoculation the infectivity titre had risen to approximately 4.2
log i.e. ID5o/g (Table 3.2; Fig 3.1). By 21 days after inoculation the level of
infectivity in the right ILN had increased to 5.5 log i.e. ID50/g, which was
significantly greater than the level measured at 7 days after inoculation as determined
by statistical analysis of disease incubation periods for each group of indicator mice
(P = 0.001). By 42 days after inoculation the level of infectivity in the right ILN had
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Table 3.1- Scrapie infectivity in pooled samples (n = 4) of skin tissue taken
from the site of inoculation.
Time Incidence3 Mean incubation period Titreb
post-inoculation (days) ± S.E.M
Spikec 6/6 198 ±6 6.5
30 mins 7/7 251 ±3, 4.0
24 hrs 8/8 238 ± 6, 4.5
7 days 2/6 257 ± 5, 4X > 308 <3.9
a; Incidence = number of animals affected/number of animals tested. The
notation "N X > 308" means the mice were free of the signs of scrapie up to
at least this time after inoculation.
b; Scrapie infectivity titres expressed as log i.e. 50% infectious dose units/g
tissue.
c: 24 pi of terminally scrapie-affected brain homogenate was added to a
pooled (n = 4) thigh skin homogenate from un-inoculated mice.
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Time post-inoculation
Figure 3.1- Scrapie infectivity titres in pooled samples (n = 4) of skin (blue) at the
site of challenge, draining right inguinal lymph nodes (green), left non-draining
inguinal lymph nodes (yellow) and spleens (red) at various times after inoculation
with the scrapie agent via skin scarification. Closed circles represent groups of assay
mice in which the majority of assay mice succumb to scrapie infection. Hatched
circles represent groups of assay mice where approximately half of the mice
succumb to scrapie infection and open circles represent groups of assay mice in
which less than half or no mice succumb to scrapie infection. • starting titre of the
original terminally scrapie-affected brain homogenate used to inoculate mice via the
skin. Scrapie titres expressed as log i.c 50% infectious dose units/ gram tissue
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Table 3.2- Scrapie infectivity in pooled samples (n = 4) of right inguinal lymph
nodes draining the site of inoculation.
Time
post-inoculation
Incidence3 Mean incubation period
(days) ± S.E.M
Titreb
30 mins 0/7 7X > 308 <3.7
24 hrs 1/5 251, 4X >308 <3.9
7 days 7/8 255 ±3, 1X > 308 4.2
21 days 6/6 218 + 5 5.5
42 days 9/9 197 ±2 7.4
a: Incidence = number of animals affected/number of animals tested. The
notation "N X > 308" means the mice were free of the signs of scrapie up to
at least this time after inoculation.
b: Scrapie infectivity titres expressed as log i.e. 50% infectious dose units/g
tissue.
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increased a further 100 fold to 7.4 log i.e. ID5o/g (Table 3.2; Fig 3.1), which was
significantly higher than the level measured at 21 days after inoculation (P = 0.001).
3.3.4 Accumulation of scrapie infectivity within the non draining inguinal lymph
node
In contrast to the right ILN, trace levels of scrapie infectivity were detectable within
the left ILN 30 mins after inoculation however, only 1/9 assay mice developed
clinical scrapie (Table 3.3; Fig 3.1). At 24 hrs, 7 days and 21 days after inoculation
all assay mice remained free from the signs of the disease up to 282 dpi, suggesting a
scrapie infectivity titre if present below < 3.7 log i.e. ID5o/g (Table 3.3; Fig 31.). By
42 days after inoculation, detectable levels of infectivity were present all assay mice,
which developed clinical disease at approximately 248 ± 7 dpi, suggesting an
infectivity titre of 4.5 log i.e. IDso/g (Table 3.3; Fig 3.1).
3.3.5 Accumulation of scrapie infectivity within the spleen
Spleens were analysed from 42-100 days after inoculation. Experiments
demonstrated that low levels of scrapie infectivity (approximately 4.1- 4.6 log i.e.
ID50/g) were detectable in the spleen between days 42-50 after inoculation (Table
3.4; Fig 3.1). Significantly higher levels of infectivity were detected by 63 days after
inoculation (6.0 log i.e. ID50/g; P = 0.001). Furthermore, the levels of infectivity in
the spleen had reached plateau levels by 63 days after inoculation (Table 3.4; Fig
3.1), as no significant difference in infectivity levels in the spleens taken from mice
between 77-100 days after inoculation was observed (range 5.9 -6.5 log i.e. ID5o/g)
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when compared to levels in spleens taken at 63 days after inoculation (P = 0.870 and
P = 0.206 respectively; Table 3.4; Fig 3.1).
Table 3.3- Scrapie infectivity in pooled samples (n = 4) of non-draining left
inguinal lymph nodes at serial time points.
Time
post-inoculation
Incidence3 Mean incubation period
(days) ± S.E.M
Titreb
30 mins 1/9 271, 8X> 308 <3.8
24 hrs 0/9 9X >308 <3.7
7 days 0/9 9X > 308 <3.7
21 days 0/6 6X > 308 <3.7
42 days 9/9 248 ± 7, 4.5
a: Incidence = number of animals affected/number of animals tested. The
notation "N X > 308" means the mice were free of the signs of scrapie up to
at least this time after inoculation.
b: Scrapie infectivity titres expressed as log i.e. 50% infectious dose units/g
tissue.
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Table 3.4- Scrapie infectivity in pooled spleen samples (n = 4).
Time Incidence3 Mean incubation period Titreb
post-inoculation (days) ± S.E.M
42 days 7/8 235 ±3, 1X > 308 4.6
50 days 8/8 246 ±7 4.1
63 days 8/8 208 ±5 6.0
77 days 7/7 210 ± 8 5.9
100 days 7/9 198 ±5, 2X > 308 6.5
a; Incidence = number of animals affected/number of animals tested. The
notation "N X > 308" means the mice were free of the signs of scrapie up to
at least this time after inoculation.




To determine the time course and targeting of scrapie infectivity following
inoculation via the skin, skin at the site of inoculation, right draining ILNs, left non
draining ILNs and spleens were collected at various times after inoculation and
infectivity titres estimated by incubation period assays in indicator mice. Data
presented in this chapter demonstrates that only trace levels of scrapie infectivity
were present in the skin between 24 hrs - 7 days after inoculation. However, scrapie
infectivity did first accumulate in the draining ILN where it accumulates to high
levels prior to targeting the non-draining ILN and the spleen at approximately 42
days after inoculation.
Previous studies have shown that both keratinocytes and Langerhans cells which
reside within the epidermal layers of the skin express the host protein PrPc (Pammer
and Tschachler, 2002; Pammer et al., 1998; Sugaya et al., 2002). Thus, these cell
types might be the first cellular targets for TSE replication following exposure via
the skin. It was important to establish whether scrapie infectivity replicated within
the skin after inoculation, as this could have possible implications with regard to the
spread of infectivity iatrogenically, as many medical procedure breach the skin
barrier. Furthermore, shedding of infected skin by animals could lead to possible
environmental contamination and subsequent spread of infection. Data presented in
this chapter demonstrates that low levels of scrapie infectivity are detectable within
the skin at 30 mins and 24 hrs after inoculation, and only trace levels of infectivity
are detectable in the skin at 7 days after inoculation. This demonstrates that scrapie
infectivity does not replicate in the skin following inoculation via skin scarification.
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These data are in agreement with the hypothesis that PrPc expression alone is not the
only cellular requirement for the replication of the scrapie agent (Montrasio et al.,
2001; Raeber et al., 1999a). It is possible that the decline in scrapie infectivity
within the skin over the 7 day observation period will be due to shedding of
infectivity from the skin in association with dead skin cells. However, data presented
here suggests it is also probable that some infectivity is transported from the skin to
the draining ILN as the decline in scrapie infectivity within the skin corresponds with
the subsequent increase in scrapie infectivity within the draining ILN.
Antigens are normally transported out of the epidermis to the draining lymph node
within the first 24 hours of exposure (Kimber et al., 1999; Lappin et al., 1996;
Silberberg-Sinakin et al., 1976). Following intra-ocular challenge with scrapie strain
ME7, infectivity is detectable within the draining lymph nodes 24 hrs after
inoculation (Fraser, 1996). In contrast, in this study only trace levels of scrapie
infectivity were detectable within the draining ILN at 24 hrs after inoculation and did
not increase to measurable levels until 7 days after inoculation. However, following
peripheral challenge the time course of accumulation of scrapie infectivity within the
draining lymph node varies with route challenge and strain of agent administered
(Eklund et al., 1967; Farquhar et al., 1994; Fraser, 1996; Kimberlin and Walker,
1989b). For example: following either intra-peritoneal or subcutaneous challenge
with either the 139A or Chandler scrapie strains experiments have shown that scrapie
infectivity is not detectable within the draining lymph nodes until 21 days after
inoculations (Eklund et al., 1967; Kimberlin and Walker, 1989b). Thus, following
inoculation via skin scarification accumulation of detectable levels of infectivity
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within the draining ILN is slower than that observed following intra-ocular
inoculation (Fraser, 1996) but faster than that observed following either intra-
peritoneal(Kimberlin and Walker, 1989a) or subcutaneous challenge (Eklund et al.,
1967)
Previous studies have traditionally pooled both the right and left draining lymph
nodes for determination of scrapie infectivity titres. Therefore, in these studies it was
not possible to determine which lymph node was targeted first following inoculation
(Eklund et al., 1967; Farquhar et al., 1994; Fraser, 1996; Kimberlin and Walker,
1989b). In this study, right and left lymph nodes were pooled separately to allow the
targeting of scrapie infectivity to individual lymph nodes after inoculation to be
determined. Data presented here demonstrate that scrapie infectivity firsts targets the
draining lymph node prior to targeting the non-draining lymph node following
inoculation by skin scarification. Furthermore, similar levels of scrapie infectivity
are detected within the left ILN and spleen at 42 days after inoculation. As the left
ILN and the spleen are anatomically distinct this suggests that infectivity might be
spread heamogenously from the draining ILN. Taken together, these data show that
the draining ILN has a significant contribution to the initial accumulation of scrapie
infectivity following transmission via the skin. Comparable targeting has been
reported in goats and mink following subcutaneous challenge (Hadlow et al., 1974;
Hadlow et al., 1987). Following subcutaneous inoculation of goats with the scrapie
agent infectivity is first detected primarily within the lymph node draining the site of
inoculation (Hadlow et al., 1974). Following challenge ofmink with the TME agent
the peripheral replication of infectivity is confined to the lymph node draining the
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site of challenge and infectivity is only detectable within other lymphoid tissues after
infection has spread to the CNS (Hadlow et al., 1987).
Following intra-peritoneal challenge with the ME7 scrapie strain, scrapie infectivity
is detectable within the spleen 35 days after inoculation and reaches plateau levels by
70 days after inoculation (Brown et al., 1999; Fraser, 1996; Mabbott et al., 2000b)
Similar targeting and accumulation of scrapie infectivity in the spleen is observed
following skin scarification. Data presented here demonstrates that scrapie
infectivity is detectable within the spleen at 42 days after inoculation via the skin and
plateaus at approximately 63 days after inoculation. The importance of the spleen
for the accumulation of scrapie infectivity following peripheral challenge has been
demonstrated by splenectomy and genetic asplenia of rodent models either prior to or
shortly after challenge (Clarke and Haig, 1971; Fraser and Dickinson, 1970; Fraser
and Dickinson, 1978). Splenectomy or genetic asplenia of scrapie infected rodent
models significantly extends survival time (Clarke and Haig, 1971; Fraser and
Dickinson, 1970; Fraser and Dickinson, 1978). However, the presence of the spleen
is not obligate to establishing scrapie infection as splenectomy of rodent models does
not affect disease susceptibility, suggesting that other tissues are able to sustain
accumulation of the scrapie agent in the absence of the spleen. Furthermore,
splenectomy of mice either shortly before or after subcutaneous inoculation with the
scrapie agent has no affect on the disease incubation period (Fraser et al., 1992;
Kimberlin and Walker, 1989a). In this study scrapie infectivity accumulated to high
levels within the draining ILN prior to its detection within the spleen, suggesting that
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the spleen is likewise unlikely to play an important role in the accumulation of the
agent following inoculation via the skin.
Data presented here demonstrates that scrapie infectivity does not replicate in the
skin following skin scarification but first accumulates in the draining ILN between
24 hrs and 7 days after inoculation. Scrapie infectivity accumulates to high levels
within the draining ILN prior to spreading to other lymphoid tissues. These data also
suggest that scrapie infectivity is transported from the draining ILN to other
lymphoid tissues via the blood due to the similar time course of targeting of
infectivity to the left ILN and spleen after inoculation. Furthermore, the spleen is
unlikely to play a critical role in scrapie pathogenesis after inoculation via the skin as
scrapie infectivity was not detected within the spleen until 42 days after inoculation,
a time point at which infectivity had already accumulated to high levels within the
draining ILN. In conclusion, high levels of scrapie infectivity accumulate in
lymphoid tissues during the first few weeks after inoculation by skin scarification.
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Accumulation of the scrapie agent in lymphoid tissues after
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Previous studies in this thesis (Chapter 3) have shown that following inoculation via
the skin, scrapie infectivity accumulates within lymphoid tissues. Furthermore,
studies by others have suggested that this accumulation within lymphoid tissues is
critical for the transmission of the scrapie agent to the brain, as severe combined
immunodeficiency mice are refractory to infection. Until now, it was not known
which components of the immune system are required for efficient neuroinvasion of
the scrapie agent after skin scarification. A chimeric mouse model was utilised
which had a mismatch in PrP status between FDCs and other bone-marrow derived
cells. This mouse model was produced by grafting of SCID/Prnp+/+ mice with either
PrP expressing (Prnp+/+) or PrP deficient (Prnp") bone-marrow from
immunocompetent mice. The resulting mismatch in PrP status between cell
populations allowed for the identification of the cell population that was critical for
the accumulation of the scrapie agent within lymphoid tissues. Here it is
demonstrated that mature follicular dendritic cells are essential for the accumulation
of PrPSc and infectivity within lymphoid tissues and the subsequent transmission of
the scrapie agent to the brain. Furthermore, the accumulation of PrPSc and infectivity




In many TSE diseases, following peripheral inoculation, high levels of infectivity
and PrPSc usually accumulate in lymphoid tissues prior to the dissemination of
infection to the central nervous system (CNS). Within the lymphoid tissues of TSE
infected hosts, disease-specific PrP accumulation initially takes place within
germinal centres in association with follicular dendritic cells (FDCs) (Hill et al.,
1999; Jeffrey et ah, 2000b; Mabbott et ah, 2000b; McBride et ah, 1992; Sigurdson et
ah, 1999; van Keulen et ah, 1996). Studies in rodents inoculated intra-peritoneally
with the scrapie agent have shown that mature FDCs are critical for accumulation of
the scrapie agent in lymphoid tissues (Brown et ah, 1999; Fraser et ah, 1996;
Mabbott et ah, 2000a; Mabbott et ah, 2002; Mabbott et ah, 2000b). Furthermore, in
the absence of mature FDCs, the spread of disease to the central nervous system
(CNS) is significantly impaired (Brown et ah, 1999; Fraser et ah, 1996; Klein et ah,
1998; Mabbott et ah, 2000a; Mabbott et ah, 2002; Mabbott et ah, 2000b; Montrasio
et ah, 2000; Prinz et ah, 2002).
Previous studies in this thesis have shown that following inoculation via the skin,
scrapie infectivity accumulates within lymphoid tissues (Chapter 3). Taylor et al
(1996) also suggested that a functional immune system is critical for the
translocation of the scrapie agent to the CNS following skin scarification, as severe
combined immunodeficiency (SCID) mice, which lack functional T-lymphocytes, B-
lymphocytes and mature FDC networks, are refractory to scrapie infection by this
route of inoculation (Taylor et ah, 1996a). These studies also demonstrated that after
skin scarification, neuroinvasion does not occur from the skin via direct
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haematogenous spread or by direct uptake by peripheral nerves. The components of
the immune system that are required for efficient neuroinvasion by this route are not
known. However candidate cells within the lymphoid tissues include FDCs, which
are critical for the efficient transmission of the disease to the CNS following other
peripheral routes of inoculation (Brown et al., 1999; Fraser et ah, 1996; Klein et ah,
1998; Mabbott et ah, 2000a; Mabbott et ah, 2002; Mabbott et ah, 2000b; Montrasio
et ah, 2000; Prinz et ah, 2002).
To maintain TSE infection, host cells must express the cellular isomer of the host
• C* /
prion protein, as mice deficient in PrP (Pmp~' mice) do not develop disease (Bueler
et ah, 1993; Manson et ah, 1994a). Thus, in order to determine which cells are
critical for the efficient transmission of the scrapie agent to the CNS after inoculation
via the skin, a chimeric mouse model was used that had a mismatch in PrPc status
between FDCs and other bone-marrow derived cells within lymphatic tissues (Brown
et ah, 1999). These chimeric mice were inoculated with the scrapie agent by skin
scarification to allow the separate roles of FDCs and lymphocytes in peripheral
scrapie pathogenesis to be determined.
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4.3 Results
4.3.1 Bone-marrow reconstitution of SCIDIPrnp+/* mice restores scrapie
susceptibility after inoculation by skin scarification
To test the hypothesis that mature FDCs are critical for the translocation of the
scrapie agent to the CNS after skin scarification, a chimeric mouse model was used
which had a mismatch in PrP status between its FDCs and lymphocyte populations
(Brown et al., 1999). The mouse models were produced by grafting SCID/Prnp+/+
mice with either PrP expressing (Prnp+/+) or PrP-deficient (Prnp'~) bone-marrow
(BM) from immunocompetent 129/Ola mice (Chapter 2; section 2.3.1). As FDCs (in
contrast to lymphocytes) are not considered to be derived from BM in adult mice
(Kaspasi et al., 1998; Tkachuk et ah, 1998), the lymphoid tissues of SCID/Prnp+/+
mice grafted with Prnp' BM (SCID/Prnp+/+ + Prnp'' BM) have PrP expressing
FDCs and other stromal derived cells, but lack PrP expression on lymphocytes. In
contrast SCID/Prnp+/+ mice grafted with Prnp+/+ BM (SCID/Prnp+/+ + Prnp+/+ BM)
contain both PrP expressing FDCs and lymphocytes.
Twenty-eight days after BM grafting, wild-type 129/Ola mice, SCJD/Prnp+/+ mice,
SCID/Prnp+/+ + Prnp+/+ BM mice and SC\D/Prnp+/+ + Prnp'' BM mice were
inoculated with the ME7 scrapie strain by skin scarification. All immunocompetent
wild-type 129/Ola mice developed clinical signs of scrapie approximately 333 ± 13
days post-inoculation (n = 12; Fig. 4.1). Characteristic disease-specific PrP
accumulation (Fig. 4.2, panel a), spongiform pathology (Fig.4.2, panel e) and
pathological targeting of vacuolation (Fig. 4.3) typical of a peripheral infection with
the ME7 scrapie strain was detected in the brains of all wild-type mice which
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Figure 4.1- Reconstitution of SCID/Prnp+/+ mice with immunocompetent BM
restores susceptibility to scrapie when inoculated by skin scarification. Wild-type
(WT) mice (|), SCID/Prnp+ + mice, SCID/Prnp+/+ mice reconstituted with Prnp+/+
BM (i
Prnp
strain by skin scarification (scarif.)
|; SCID/Prnp+/+ + Prnp+/+ BM) and SCID/Prnp+/+ mice reconstituted with
BM (□; SCID!Prnp+/+ + Prnp''' BM) were inoculated with the ME7 scrapie
Wild-type mice were also inoculated by i.e.
injection as a titre control (j:|::;; WT i.c). Each bar represents the mean incubation
period ± S.E.M. (o) Incubation periods for individual mice that succumbed to
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_ SCID/Prnp+/*+ Prnp"'" BM
Scrapie strain 79A
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Scoring Area Of Brain
SCORING AREA Anatomical Location in the Brain
G1 Medulla







G9 Secondary motor and cinqulate cortex
W1* Inferior and middle cerebellar peduncles
W2* Decoction of superior cerebella peduncles
W3* Cerebral peduncles
Figure 4.3- Reconstitution of SCID//V/;/?+/+ mice with immunocompetent bone
marrow (BM) does not significantly affect the pathological targeting of vacuolation
in the brain when compared to the vacuolation observed in scrapie challenged wild-
type mice. Wild-type mice (black trace), SCID/Prnp+/Jr + Prnp+'+ BM mice (blue
trace) and SCID/Prnp+,+ + Prnp7 BM mice (green trace) were inoculated with ME7
scrapie strain by skin scarification. Each point represents the mean vacuolation score
± S.E.M. for each experimental group of mice within a particular scoring area of the
brain. The lesion profile of C57BL mice inoculated with scrapie strain 79A is shown
for comparison (orange trace).
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developed clinical disease. In contrast, previous studies have shown that SCID mice
are refractory to challenge with the ME7 scrapie strain by skin scarification up to 586
days post-inoculation (Taylor et al., 1996a). Unfortunately, despite careful
husbandry, all ungrafted immunodeficient SCID/Prnp+,+ mice in this study
succumbed to non-TSE diseases up to 274 days post-inoculation (Fig. 4.1).
Immunohistochemical analysis of brain tissue from all SCID/Prnp+/+ mice
inoculated with the scrapie agent failed to detect any signs of disease-specific PrP
accumulation (Fig. 4.2, panel b) or spongiform pathology (Fig. 4.2, panel f)
consistent with the hypothesis that these mice are refractory to scrapie infection
following peripheral inoculation. However, the susceptibility ofmost SCID/Prnp+/+
mice to scrapie infection was restored after grafting with, Prnp+/+ or Prnp BM (Fig.
4.1). Here 6/11 SCID/Prnp+/+ mice grafted with Prnp+/+ BM developed scrapie with
a mean incubation period of 380 ± 12 days post-inoculation. Likewise 8/10
SCID/Prnp+/+ mice grafted with Prnp' BM developed scrapie with a mean
incubation period of 378 ± 4 days post-inoculation. Characteristic spongiform
pathology (Fig. 4.2, panels g and h respectively) and disease-specific PrP
accumulation (Fig. 4.2, panels c and d respectively) was detected in the brains of all
grafted SCIDIPrnp+/+ mice that succumbed to clinical disease.
No significant difference was observed between the mean disease incubation periods
of SCID/Prnp+/+ mice grafted with either Prnp+/+ or Prnp'' BM. However, a
significant statistical difference was observed between the mean incubation periods
of SCID/Prnp+/+ mice grafted with either Prnp+/+ BM or Prnp' ' BM when compared
to wild-type mice (P = 0.014 and P = 0.004 respectively). Grafted SCID!Prnp+/+
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mice developed clinical scrapie approximately 47 days later than the mean
incubation period of immunocompetent wild-type controls (Fig. 4.1). However, no
significant difference in the pathological targeting of vacuolation in the brain was
observed between wild-type and grafted $>C\D/Prnp+/+ mice (Fig. 4.3) suggesting
neuroinvasion had occurred via a common pathway in each case.
4.3.2 Confirmation of immune status and germinal centre architecture
Spleens and sera were taken from all mice to monitor immune status. Consistent
with the absence ofmature B-lymphocytes in SCID mice (Bosma et al., 1983; Kapasi
et ah, 1993), serum from all ungrafted SCID/Prnp+/+ mice contained undetectable
levels of immunoglobulin (Ig) (mean OD 490 nm = 0.05 ; approximately <10 ng/ml;
Fig 4.4) when compared with those of wild-type mice (mean OD 490 nm = 1.78
;approximately > lmg/ml; Fig 4.4). Therefore there is at least a 1000 fold difference
in Ig content between these two groups. However, ELISA analysis confirmed that
reconstitution of SCID/Prnp+/+ mice with immunocompetent BM from either
Prnp+/+ or Prnpmice restored serum Ig levels to those observed in wild-type mice
(mean OD 490 nm =1.81 and 1.68 respectively; approximately >lmg/ml; Fig 4.4).
Thus functional BM derived B-lymphocytes had been successfully grafted into
recipient SCIDIPrnp+/+ mice.
Next the Prnp genotype in the spleens of grafted mice was determined by PCR
analysis of total splenic DNA (Fig. 4.5). Analysis ofDNA from SCID/Prnp+/+ mice
grafted with Prnp+/+ BM detected the presence of only the Prnp gene by the





















Figure 4.4- Reconstitution of SCID/Pmp+ + mice with immunocompentent bone
marrow restores serum immunoglobulin levels. Serum samples from wild-type
(WT) (O), SCIDIPrnp+/+ mice reconstituted with Prnp+/+ bone marrow
(SCID/Prnp+/+ + Prnp'n BM) (O), SCID/Pr«p+/+ mice reconstituted with Prnp1'
bone marrow (SClT)IPrnp+/+ + Prnp' BM) (O) and SCID/Prnp+/+ mice ((>) were
diluted 1/1000 and total immunoglobulin levels determined by ELISA. Samples
were assayed in duplicate and each circle represents the mean optical density
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Figure 4.5- Confirmation of the Prnp genotype in the spleens of terminally scrapie
affected, (a) SCID//V«p+/+ mice reconstituted with Prnp+ + bone marrow
(SCID/TV///?'* + Prnp+I+ BM) and (b) SClD/Prnp+,+ mice reconstituted with Prnp'1'
bone marrow (SCID/Prnp+I+ + Prnp' ' BM), was determined by PCR analysis of total
splenic DNA. All products were resolved through gel electrophoresis containing
ethidium bromide, (a) PCR analysis ofDNA from SCID/Prnp+I+ mice + Prnp+I+ BM
confirmed the presence of the Prnp gene by the visualisation of a single band at 750
bp (Lanes 1-4). (b)The visualisation of two bands at 750 bp and 550 bp (Lanes 1, 2,
4-7) confirmed the presence of both Prnp gene and a portion of the neomycin gene
respectively within DNA from SCID/Prnp+,+ mice + Prnp'1' BM. (c) Determination
of Prnp genotype of grafted SCID/7V«/?+ + mice, which remained free from the signs
of scrapie 521 days post-inoculation. Lane M, 100 bp molecular size marker.
Controls included Cl = Splenic DNA from a SCIDIPrnp^1* + Prnp'1' BM mouse, C2=
Splenic DNA from wild-type/.P/77/?+/+ mouse and C3= Splenic DNA from a Prnp''
deficient mouse. (W) PCR amplified water was used as a negative control.
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were detected in splenic DNA samples from SCID/Prnp+/+ mice grafted with Prnp''
BM, demonstrating the presence of both the Pmp gene (750 bp) and the neomycin
resistance gene (550 bp) (Fig. 4.5 b, lanes 1-2, 4-7). Thus, these results confirmed
the presence of only Prnp+/+ cells within the spleens of SCID/FV«/?+/+ + Prnp+,+ BM
mice, and the presence of both Prnp+/+ and Prnp' cells within the spleens of
SCID//Vh/?+ + + Prnp' ' BM mice.
Germinal centre architecture in the spleen was analysed by immunohistochemistry.
As expected, FDC-M2 and CD35 expressing FDC networks and B-lymphocytes
(CD45R/B220) were detected in the spleens of all immunocompetent wild-type mice
(Fig. 4.6, panels a, e and i respectively). In contrast, both FDC networks and B-
lymphocytes were absent in spleens of ungraded SCID/Prnp+/+ mice (Fig. 4.6, panels
b, f and j respectively), consistent with the previously described immunodeficent
phenotype of SCID mice (Bosma et al., 1983; Kapasi et ah, 1993). However, FDC
networks and B-lymphocytes were restored in spleens of SCID/Prnp+/+ mice after
grafting with either Prnp+/+ or Prnp' ' BM (Fig. 4.6, panels c, g and k and Fig. 4.6,
panels d, h and 1 respectively). Thus, the restoration of germinal centre architecture
in the lymphoid tissues of SCID/Prnp+/+ mice after BM grafting coincided with the
restored susceptibility of these mice to scrapie infection.
4.3.3 Scrapie infectivity and PrPSc accumulation in the spleen
After skin scarification with the ME7 scrapie strain, high levels of infectivity
accumulate in the spleen within from 42 days post-inoculation and are maintained
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were taken from four mice from each experimental group of mice 220 days post-
inoculation. The scrapie infectivity titre in spleen lysates from each group was
estimated by bioassay in groups of up to 12 indicator mice. As expected, spleens
from wild-type mice inoculated with the scrapie agent contained high levels of
infectivity (approximately 5.7 log i.e. ID50/g). In contrast, scrapie infectivity was
undetectable in spleen samples from ungrafted SCTD/Prnp+ + mice assayed 220 days
post-inoculation suggesting a scrapie infectivity titre, if present, below 2.7 log i.e.
ID50/g (at least 1000 fold less than the level detected in spleens of wild-type mice
assayed at the same time post inoculation). Scrapie infectivity accumulation was
restored in the spleens of SCID/Prnp+/+ mice after grafting with either Prnp+/+ or
Prnp~ ~ BM to the same magnitude observed in wild type mice at the same time point
(approximately 6.7 and 5.7 log i.e. ID50/g, respectively).
Similarly, immunoblot analysis of spleen tissue from terminally scrapie-affected
wild-type mice detected large accumulations of detergent-insoluble proteinase-K
resistant PrPSc (Fig. 4.7 a, lane 2 and Fig. 4.7 b, lanes 2 and 4). A typical three-
banded pattern was observed between molecular mass values of 20-30 kDa,
representing the unglycosylated, monoglycosylated and diglycosylated isomers of
PrP (in order of increasing molecular mass). However, no PrPSc accumulation was
detectable within the spleens of any ungrafted SCIDIPrnp+/+ mice assayed at various
time points after inoculation (Fig. 4.7 a, lanes 4, 6 and 8). In comparison, PrPSc
accumulation was restored in the spleens ofterminally scrapie-affected SCIDIPrnp+/+
mice grafted with either Pmp+/+ or Prnp" BM to levels similar to those observed in
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Figure 4.7- Immunoblot analysis of spleen tissue from wild-tyj>e mice (WT),SCID/Prnp+ + mice, SCIDIPrnp+ + mice reconstituted with Prnp+ + bone marrow
(SCID!Prnp+/+ + Prnp+/+ BM) and SCID/Pmp' ' mice reconstituted with Prnp'
bone marrow (SCID/Prnp+ + + Prnp' BM) following skin scarification with scrapie
strain ME7. Samples were treated in the absence (-) or presence (+) of proteinase K
prior to electrophoresis, (a) High levels of PrPaccumulation were detected in the
spleens of terminally scrapie affected WT mice but none was detected in the tissues
SCIDIPrnp+/+ mice at any time point, (b) However, high levels of PrPs<" were
detected in spleens of SCID/Prnp+/+ mice grafted with either Prnp+/+ or Prnp " BM
(SCIDIPrnp+/+ + Prnp BM or SCID/Prnp+/+ + Prnp'' BM mice respectively)
Lane B is blank, pos., mice that developed clinical signs of scrapie; neg., mice that
were free from the signs of scrapie; dpi., days post-inoculation at which the tissues
were analysed.
117
4.3.4 Reconstituted SCID/Prnp+/+ mice which did not succumb to scrapie
infection
Although the grafting of most SCJD/Prnp+/+ mice with immunocompetent BM
restored susceptibility to scrapie, 5/11 SCID/Prnp+,++ Prnp+/+ BM mice and 2/10
SCID/Prnp+/+ + Prnp" BM mice remained free from the signs of scrapie up to 521
days post-inoculation, at which point the experiment was terminated (Fig. 4.1).
Immunohistochemical analysis of brain tissue from all surviving mice failed to detect
any spongiform change (Fig. 4.8, panels c and d) or PrPSL accumulation (Fig. 4.8,
panels a and b). Similarly no PrPSc was detected, by immunoblot analysis, in the
spleens from these surviving mice, taken 521 days post-inoculation (Fig. 4.9 lanes 4,
6 and 8). Taken together these data suggest these mice would have not developed
clinical scrapie at a later stage.
The immune status of all surviving mice was determined by measuring serum Ig
levels by ELISA and the presence of grafted cells in the spleen by PCR analysis.
The serum Ig levels of each of the five SCID/Prnp+/+ + Prnp+/+ BM mice (mean OD
490 nm = 1.81; approximately > lmg/ml; Fig 4.4) and the two SCIDIPrnp+ + + Prnp'
"BM mice (mean OD = 1.68; approximately > lmg/ml; Fig 4.4) were similar to the
serum Ig levels displayed by the wild-type mice, suggesting these mice had been
successfully grafted and functional B-lymphocytes were present. Next the Prnp
genotype in the spleens of the grafted surviving SCID/Pmp+/Jr was determined by
PCR analysis. PCR analysis of DNA from the five surviving SCID/Prnp+/+ +
Prnp+I+ BM mice confirmed the presence of the Prnp gene (750 bp) (Fig. 4.5 c, lanes
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Figure 4.8- Histological analysis of brain tissue from SCIDIPrnp+l+ mice
reconstituted with either Prnp+,+ BM (SCID/Prnp+,+ + Prnp" BM) (a and c) or Prnp'
BM (SCID/Prnp+I+ + Prnp'1' BM) (b and d) that remained free of the signs of
scrapie 521 days post-inoculation, (a and b) No PrP accumulations (brown) were
detected in the hippocampus. PrP was detected with the PrP-specific monoclonal
antiserum 6H4 and sections were counterstained with hematoxylin (blue), (c and d)
Adjacent sections were stained with hematoxylin and eosin (H&E) and no TSE-
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Figure 4.9- Immunoblot analysis of spleen tissue from terminally scrapie infected
wild-type mice (WT), SCJD/Prnp+ + mice reconstituted with either Prnp+/+ BM
(SCIDAPra/?+/+ + Prnp ' BM) or Prnp" BM (SCID//V/;// ' + Prnp' BM) which
remained free of signs of scrapie 521 days post-inoculation, following scarification
with scrapie strain ME7. Samples were treated in the presence (+) or absence (-) of
proteinase K (PK) prior to electrophoresis. PrPSt accumulation was detected within
the spleens of terminally scrapie affected WT mice, however no PrPSL accumulation
could be detected within the scrapie negative SCID/Prnp+/+ + Prnp+/+ BM mice or
SCID/Prnp+ + + Prnp' BM mice. Lane M contains a molecular size marker.
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neomycin resistance gene (550 bp) were detected within the spleens of the two
surviving SCID/Prnp+ + + PrnpBM mice (Fig. 4.5c, lanes 2 and 4), confirming that




Previous studies in mice have shown that skin scarification is an effective means of
scrapie transmission in immunocompetent mice (Taylor et ah, 1996a). However
highly immunodeficient SCID mice are refractory to scrapie infection following
inoculation via this route, suggesting that a functional immune system is critical to
the transmission of the scrapie agent to the CNS after inoculation via the skin
(Taylor et ah, 1996a). In this study it has been demonstrated that reconstitution of
SCJD/Prnp+/+ mice with immunocompetent BM restores scrapie susceptibility after
skin scarification. This effect also coincides with the restoration of mature FDC
networks within the spleens of grafted SCID//V«/?+ + mice. Furthermore it has been
shown that scrapie transmission to the CNS is independent of the PrP status of
lymphocytes and other BM derived cells. Taken together these findings are
consistent with previous studies, which have demonstrated that after peripheral
exposure with scrapie strain ME7, a functional immune system, and more critically
PrP-expressing FDCs, are required for transmission of the agent to the CNS (Brown
et ah, 1999; Farquhar et al., 1994; Kimberlin and Walker, 1979; Mabbott et ah,
2000a; Mabbott et ah, 2000b).
SCID mice suffer from a congenital syndrome that is characterized by the deficiency
of both B and T- lymphocyte immunity (Bosnia et ah, 1983). Secondary to this
defect they also lack functional FDCs as cytokine stimulation from B-lymphocytes is
important for the maturation and maintenance ofFDC networks (Kapasi et ah, 1993).
Unfortunately, despite careful husbandry, due to their dysfunctional immune system
all ME7 challenged SCID!Prnp+/+ mice in this study succumbed to non-TSE related
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diseases up to 274 days post-inoculation (Fig. 4.1). These diseases were non¬
infectious (e.g. thymic tumours) and were not a reflection of the microbiological
status of the husbandry conditions, which were maintained to a high standard of
hygiene. Previous data from this laboratory (Taylor et ah, 1996a) has shown that, in
contrast to wild-type mice, SCID mice did not succumb to clinical scrapie after
exposure to a similar dose of scrapie-affected brain homogenate via skin scarification
(mean survival period = 442 ± 21 days post-inoculation, n = 23, range = 259-586
days). After intra-peritoneal inoculation with ME7 scrapie strain, disease-specific
PrP is detected in the brain considerably before the onset of clinical signs (Farquhar
et ah, 1994). In this study no disease-specific PrP accumulation or vacuolation was
detected within the brains of SCID/Prnp+/+ mice (Fig. 4.2, panel b), supporting the
hypothesis that they would not have developed clinical scrapie. Furthermore, scrapie
infectivity was undetectable in the spleens of SCID/Prnp+/+ mice assayed 220 days
post-inoculation. Similarly immunoblot analysis of spleen tissue from SCID/Prnp+/+
mice confirmed that lymphoid tissues in these animals were incapable of supporting
the peripheral replication of the agent after skin scarification as no PrPSc
accumulation could be detected within their spleens (Fig. 4.7 a). Although unlikely,
these data does not exclude the possibility that the SC\D/Prnp+/+ mice in this study
might have gone on to develop scrapie via a lymphoid independent route. However
this would contradict studies by Taylor et al (Taylor et al., 1996a) which showed that
after skin scarification SCID mice remained free from the signs of scrapie. Although
it has been previously demonstrated that it is possible to transmit BSE by blood
transfusions in sheep (Houston et al., 2000; Hunter, 2003; Hunter and Houston,
2002), these data suggest that after skin scarification, infectivity is unable to reach
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the CNS directly via the blood stream or peripheral nerves within the skin, but
instead reaches it indirectly via the lymphoreticular tissues.
Engraftment of SCID/Prnp+,+ mice with immunocompetent BM restored functional
lymphocyte populations within the spleen. Furthermore, these lymphocytes were
functional as they produced immunoglobulins and were able to stimulate FDC
maturation and network formation (Bosma et al., 1983; Kapasi et al., 1993). The
development of germinal centre architecture comparable to immunocompetent
animals coincided with restored scrapie susceptibility and the accumulation of
infectivity and PrPSt in lymphoid tissues of these mice. Thus, these data demonstrate
that after inoculation through scarified skin the scrapie agent accumulates in
lymphoid tissues prior to neuroinvasion, as observed with other peripheral routes of
exposure (Brown et al., 1999; Fraser et al., 1996; Mabbott et al., 2000a; Mabbott et
al., 2002; Mabbott et al., 2000b).
The reconstitution of SCIDIPrnp+ + mice with either Prnp+/+ or Prnp' BM did not
result in any visible differences in the levels of PrPSt" accumulation within the spleen
or in the timing of the development of the neurological disease. These results are
consistent with the demonstration that PrP-expression on FDCs, and not
lymphocytes, is critical for the peripheral accumulation and subsequent
neuroinvasion of ME7 scrapie (Brown et al., 1999; Klein et al., 1998; Montrasio et
al., 2001). As PrP( expression is a pre-requisite for the transfer of TSE infection
from the periphery to the CNS (Bueler et al., 1993), the above results provide no
evidence for the direct involvement of BM derived cells such as B-lymphocytes in
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the replication and subsequent neuroinvasion of scrapie strain ME7. As
SCIDIPrnp+/+ mice were not y-irradiated prior to reconstitution a proportion of BM
derived cells such as dendritic cells and macrophages in grafted mice may be of host
origin (i.e. PrP expressing) and a proportion of recipient origin (PrP deficient). These
data suggests that the PrP status of BM derived cells such as dendritic cells, which
are a potential candidate transport mechanism of the agent to the lymphoid tissues
(Chapter 7) (Aucouturier et ah, 2001; Huang et ah, 2002) does not appear to be
critical to scrapie pathogenesis. This is consistent with previous findings by Brown
and colleagues, who using a chimeric mouse model equivalent to the one used in this
study, determined that after intra-peritoneal inoculation with scrapie strain ME7, PrP
expressing FDCs were critical for the replication of the scrapie agent in the spleen.
This replication was also independent of the PrP status of the lymphocytes and other
bone-marrow derived cells (Brown et al., 1999).
Interestingly, grafted SCID/FVtj/C + mice did display significantly longer incubation
periods in comparison to immunocompetent wild-type mice. Similar results have
also been observed in grafted SCID mice inoculated with scrapie strain C506M3 by
intra-peritoneal injection (Lasmezas et al., 1996). The reason for the delay in the
onset of the neurological disease in BM-grafted SCID/Prnp+ + mice is not known,
but it might be that at the time of inoculation the restoration of germinal centre
functionality in these mice was incomplete. This effect could have reduced the
number of potential peripheral target cells, such as FDCs, available for agent
replication at the time of inoculation. In the temporary absence of FDCs at the time
of inoculation both the replication of the scrapie agent in the spleen and its
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subsequent neuroinvasion are significantly delayed (Mabbott et al., 2000a). To
achieve efficient reconstitution it has been suggested that mice are sub-lethally y-
irradiated prior to cell transfer, to encourage full maturation of grafted bone-marrow
cells (Fulop and Phillips, 1986). This procedure was not undertaken in this study as
SCID mice have an increased sensitivity to y-irradiation due a general defect in their
DNA repair mechanisms which is believed to be closely linked to the scid mutation
(Fulop and Phillips, 1990). It was a concern that y-irradiation may have adverse
affects on the architecture of the skin, blood-brain barrier or nerve-brain barrier of
SCID mice, any of which may have facilitated neuroinvasion by an atypical
mechanism. Although neuroinvasion was delayed in the reconstituted SCID/FV«/?+/+
mice, no significant difference was observed in the severity or distribution of
vacuolation or disease-specific PrP accumulation within the brains of wild-type and
grafted SCIDIPmp+/+ mice, suggesting that neuroinvasion had occurred in these
mice via a common pathway.
Although the grafting of SCID/Prnp+/+ mice with immunocompetent BM restored
scrapie susceptibility in most cases, 5/11 SCIDIPrnp+/+ + Prnp+ + BM mice and 2/10
SCID/Prnp+/+ + Prnp ' BM mice remained free from the signs of scrapie 521 days
post-inoculation, at which point the experiment was terminated. ELISA and PCR
genotyping analysis suggested that reconstitution had been successful in these
surviving mice, yet they were refractory to peripheral inoculation. It takes
approximately 4-6 weeks for full restoration of BM derived cell populations and
germinal centre architecture (Fulop and Phillips, 1986). As this time period may
vary between individual animals it is conceivable that in this study the surviving
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grafted SCID/Prnp+/+ mice may not have achieved a mature, fully functional immune
status, prior to inoculation. Thus, this may have prevented the replication of the
scrapie agent due to a lack of functional peripheral target cells such as FDCs
(Mabbott et al., 2000a). In the absence ofmature FDCs at the time of inoculation it
is likely that a significant amount of the inoculum is destroyed by macrophages
(Beringue et al., 2000b; Carp and Callahan, 1982). This delay is again consistent
with the hypothesis that scrapie infectivity is unlikely to reach the CNS from the skin
by the direct translocation of infectivity by nerves within the skin or by direct
transport via the bloodstream.
Data presented here demonstrates that the accumulation of the scrapie agent in the
spleen following inoculation by skin scarification occurs only in the presence of
mature FDCs and is independent of the PrP status of surrounding splenic
lymphocytes and other bone-marrow derived cells. Furthermore, these results
indicate that functionally mature FDCs are required for subsequent neuroinvasion.
These data are consistent with previous research using the ME7 scrapie strain which
suggests that FDCs are critical for efficient neuroinvasion following intra-peritoneal
exposure (Brown et al., 1999; Mabbott et al., 2000a; Mabbott et al., 2000b). Once
the TSE agent spreads to the CNS the neurodegeneration they cause is considered
irreversible. The identification of an important role for FDCs in the pathogenesis of
disease after skin scarification provides an opportunity for therapeutic intervention
prior to neuroinvasion. The potential for FDCs in therapeutic intervention is already
being investigated following other peripheral routes of exposure (Mabbott et al.,
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2001; Mabbott et al., 2000a; Mabbott et al., 2002; Montrasio et al., 2000) and is
investigated in this thesis (Chapter 5).
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Follicular dendritic cell dedifferentiation reduces scrapie
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Previous studies in this thesis (Chapter 4) have suggested that mature PrPc-
expressing follicular dendritic cells (FDCs) are critical for the accumulation of
scrapie infectivity and PrPSc within lymphoid tissues. FDCs require lymphotoxin
signals from B-lymphocytes in order to maintain their dedifferentiated state and
blockade of this signalling with a lymphotoxin (3-receptor immunoglobulin (LT(3R-
Ig) fusion protein results in the temporary dedifferentiation of FDCs within 3 days of
treatment for approximately 28 days. To further investigate the role of FDCs in
scrapie pathogenesis after inoculation via skin scarification, LTpR-Ig was
administered to C57BL/Dk mice either 3 days before or 14 or, 42 days after
inoculation. Data presented here shows that treatment with LT|3R-Ig before
inoculation with the scrapie agent, blocks the early accumulation of scrapie
infectivity and PrPSc within the draining inguinal lymph node (ILN) and spleen.
These effects coincided with the dedifferentiation of FDCs within the ILNs and
spleen within 3 days of treatment. Furthermore, LTpR-Ig treatment before
inoculation with the scrapie agent significantly reduces disease susceptibility and
extends the disease incubation period. Treatment with LTpR-lg 14 days after
inoculation with the scrapie agent also significantly extends the disease incubation
period. Taken together these data suggest that FDCs are critical for efficient
neuroinvasion of the scrapie agent after inoculation via the skin. However, treatment
with LTpR-Ig at 42 days after inoculation with the scrapie agent had no significant
affect on disease susceptibility or on the disease incubation period, suggesting that




Studies in mouse scrapie models have shown that mature PrPc -expressing follicular
dendritic cells (FDCs) are critical for the accumulation of the scrapie agent within
lymphoid tissues and the subsequent neuroinvasion of the agent after either intra¬
peritoneal (i.p.) or oral exposure (Brown et ah, 1999; Mabbott et ah, 2000a; Mabbott
et ah, 2002; Mabbott et ah, 2000b; Mabbott et ah, 2003). Studies in this thesis have
also suggested that mature PrP( -expressing FDCs are critical for the accumulation of
the scrapie agent within lymphoid tissues after inoculation by skin scarification
(Chapter 4). FDCs therefore represent a potential therapeutic target for the
intervention in peripherally acquired transmissible spongiform encephalopathies
(TSEs).
FDCs require a number of different cytokine signals to maintain their development
and maturation (Chaplin and Fu, 1998; Kosco-Vilbois et ah, 1997). Lymphotoxin
(LT) is a cytokine produced by B-lymphocytes, T-lymphocytes and natural killer
cells and is expressed as a membrane bound heterotrimer (LT011P2) (Ware et ah,
1995). LT011P2 mediates its signalling through the LTP receptor (LTpR) expressed
on FDCs or its precursor cells (Endres et ah, 1999). Mice which are genetically
deficient in LTa, LTP or LTPR do not develop mature FDC networks (Futterer et ah,
1998; Koni et ah, 1997; Matsumoto et ah, 1996a). Similarly, in adult mice, pre¬
existing FDC networks can be dedifferentiated through the pharmacological
blockade of the LTPR signalling pathway (Mackay and Browning, 1998). Previous
studies of i.p or orally inoculated scrapie mouse models have shown that the
temporary dedifferentiation of FDCs, by treatment with the LTPR immunoglobulin-
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fusion protein (LTPR-Ig; (Force et al., 1995)), blocks the early accumulation of PrPSc
and scrapie infectivity in lymphoid tissues, delays subsequent neuroinvasion and
significantly reduces disease susceptibility (Mabbott et al., 2000a; Mabbott et al.,
2003; Montrasio et al., 2000).
Although studies in this thesis (Chapter 4) have suggested that mature PrP -
expressing FDCs are critical for the accumulation of PrPSc and infectivity in
lymphoid tissues after inoculation via the skin, their precise role in neuroinvasion
was not fully defined. Unfortunately, SCID/Prnp+/+ mice in Chapter 4 succumbed to
non-TSE diseases before the expected onset of the clinical symptoms of scrapie
infection. Furthermore, scrapie pathogenesis in mice expressing PrPc on lymphocyte
populations but not FDCs could not be investigated as SCIDIPrnp' ' mice (Brown et
al., 1999) were not available. Thus further experiments were performed in this
chapter to answer the following questions;
1) Are FDCs required for neuroinvasion of the scrapie agent after inoculation
via the skin?
2) Is disease susceptibility reduced in the absence of FDCs?
3) What is the time period of FDCs involvement prior to neuroinvasion?
In order to answer these questions, FDCs were temporarily dedifferentiated by
treatment with a single i.p. injection of LT(3R-Ig either before or shortly after




5.3.1 Effect of LTpR-Ig treatment on FDC status
Temporary blockade of the LTpR signalling pathway was achieved by a single i.p.
injection of 100 pg of LT[3R-Ig (Force et ah, 1995), (Chapter 2. section 2.3.3). Three
days after treatment with LTpR-Ig, expression of the FDCs markers FDC-M2
(Kosco-Vilbois et ah, 1997)) and CD35 (complement receptor 1) were undetectable
in the lymphoid follicles of inguinal lymph nodes (ILNs; Fig. 5.1). The expression
of FDCs markers FDC-M1, FDC-M2 and CD35 were also undetectable in spleen
tissues taken 3 days after treatment (Fig. 5.2). The effects of LTpR-Ig treatment on
FDCs are temporary and last approximately 28 days (Mabbott et ah, 2003; Mackay
and Browning, 1998). FDCs functionally trap and retain antigens on their surface
through interactions with complement components and cellular complement
receptors such as CD35 (Nielsen et ah, 2000; Pepys, 1976). Here the loss of the
expression of complement receptor 1 (CD35) in the lymphoid tissues of LTpR-Ig
treated mice coincided with the subsequent loss of expression, complement
component C4 (FDC-M2) (Fig. 5.1 and Fig. 5.2). Taken together these data suggest
that within 3 days of treatment with LTpR-Ig, FDCs were dedifferentiated and had
lost their ability to trap and retain antigens. Treatment of mice with 100 pg of
polyclonal human immunoglobulin IgG (hu-Ig) as a control had no adverse effects
on FDC status in the ILNs (Fig. 5.1) or spleen (Fig. 5.2).
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Figure 5.1- Effect of LTPR-Ig treatment on FDC status in inguinal lymph nodes of
uninfected mice. Tissues were taken 3 days after injection with hu-lg (control) or
LTpR-lg and adjacent frozen section stained with FDC-M2 (top row; red) and CD35
(bottom row; red) monoclonal antiserum to detect FDCs. FDCs were undetectable in
inguinal lymph nodes 3 days after LTpR-lg treatment. All sections were
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5.3.2 Effect of LTpR-Ig treatment on the early accumulation of PrPSc within
lymphoid tissues.
After inoculation of immunocompetent mice with the ME7 scrapie strain by skin
scarification, high levels of infectivity accumulate in lymphoid tissues within the first
few weeks post-inoculation and are maintained throughout the course of infection
(Fig. 3.1; Chapter 3). Groups of mice were treated with either hu-Ig or LT|3R-Ig
either 14 or 42 days after inoculation with the scrapie agent by skin scarification and
spleens and both ILNs were taken from two mice from each group 3 days later (day
17 and 45, respectively).
The accumulation of PrPSc within the ILNs and spleen were determined by paraffin
embedded tissue (PET) immunoblot analysis ((Schulz-Schaeffer et al., 2000);
Chapter 2 section 2.5.3)). PET blots shown (Table 5.1; Fig. 5.3) are representative of
two mice from each treatment group and of five section analysised. Experiments
demonstrated that PrPSc was detected in the right draining ILN of hu-Ig control
treated mice within 17 days after inoculation. In contrast PrPSc was not detectable in
the non-draining (left) ILN or the spleen from the same mice at this time point
(Table. 5.1). Analysis of tissues from control treated mice 45 days after inoculation
demonstrated PrPSc was present in a greater number of lymphoid follicles in the right
draining ILN (Table 5.1 and Fig. 5.3). Furthermore, PrPSc was now also detectable
in a single lymphoid follicle in both the left ILN and spleen (Table 5.1; Fig. 5.3).
Thus these data demonstrate that PrPSc first targets the right ILN draining the site of
challenge within 17 days after inoculation via the skin, and then subsequently
spreads to the left ILN and spleen between 17 and 45 days post-inoculation.
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Table 5.1- The effect of LTpR-lg treatment on the early accumulation of PrPSc
in inguinal lymph nodes and spleen tissue taken 3 days post-treatmenta,b.
hu-lg LTpR-lg
Day of Right LNC Left LNd Spleen Right LN Left LN Spleen
Treatment
14 ++ +/-
42 +++ + + +/- - - /+
a: Mice were given a single i.p. injection (100 pg) of LT(3R-lg or hu-lg as a
control on the days indicated after inoculation with scrapie via skin
scarification of the right thigh.
b; prpSe accumulation in inguinal lymph nodes and spleen tissue (n = 2) was
scored on the basis of the number of lymphoid follicles which immunostained
positive for PrPSc;
+++; 3> or more lymphoid follicles
++; 2-3 lymphoid follicles
+; one lymphoid follicles
one lymphoid follicle in only one of the samples
no PrPSc detected.
c; inguinal lymph node draining the site of inoculation
d; non-draining lymph node
nb- This table is representative of two mice from each group. Five serial























Figure 5.3- Effect of LTPR-Ig treatment on PrPSc accumulations in the right inguinal
lymph node draining the site of scrapie challenge and spleen tissue 45 days after
scrapie challenge. Mice received either hu-lg (control; a and c) or LTpR-lg (b and d)
at 42 days post-inoculation and tissue samples were then collected 3 days after
treatment. PrPSc accumulations (blue/purple staining) were detected in the draining
inguinal lymph (a) and spleen tissue (c) of all hu-lg treated animals. PrP specific
staining was undetectable in all tissue samples from LTPR-Ig treated mice (b and d).
Terminally scrapie affected brain tissue (e) and normal brain tissue (f) was included
as controls.
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When mice were treated with LTpR-Ig, the number of follicles containing PrPSc in
the draining ILNs and spleen were visibly reduced or completely absent (Table 5.1
and Fig. 5.3). These data demonstrate that the temporary dedifferentiation of FDCs
correlates with a rapid reduction in the number of lymphoid follicles containing PrPSc
in the ILNs and spleen.
5.3.3 Effect of LTpR-Ig treatment on the accumulation of scrapie infectivity and
PrPSc within lymphoid tissues 70 days post-inoculation.
Draining ILNs and spleen tissues were taken from two mice from each control and
LTPR-Ig treatment group 70 days after inoculation with the scrapie agent by skin
scarification. The scrapie infectivity titre in pooled (n = 2) tissue homogenates was
estimated by bioassay in groups of indicator mice. As expected, ILNs from control
mice treated with hu-Ig 3 days before or 14 or 42 days after inoculation contained
high infectivity titres (6.0 - 6.8 log i.e. ID50/g, as estimated by incubation period
assay; Table. 5.2). After treatment of mice with LTpR-Ig 3 days before inoculation
with the scrapie agent, scrapie infectivity was undetectable in ILNs suggesting a
scrapie infectivity titre, if present, below 3.5 log i.e. ID5o/g (at least 1000 fold less
than the level detected in ILNs of control-treated mice assayed at the same time post-
inoculation) (Table. 5.2). Thus these data suggest that temporary dedifferentiation of
FDCs before inoculation with the scrapie agent blocks the early accumulation of
scrapie infectivity in the draining ILN. Analysis of ILNs from mice treated with
LTPR-Ig 14 or 42 days after inoculation, suggested they contained detectable but
significantly lower levels of infectivity than those measured in ILNs from control
treated mice (Table. 5.2).
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Table 5.2- Effect of LTpR-lg treatment on the accumulation of scrapie
infectivity in draining inguinal lymph nodes 70 days post-inoculation by skin
scarification as determined by a incubation period bioassaya.
hu-lg LTpR-lg
Day of lncidenceb Mean incubation Titrec Incidence6 Mean incubation Titrec
treatment period (days) period (days)
± S.E.M ± S.E.M
-3 8/8 192 ±6 6.8 0/8 9X> 300 <3.5
+14 8/8 203 ±4 6.3 9/9 226 ±10 5.0
+42 7/7 192 ±6 6.0 6/8 265 ± 10, 2X >300 3.8
a; Mice were given a single i.p. injection (100 pg) of LTpR-lg or hu-lg as a
control on the days indicated before or after inoculation with scrapie via skin
scarification of the right thigh. Inguinal lymph nodes draining the site of
inoculation were pooled from two mice and infectivity levels determined by
i.e. injection of lysates into groups of C57BL/Dk indicator mice.
b; Incidence = number of animals affected/number of animals tested. The
notation "N X > 300" means that mice were free of the signs of scrapie up to
at least this time after inoculation.
c;Scrapie infectivity titres expressed as log i.e. 50% infectious dose (ID50)/g.
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Table 5.3- Effect of LT(3R-lg treatment on the accumulation of scrapie
infectivity in the spleen 70 days post-inoculation by skin scarification as











-3 9/9 187 ± 3 7.1 0/9 9X>300 <3.5
+14 9/9 208 ±9 6 3/8 295 ± 6 , 5X>300 <3.5
+42 8/9 187 ±4 7 6/9 273 ±11. 3X>300 3.7
a ;Mice were given a single i.p. injection (100 pg) of LT(BR-lg or hu-lg as a
control on the days indicated after inoculation with scrapie via skin
scarification of the right thigh. Spleens were pooled from two mice and
infectivity levels determined by i.e. injection of lysates into groups of
C57BL/Dk indicator mice.
b;lncidence = number of animals affected/number of animals tested. The
notation "N X > 300" means that mice were free of the signs of scrapie up to
at least this time after inoculation.
c; Scrapie infectivity titres expressed as log i.e. 50% infectious dose (ID50)/g.
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Similarly, spleen tissue from each group of control-treated mice contained high
levels of scrapie infectivity when measured 70 days after inoculation (6.0 - 7.1 log
i.e. ID50/g). However, after treatment ofmice with LTpR-Ig 3 days before or 14 days
after inoculation with the scrapie agent, infectivity was undetectable in the spleen
suggesting a scrapie infectivity titre, if present, below 3.5 log i.e. ID50/g (at least a
1000 fold less than the level detected in spleens of control-treated mice assayed at
the same time post-inoculation; (Table. 5.3). However, spleen tissue from mice
treated with LTpR-Ig 42 days after inoculation, contained trace levels of infectivity
(3.7 log i.e. ID50/g) but significantly lower levels of infectivity (at least 100 fold less
than those measured in spleen tissues from control-treated mice; (Table 5.3).
The level of PrPSc accumulation was also determined in spleen tissue from both
control and treated mice 70 days after inoculation. As expected, spleens from control
mice contained abundant accumulations detergent insoluble proteinase K (PK)
resistant PrPSc (Fig. 5.4, lanes 2 and 4). A typical three-banded pattern was observed
between the molecular mass values of 20-30 kDa, representing the unglycosylated,
monoglycoslated and diglycoslated isomers of PrP (in order of increasing mass).
However, after treatment with LTpR-Ig, either before or shortly after inoculation
with the scrapie agent, no accumulations of PrPSc were detected (Fig. 5.4, lanes 6 and
8). These data demonstrate that blockade of the LTPR signalling pathway impairs

























Figure 5.4- Treatment with LTPR-Ig prior to or shortly after scrapie inoculation via
skin scarification blocks the early accumulation of PrP c in spleen tissue (a, b and c)
taken 70 days post-inoculation with scrapie. Mice were treated with LTpR-lg or hu-
lg (control) either, 3 days before (a) or 14 (b) or 42 (c) days after scrapie challenge.
Samples were treated in the absence (-) or presence (+) of proteinase K (PK) prior to
electrophoresis. Abundant levels of PrPSc accumulation were detected in the spleens
of all hu-lg treated mice (lanes 2 and 4). No PrP
LTpR-lg treated mice (lanes 6 and 8).
Sc
was detected in the spleens of
143
5.3.4 Effect of LTpR-Ig treatment on the accumulation of PrPSc in lymphoid
tissues from terminally scrapie affected mice
To determine whether LTpR-Ig treatment affected the accumulation of PrPSc within
lymphoid tissues of terminally scrapie affected mice, ILNs and spleen tissues were
collected from all hu-Ig and LTpR-Ig treated mice that developed the clinical signs
of scrapie. Immunoblot analysis of pooled ILNs and spleen tissue (n = 2) taken from
terminally scrapie-affected control mice detected abundant accumulations of PrPSc
(Fig. 5.5, Fig. 5.6). Abundant accumulations of PrPSc were also detected in the ILNs
(Fig. 5.5) and spleen tissue (Fig. 5.6) of all LTpR-Ig treated mice which developed
clinical signs of scrapie. The effects of LTpR-Ig treatment on FDC dedifferentiation
are temporary and mature FDC networks begin to reappear approximately 28 days
after treatment (Mabbott et al., 2003; Mackay and Browning, 1998). Therefore, the
detection of abundant PrPSc in ILNs and the spleen of clinically scrapie-affected
LTpR-Ig treated mice are consistent with accumulation of residual PrPSc on restored
FDC networks within these tissues.
5.3.5 Effect of LTP-Ig treatment on scrapie susceptibility
Mice were treated with LTpR-Ig (or hu-Ig as a control) at one of three time points
either prior to or shortly after inoculation with a 1% dilute of terminally scrapie-
affected mouse brain homogenate. LTpR-Ig treatment was given either; 1) three
days prior to inoculation with the scrapie agent to ensure no FDC networks were
present within lymphoid follicles at the time of inoculation, 2) 14 days after
inoculation with the scrapie agent shortly after the onset of PrPSc accumulation in the
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Figure 5.5- PrPSc accumulation in pooled draining inguinal lymph nodes (n = 2)
from terminally scrapie-affected mice. Mice were treated with LTpR-lg or hu-Ig
(control) either, 3 days before (a) or 14 (b) or 42 (c) days after scrapie challenge.
Immunoblots show the accumulation of detergent insoluble, relatively proteinase K
(PK) resistant PrPSc in all treatment groups at the terminal stage of the disease.
Treatment of tissues in the presence (+) or absence (-) of proteinase K (PK) prior to
electrophoresis is indicated, pos., mice that developed clinical signs of scrapie; dpi,
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Figure 5.6- PrPSL accumulation in spleen tissue from terminally scrapie-affected
mice. Mice were treated with LT[3R-lg or hu-lg (control) either, 3 days before (a) or
14 (b) or 42 (c) days after scrapie challenge. Immunoblots show the accumulation of
detergent insoluble, relatively proteinase K (PK) resistant PrPSc in all treatment
groups at the terminal stage of the disease. Treatment of tissues in the presence (+)
or absence (-) of proteinase K (PK) prior to electrophoresis is indicated, pos., mice
that developed clinical signs of scrapie; dpi, days post-inoculation at which the
tissues were taken for analysis.
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PrPSc are detectable within ILNs (Table. 5.1 and Fig. 5.3).
All control mice treated 3 days before inoculation with the scrapie agent succumbed
to disease with a mean incubation period of 320 ±3 (n = 6) days (Table 5.4). In
contrast three of the seven mice treated with LTpR-Ig developed disease
approximately 75 days later, with individual incubation periods of 350, 381, 402
days post-inoculation (Table 5.4). These incubation periods were beyond the range
observed in the -3 days hu-Ig treated control mice (309 - 327 days post-inoculation).
Four of the LTpR-Ig treated mice remained free from the signs of scrapie 600 days
post-inoculation (Table 5.4). These data demonstrate that treatment with LTpR-Ig 3
days prior to inoculation with the scrapie agent significantly reduces disease
susceptibility and significantly extends survival time (Table 5.4).
All mice treated with LTpR-Ig 14 days after inoculation with the scrapie agent
developed the neurological disease with a mean incubation period of 351 ±4 days (n
= 8), 35 days later than control treated mice (P < 0.001 ; Table 5.4) which had a
mean disease incubation period of 316 ± 3 days (n = 8). However treatment ofmice
with LTpR-Ig 42 days after inoculation with the scrapie agent did not significantly
affect the disease incubation period (P = 0.158) or susceptibility, when compared to
control treated mice (Table 5.4). Together these data show that blockade of the
LTPR signalling pathway 3 days before inoculation with the scrapie agent can
significantly extend the disease incubation period and reduce disease susceptibility.
Furthermore, when LTpR-Ig was given 14 days after inoculation with the scrapie
agent the disease incubation period is significantly extended. The absence of an
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Table 5.4- Effect of LT(3R-lg treatment on scrapie susceptibility when
inoculated by skin scarification8.
hu-lg
Day of Incidence15 Mean incubation
treatment period (days) ± S.E.M
-3 6/6 320 ± 3
+14 8/8 316 ±3
+42 7/7 328 ± 6
LTpR-lg
Incidence Mean incubation
period (days) ± S.E.M
4/7 443 ±23 3X> 557
8/8 351 ± 4
8/8 343 ± 8
a; Mice were given a single i.p. injection (100 pg) of LTpR-lg or hu-lg as a
control on the days indicated before or after inoculation with scrapie via skin
scarification of the right thigh.
b; Incidence = number of animals affected/number of animals tested. The
notation "N X > 557" means that mice were free of the signs of scrapie up to
at least this time after inoculation.
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effect when LTPR-Ig treatment was given at 42 days after inoculation with the
scrapie agent is consistent with the hypothesis that the scrapie agent has already
spread to the peripheral nervous system at this time point.
Histopathological analysis of brain tissue from terminally scrapie-affected mice from
each treatment or control group displayed the characteristic spongiform pathology,
gliosis and disease-specific PrP accumulations typical of a peripheral inoculation
with the ME7 scrapie strain (Fig. 5.7). However, no characteristic ME7 specific
histopathology was observed in the brains of mice from -3 days FTpR-Ig treatment
group which did not succumb to scrapie infection (Fig 5.7). No significant
difference in the severity or distribution of the pathological targeting of vacuolation
in the brain was observed between treatment and control groups (Fig. 5.8). These
data demonstrate that neuroinvasion had occurred via a common pathway in the
control and FTpR-Ig treated mice that developed clinical disease.
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LTpR-lg LTpR-lg
dpi 309 381 482
clinical pos. pos. neg.
Figure 5.7- Histological analysis of brain tissue from terminally scrapie affected mice
which received either LTpR-lg or hu-Ig (control) treatment either 3 days before (a) or 14
or 42 days after (b) scrapie inoculation by skin scarification. Large PrP accumulations
(brown) were detected in the hippocampi of all mice which developed clinical signs of
scrapie (upper row). Immunostaining of adjacent sections for glial fibrillary acidic protein
(GFAP; red) shows diffuse gliosis in the hippocampi of all terminally scrapie affected
mice (middle row). Adjacent sections were also stained with hematoxylin and eosin and
all displayed extensive vacuolation (bottom row). All sections were counterstained with
hematoxylin (blue). Original magnification X200. dpi; days post-inoculation tissues were
taken for analysis.
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1 2 3 4 5 6 7 8 9 1* 2* 3*
Brain Region
1 2 3 4 5 6 7 8 91* 2* 3*
Brain Region
2 5
1 2 3 4 5 6 7 8 9 1* 2* 3*
Brain region
1 2 3 4 5 6 7 8 9 1* 2* 3*
Brain Region
Figure 5.8- Treatment with the LTpR-Ig either 3 days before (a) or 14 (b) or 42 (c)
days after inoculation with scrapie strain ME7 by skin scarification does not effect
pathological targeting of vacuolation in the brain when compared to hu-Ig treated
controls (d). Vacuolation in the brain was scored on a scale of 0-5 in the following
grey-matter (G1-G9) and white-matter (W1-W3) areas: Gl, dorsal medulla; G2,
cerebellar cortex; G3, superior colliculus; G4, hypothalamus; G5, thalamus; G6,
hippocampus; G7, septum; G8, retrosplenial and adjacent motor cortex; G9,
cingulate and adjacent motor cortex; Wl, inferior and middle cerebellar peduncles;
W2, Decoction of superior cerebellar peduncles; W3, Cerebral peduncles. Each
point represents mean vacuolation score ± S.E.M for groups of 5-9 mice.
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5.4 Discussion
In order to further investigate the role of FDCs in scrapie pathogenesis following
inoculation via the skin, FDCs were temporarily dedifferentiated by a single i.p.
injection of LTpR-Ig either, 3 days before or 14 or 42 days after inoculation with the
scrapie agent by skin scarification. Data presented here shows that LTpR-Ig
treatment blocked the early accumulation of scrapie infectivity and PrPSc in the
draining ILNs and spleen. These effects coincide with the temporary
dedifferentiation of FDCs in ILNs and the spleen. LTpR-Ig treatment 3 days before
inoculation with the scrapie agent significantly extended the disease incubation
period and reduced disease susceptibility, when compared to control mice.
Treatment with LTPR-Ig 14 days after inoculation with the scrapie agent also
significantly extended the disease incubation period but did not affect disease
susceptibility. In contrast, LTpR-Ig treatment at 42 days after inoculation with the
scrapie agent did not affect the disease incubation period or disease susceptibility,
suggesting that infectivity may have already began to spread to the peripheral
nervous system by this time point.
LTpR-Ig treatment, either before or shortly after inoculation with the scrapie agent
by skin scarification, resulted in the loss of functional FDCs within draining ILNs
and spleen tissue within 3 days of treatment. FDCs functionally trap and retain
antigens on their surface through interactions with complement components and
cellular complement receptors (Nielsen et al., 2000; Pepys, 1976). Data presented
here demonstrates that LfflR-Ig treatment resulted in the temporary loss of
complement receptor 1 (CD35) and complement component C4 (FDC-M2;) (Taylor
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et al., 2002) specific immunostaining in the ILNs and spleen within 3 days of
treatment. Therefore these data suggest that any FDCs if present in LTfSR-Ig treated
mice would be unable to trap and retain complement opsonized antigens. Previous
research has suggested that complement and cellular complement receptors may play
a role in the localization and retention of PrPSc to FDCs (Klein et al., 2001; Mabbott
et al., 2001). In addition recent research has suggested that Clq may induce the up-
. f . ...
regulation of PrP by FDCs rendering the host more susceptible to scrapie infection
(Lotscher et al., 2003). Taken together these data would suggest that the capacity of
FDCs to capture and retain PrPSc and scrapie infectivity through association with
complement components would be abolished after LT|3R-Ig treatment.
The fate of FDCs after LTpR-Ig treatment is unknown but several mechanisms could
contribute to their temporary absence in lymphoid tissues: Firstly, FDCs could
dedifferentiate to an immature state that lacks the ability to trap and retain antigen;
secondly FDCs may undergo apoptosis, or alternatively LTpR-Ig may disrupt
chemokine gradients responsible for the organisation of lymphoid follicles resulting
in the dispersal of FDCs. Each of these possibilities would result in the loss of
immunostaining for the FDC markers FDC-M1, FDC-M2 and CD35. Further
research is necessary to determine the precise fate of FDCs after LTpR-Ig treatment.
After inoculation with the scrapie agent, control mice accumulated detectable
amounts of PrPSc in their right ILNs draining the site of inoculation within 17 days
after inoculation. The subsequent detection of PrPSc in the left non-draining ILN and
spleen further contributes to the hypothesis (Chapter 3) that the scrapie agent
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disseminates systemically to other lymphoid tissues from the right draining ILN via
the bloodstream. In contrast, mice which received LTpR-Ig at 14 or 42 days after
inoculation with the scrapie agent had either visibly reduced accumulations or
undetectable levels PrPSc within the ILNs and spleen within 3 days of treatment. The
absence or reduction of PrPSc coincides with the loss of FDCs in the ILNs and
spleen. The loss of PrPSc accumulations within in these lymphoid tissues is most
likely due to the release PrPSc from complement receptors expressed by FDCs, and
its clearance by phagocytic cells (Beringue et al., 2000b; Carp and Callahan, 1981;
Carp and Callahan, 1982; Luhr et al., 2004; Luhr et al., 2002).
After skin scarification of immunocompetent mice with the ME7 scrapie strain, a
high level of infectivity accumulate within the spleen by 63 days post-inoculation,
and subsequently plateaus for the remainder of the disease (Chapter 3; Fig. 3.1). In
this study, pooled ILNs and spleen tissues from all control mice, contained high
levels of scrapie infectivity at 70 days post-inoculation. However, when mice were
treated with LT[3R-Ig 3 days before inoculation with the scrapie agent infectivity was
undetectable within the ILNs at 70 days post-inoculation, approximately 40 days
after the expected reappearance of mature FDCs. Similarly only trace levels of
infectivity and no PrPSc were detected in the spleen of the same mice at 70 days post-
inoculation.
In contrast pooled ILNs from mice treated with LTpR-Ig either 14 or 42 days post-
inoculation did contain low levels of infectivity (approximately 4.4 log i.c ID50/g).
Similarly, trace levels of infectivity were detected in the spleen 70 days post-
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inoculation in mice which were treated with LT(3R-Ig 42 days post-inoculation.
ILNs and spleen tissue from LTpR-Ig treated mice which developed the clinical
signs of scrapie contained abundant accumulations of PrPSc in these lymphoid tissues
at the terminal stage of the disease.
The most likely explanation for these observations is that in the temporary absence of
FDCs, a proportion of the original inoculum is destroyed by phagocytic cells but a
low level of scrapie infectivity is able to persist. Therefore upon the re-appearance
of FDCs, the fraction of scrapie infectivity which had persisted would then be able to
initiate replication on regenerated FDC networks, resulting in the accumulation of
the scrapie agent in lymphoid tissues at the terminal stage of the disease. This
hypothesis is consistent with the observation that LTpR-Ig treatment prevents the
early accumulation of the scrapie agent within lymphoid tissues in the absence of
FDC networks but high levels of PrPSc and infectivity are detectable at the terminal
stage of the disease following the subsequent reappearance ofFDC networks.
Data in this chapter demonstrates that a temporary absence of FDCs at the time of
inoculation results in a significantly extended disease incubation period and reduced
disease susceptibility. The reduced disease susceptibility of mice which received
LTpR-Ig treatment 3 days before inoculation with the scrapie agent is most likely
due to the clearance of scrapie infectivity by phagocytic cells such as macrophages
(Beringue et al., 2000b; Carp and Callahan, 1981; Carp and Callahan, 1982) or
dendritic cells (Luhr et al., 2004; Luhr et al., 2002) both, of which have been shown
to have the potential to sequester and degrade the scrapie agent. The extended
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survival time in mice treated with LTPR-Ig 3 days before inoculation with the scrapie
agent suggests that in some mice a fraction of inoculm persists until the reappearance
of FDCs 28 days after treatment, allowing for replication of the scrapie agent to
resume. However, the delay in onset of the clinical disease (approximately 75 days
later than controls) is greater than the 28 day time period which FDCs are absent
from the lymphoid tissues. This data suggests that the may be variations in the
clearance of the scrapie agent from the host in the absence of FDCs resulting in
variable rates of replication of scrapie infectivity following their reappearance and
thus subsequently altering the onset of the clinical disease.
LTPR-Ig treatment 14 days after inoculation with the scrapie agent significantly
extends the disease incubation but has no effect on disease susceptibility. Data
suggests that PrPSc had already begun to accumulate on FDCs within the lymphoid
tissues prior to LTPR-Ig treatment at 14 days post-inoculation. Thus, the extended
disease incubation period in the absence of reduced disease susceptibility is most
likely due to the accumulation of infectivity prior to LTpR-Ig treatment, which may
have been at a level that was sufficient to avoid substantial clearance by phagocytic
cells in the absence of FDCs. Residual scrapie infectivity would be unable to
replicate until the reappearance of mature FDCs 28 days after treatment, delaying
subsequent neuroinvasion and resulting in a protracted disease incubation period.
Treatment with LTPR-Ig has no affect on disease pathogenesis once infection is
established within the peripheral or central nervous system (Mabbott et al., 2000a;
Mabbott et al., 2003). The lack of any observable effect of LTPR-Ig treatment on
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disease pathogenesis when given 42 days after inoculation with the scrapie agent is
consistent with the hypothesis that neuroinvasion had already occurred. It also
suggests that early neuroinvasion may have occurred directly from the draining ILN
which had a heavy deposition of PrPSc prior to LT(3R-Ig treatment at 42 days post-
inoculation, whereas the spleen had accumulated only limited amounts of PrPSc in
some mice at this time point. Removal of the spleen prior to i.p. inoculation with the
scrapie agent significantly extends the disease incubation period, suggesting an
important role for this tissue in neuroinvasion after i.p. inoculation (Fraser and
Dickinson, 1970). In contrast, removal of the spleen prior to subcutaneous
inoculation with the scrapie agent had no effect on the disease incubation period or
disease susceptibility (Fraser et al., 1992). Taken together these data suggest, as
discussed previously in Chapter 3, that the spleen is unlikely to play a critical role in
peripheral scrapie pathogenesis following inoculation via the skin.
Treatment with LT|3R-Ig can inhibit or prevent the development of experimental
autoimmune encephalomyelitis (Gommerman et ah, 2003). In this model the LTfiR-
mediated disease prevention is associated with defects in T-lymphocyte responses
and migration (Gommerman et ah, 2003). LIGHT is a 29 kDa type II
transmembrane protein produced by activated T-lymphocytes that also binds to
LTPR (Mauri et ah, 1998). However, the effects of LTPR-Ig treatment on scrapie
pathogenesis are unlikely to be due to impaired LTPR or LIGHT-mediated T-
lymphocyte responses as previous studies have shown that pathogenesis is unaffected
in mice deficient in T-lymphocytes (Fraser and Dickinson, 1978; Klein et ah, 1997;
Klein et ah, 1998). Signalling via LTpR has been shown to be important for the
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presence ofmigratory dendritic cells in the spleen (Wu et al., 1999). Therefore, it is
plausible that blockade of the LT[3R-signalling pathway might have affected cell
trafficking or the transport of scrapie infectivity to the draining ILN. However, data
presented here shows that treatment with LTpR-Ig 14 days after inoculation with the
scrapie agent significantly extends the survival time. These data suggest it is
unlikely that the effects of treatment on scrapie pathogenesis are due to affects on
cell trafficking as dendritic cells migrate to draining lymphoid tissues within hours of
antigen encounter (Banchereau et al., 2000). Collectively these observations suggest
it is highly unlikely that the major affects of LTpR-Ig-treatment on scrapie
pathogenesis are independent of its effects on FDC maturation.
Previous studies by Mabbott et al (Mabbott et al., 2000a; Mabbott et al., 2003) and
others (Montrasio et al., 2000) have shown that treatment with LTPR-Ig before either
i.p. or oral inoculation with the scrapie agent significantly reduces disease
susceptibility and extends the survival time. However, LTpR-Ig treatment after
inoculation with the scrapie agent has varying affects on disease pathogenesis. The
affect of LTpR-Ig treatment on disease pathogenesis is lost once infectivity reaches
the peripheral or central nervous system. Following oral challenge LTpR-Ig
treatment is ineffective 14 days after challenge, suggesting that infectivity progresses
quickly from gut associated lymphoid tissues to the peripheral nerves (Mabbott et al.,
2003). In contrast, following i.p. inoculation LTpR-Ig treatment is effective up to 42
days after inoculation (Mabbott et al., 2000a). Data presented in this chapter
demonstrate that LTpR-Ig treatment is effective up to 14 days after inoculation but
ineffective 42 days after inoculation. These data suggest that the time period in
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which FDCs can be manipulated to alter disease pathogenesis varies considerably
depending on the route of exposure.
Data presented here shows that mature FDCs are critical to the replication and
subsequent neuroinvasion of the scrapie agent after inoculation via skin scarification.
In addition these data show that the scrapie agent first accumulates in the draining
ILN prior to spreading to other lymph nodes and the spleen. These data also suggest
that neuroinvasion is most likely to occur between 17-45 days post-inoculation.
Furthermore, the spleen is unlikely to play a critical role in scrapie pathogenesis after
inoculation via the skin as the treatment is ineffective at a time when only low levels
of PrPSc are detectable in the spleen. LTpR-Ig treatment offers a potential for
therapeutic intervention after TSE exposure via the skin. However, this treatment is
only effective when administrated in the short period prior to progression of the
scrapie agent to the peripheral nerves.
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Langerhans cells (LCs) are specialized antigen presenting cells that continually
sample their microenvironment within the epidermis and are able to acquire both self
and non-self molecules. The ability of LCs to acquire and capture antigens suggests
that this cell type would be likely to interact with the scrapie agent after inoculation
via the skin. XS106 cells are a mature LCs-like cell line isolated from mouse
epidermis. To investigate the potential interaction of LCs with the scrapie agent,
XS106 cells were exposed to scrapie-affected brain homogenate in vitro. Data
presented here demonstrates that XS106 cells rapidly acquire PrPSc following in vitro
exposure. In addition, XS106 cells appear to partially degrade PrPSc and scrapie
infectivity over a 96-hour observation period. These data suggest that LCs might
acquire and degrade the scrapie agent after inoculation via the skin. Interestingly, the
ability of XS106 cells to degrade PrPSc is lost following pre-treatment with LPS.
This suggests the potential of LCs to degrade the scrapie agent might be lost in the
presence of antigens such as LPS or other immunostimulatory molecules. Exposure
of XS106 cells to the scrapie agent did not alter their surface expression of PrP or
the following co-stimulatory or activation markers: CD40, CD80, CD86, Iak, CD205,
CD54 and CD 11c. These data suggest that LCs would not undergo maturation
following inoculation with the scrapie agent via the skin as the expression of surface
markers associated with LC maturation were unaltered in vitro.
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6.2 Introduction
Following inoculation via the skin the scrapie agent first accumulates within the
draining lymph node (DLN) (Chapter 3 and Chapter 5). However it is not known
how the scrapie agent is transported from the site of inoculation to the DLN.
Langerhans cells (LCs) are specialised antigen presenting cells (Banchereau and
Steinman, 1998). They continually sample their microenvironment and are able to
acquire both self and non-self molecules by a number of mechanisms such as;
phagocytosis, macropinocytosis or by mediated adsorptive endocytosis (Garret and
Mellman, 1999). Upon antigen encounter LCs receive a complex network of signals
which stimulate their maturation and migration to draining lymphoid tissue where
they present antigen in a MHC-class restricted manner to T-lymphocytes, initiating a
primary immune response (Kimber et al., 1999). The ability of LCs to recognise and
acquire antigen in the epidermis and then transport it to the DLN suggested that this
cell type is a likely candidate for the uptake and transport of the scrapie agent after
inoculation via the skin. Furthermore, previous research has shown that a small sub-
population of dendritic cells are capable of transporting PrPSc from the gut lumen to
the mesenteric lymph nodes (Huang et al., 2002).
XS106 cells are a long-term, mature, LC-like cell line isolated from the epidermis of
A/J mice (Timares et al., 1998) and have a strong similarity to LCs in vivo. These
cells have been previously characterised as being LC-like by their surface phenotype
(MHC II - Iahigh, CD80high and CD86high), growth factor requirements (GM-CSF) and
their potent capacity to activate nai've T-lymphocytes in an allogeneic mixed
lymphocyte reaction (Timares et al., 1998; Xu et al., 1995a; Xu et al., 1995b).
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The XS106 cell line has been previously used as a tool to study the potential of
genetically modified dendritic cells for use in vaccine strategies (Hayashi et al.,
2000; Matsue et al., 1999; Timares et al., 1998), and to study the expression and
function of antigens by LCs cells (Kodali et al., 2003; Mizumoto et al., 2002). These
cells have also been used to study dendritic cell responses to lipopolysaccaharide
(LPS) and the hepatitis C virus (Lu et al., 2003; Sarobe et al., 2003). In this chapter
XS106 cell line has been used to study the potential interaction of LCs with the
scrapie agent.
Experiments performed in this chapter were designed to answer the following
questions:
1) After exposure to the scrapie agent in vitro are LCs able to recognise and
associate with the scrapie agent?
2) Do LCs degrade or replicate the scrapie agent?
3) Does the surface expression of co-stimulatory and activation antigens on LCs
change after exposure to the scrapie agent?
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6.3 Results
6.3.1 Characterisation of the XS106 cell line
The XS106 and XS52 cell lines were kind gifts from Akira Takashima (Dept.
Dermatology, University of Texas, U.S.A). Upon receipt of these cell lines, cells
were expanded and passaged as stated in Chapter 2 (section 2.6.1) for 3 weeks to
obtain a large batch culture. Cells were then aliquoted and cryo-preserved for use in
subsequent experiments. For each individual experiment a new aliquot of cells was
revived and cultured for 10 days prior to use. In each instance, cells were cultured
and passaged in exactly the same manner to ensure homogeneity between cell
populations in individual experiments.
Firstly, XS106 cells were characterised according to their cellular morphology and
surface phenotype. Upon culture, XS106 cells first appear as round cells extending
numerous short pseudopodia ((Xu et al., 1995a): Fig.6.1). As cell monolayers
become confluent many cells become round in shape and some were released
spontaneously into the culture medium. This cellular morphology is characteristic of
other dendritic cell lines previously isolated from the mouse epidermis (Xu et ah,
1995a).
After 10 days of in vitro culture the surface phenotype of XS106 cells was
determined by fluorescence activated cells sorter (FACS) analysis. The 10 day time
point was chosen because the cell yield was sufficient to provide enough cells for use
in experiments. All antibodies were titrated prior to use to determine the
concentration which would give 100% saturation. The appropriate IgG2a isotype
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Figure 6.1- Morphology of XS106 cells after 2 hours in vitro culture. Cells are
typically round and extend short pseudopodia (black arrow). As cultures become
confluent focally cells become round and some are released spontaneously into the
culture medium (white arrow). Magnification X400.
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control antibodies were used in all experiments to determine background levels of
non-specific binding, which was less than 1% for all samples analysed (Fig. 6.2 a-i).
Analysis of the XS106 cell line after 10 days in culture demonstrated the surface
phenotype of this cell line to be; CD40+, CD80+, CD86+, Iak+(MHC-II), CD205+,
CD54+ and CDllc+(Fig. 6.2 a-i). The percentage of cells staining positive for the
above surface antigens was always approximately 100%. Daily analysis of XS106
cells from days 10 to 14 in culture for the surface antigens CD40, CD80, CD86 and
Iak demonstrated that this surface phenotype did not significantly alter as the level of
expression (mean fluorescent intensity) remained unaltered (Table 6.1).
The XS106 cell line has been previously characterised as having a "mature" LC
phenotype in comparison to other XS cell lines derived from the mouse epidermis
due to its high expression of Iak, CD80 and CD86 (Timares et al., 1998; Xu et ah,
1995a; Xu et ah, 1995b) . Similarly in this study the mean fluorescent intensity of
Iak, CD80 and CD86 (Fig. 6.2 b-d) by the XS 106 cell line was visibly higher than
that displayed by the XS 52 cell line (Fig 6.6), and therefore the XS 106 cells were
considered to be displaying a mature phenotype.
6.3.2 XS106 cells express PrPc
Next, the expression ofmRNA and protein for PrPc by XS106 cells was determined
by the reverse transcriptase polymerase chain reaction (RT-PCR) and FACS analysis
respectively. Using two different sets of primers (Chapter 2; section 2.7.2) the
presence ofPrPcm-RNA was confirmed by the visualisation of a single band at 1000
















Figure 6.2- FACS analysis of the surface phenotype of XS106 cells. XS106 cells
were gated as shown (a). Cells were stained with a panel of monoclonal antibodies
specific for; CD40 (b), CD80 (c), CD86 (d), Iak (e), CD205 (f), CD54 (g), CD1 lc (h)
and PrP (8H4; i) (black histograms) or isotype-matched controls (grey histograms)
and analysed by FACS. %; percentage of cells staining positive for each surface
marker. MFI; mean fluorescent intensity of cells which stained positive for the
surface marker.
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Table 6.1- Effect of extended cultivation on surface antigen expression by
XS106 cells. XS106 cells were analysed by flow cytometry from day 10 to 14
in culture for the activation markers CD40, CD80, CD86 and lak. Data
represents the mean fluorescent intensity (MFI) ± standard deviation (SD).
Days in culture
Surface Antigen 10 11 12 13 14
CD40 16 ± 0 11 ± 1 13 ± 4 13 ±4 11 ± 1
CD80 11 ±0 12 ± 1 10±0 11 ± 1 10 ±0
CD86 12 ± 1 11 ± 1 12 ±2 13 ±2 12 ± 1
lak 22 ± 1 18 ± 1 20 ± 1 16 ±4 16 ±2
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Figure 6.3- XS106 cells express mRNA for PrP . Expression was determined by
RT-PCR analysis using two separate sets of primers. All products were resolved
through gel electrophoresis containing ethidium bromide. RT-PCR analysis
confirmed the presence of PrPc m-RNA for by the visualisation of a single band at
1000 bp (lanes land 2) and also a single band at 400 bp (lanes 3 and 4). Lane M,
100 bp molecular marker.
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bp using primer combination 2 (Fig. 6.3 lanes 3 and 4). To confirm that PrPc was
also expressed by XS106 cells at the protein level, FACS analysis was performed
using the monoclonal PrP-specific antibody 8H4 (Appendix 1). The majority of cells
stained positive for PrPc (Fig. 6.2 i). Thus, these data demonstrate that XS106 cells
express both PrPcmRNA and protein.
6.3.3 XS106 cells rapidly acquire scrapie-affected brain homogenate
To determine whether XS106 cells acquire scrapie-affected brain homogenate, cells
were exposed to terminally scrapie-affected brain homogenate as detailed in Chapter
2 (section 2.8.2) for either, 10 mins, 30 mins, 16 hrs or 24 hrs. Uninfected cells and
cells exposed to an equivalent amount of normal brain homogenate were included as
controls. Immunofluorescent confocal microscopy of cytospin preparations showed
abundant accumulations of PrP in association with XS106 cells within 10 mins of
exposure to scrapie-affected brain homogenate (Fig. 6.4 panel c). Visually, the
strongest labelling for PrP was detected after 30 mins of exposure to scrapie brain
homogenate (Fig. 6.4 panel f). Thereafter, the intensity of PrP staining appeared to
decrease during the 24 hr observation period (Fig. 6.4 panels i and 1). Accumulations
of PrP were also detected in association with XS106 cells exposed to normal brain
homogenate over the same time period (Fig. 6.4 panels, b, e, h, and k).
Unfortunately, the PrP-specific antibody 8H4 does not distinguish between PrP and
PrPSc and therefore it was not possible to determine differences between
immunolabelling detected on cells exposed to normal brain to that on cells exposed
to scrapie brain homogenate. In contrast, the level of PrP immunolabelling detected
in association with uninfected cells was visibly less when compared to cells exposed
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to either scrapie brain homogenate or normal brain homogenates (Fig. 6.4 panels a, d,
g and j). Staining for PrP appeared to increase slightly in association with uninfected
cells over the 24 hr time period studied but was visibly less than that observed in
association with cells exposed to either scrapie or normal brain homogenate. Taken
together, these data show that XS106 cells rapidly acquire scrapie brain homogenate
after in vitro exposure.
6.3.4 XS106 cells degrade PrPSc
Experiments above (section 6.3.3) have shown that XS106 cells are able to acquire
scrapie brain homogenate following in vitro exposure. However in those
experiments it was not possible to determine whether the PrP detected was PrPSc or
increased expression of PrP( by XS106 cells. To further investigate whether XS106
cells acquire PrPSc in vitro cell immunoblotting experiments were performed
(Chapter 2; section 2.8.4). Monolayers of XS106 cells were cultured on sterile glass
coverslips and then exposed to terminally scrapie-affected brain homogenate for 16
hrs. Cells were then washed to remove excess brain homogenate and maintained in
culture for between 24 hrs to 96 hrs as described in Chapter 2 (section 2.8.2).
Uninfected cells and cells exposed to normal brain homogenate for the same time
period were included as controls. Following inoculation, coverslips were removed
and PrPSc levels determined by cell immunoblotting (Chapter 2, section 2.8.4).
XS106 cells exposed to scrapie brain homogenate and assayed immediately after
washing at 16 hrs contained abundant levels of proteinase K (PK) resistant PrPSc
(Fig. 6.5 a). Similarly, abundant levels of PrPScwere also detected 24 hrs post-
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Figure 6.5- XS106 cells degrade PrP"St in vitro (a). Duplicate cultures of XS106
cells were exposed to either normal brain homogenate (NBr) or scrapie brain
homogenate (ME7) for 16 hrs. Cells were maintained in culture for the times
indicated and then transferred to PVDF membranes and membranes treated in the
absence (-) or presence (+) of proteinase K (PK). Membranes were probed with the
PrP-specific monoclonal antibody 8H4. Cell blot analysis showed a progressive
decrease in PK resistant PrPSc in association with XS106 cells over the 96 hr
observation period (a). No PrPSc was detected in association with XS106 cells
exposed to normal brain homogenate (a). Nor was any PrPSc detected in association
with non-infected XS106 cells (c) or coverslips exposed to scrapie brain homogenate
(d). Ethidium bromide (Eth Br) staining of membranes confirmed the transfer of
cellular DNA (b and c). This figure is representative of 5 separate studies.
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exposure (Fig. 6.5 a). However, analysis of cells from 48 hrs onwards suggested that
the levels of PrPSc detected in association with these cells progressively decreased
over the 96 hr observation period (Fig. 6.5 a). In contrast, no PrPSc was detected in
association with uninfected cells (Fig. 6.5 c) or cells exposed to normal brain
homogenate (Fig. 6.5 a) as controls. The successful transfer of cells to the PVDF
membranes was confirmed by staining the membrane with ethidium bromide to
detect cellular DNA. In each instance cellular DNA was detected on membranes for
each cell immunoblotblot (Fig. 6.5 b). As the XS106 cells were grown on glass
coverslips further control experiments were performed to ensure that the PrPSc
detected (Fig. 6.5 a) was cell associated. No PrPSc was detected in association with
cell-free cover-slips exposed to scrapie brain homogenate as a control (Fig. 6.5 d),
suggesting that the PrPSc detected was cell-associated and not a result of adherence to
the coverslips.
6.3.5 Immature LC-like cells do not degrade PrPSc in vitro
Unlike the XS106 cell line used above, the XS52 cell line is an immature LCs-like
cell line isolated from mouse epidermis (Xu et al., 1995a). FACS analysis of XS52
cells in this study, demonstrated that these cells do not express the surface antigens
associated with LC maturation (CD40, CD80, CD86, Iad), suggesting that these cells
were of an immature phenotype in comparison to XS106 cells (Fig. 6.6). However,
these cells do express PrPc protein (Fig. 6.6 f). The XS52 cell line was used in
parallel studies to determine whether the degradation of PrPSc by XS106 cells is
typical of any in vitro cultivated cell line exposed to the scrapie agent. Under the
same experimental conditions, XS52 cells accumulated abundant PrPSc after 16 hrs
175























Figure 6.6- FACS analysis of the surface phenotype ofXS52 cells. XS52 cells were
gated as shown (a). Cells were stained with a panel of monoclonal antibodies
specific for; CD40 (b), CD80 (c), CD86 (d), hi (e), and 8H4 (PrP; f) (black
histograms) or isotype-matched controls (grey histograms) and analysed by FACS.
%; percentage of cells staining positive for each surface marker. MFI; mean
fluorescent intensity of cells which stained positive for the surface marker.
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exposure to scrapie brain homogenate (Fig. 6.7 a). However, in contrast to XS106
cells exposed to the scrapie agent, there was no progressive decrease in PrPSt over
the 96 hr observation period (Fig. 6.7 a). Ethidium bromide staining confirmed that
cells had been transferred effectively (Fig. 6.7 b). These data show that the
progressive decrease of PrPSc observed in cultures of XS106 cells exposed to scrapie
brain homogenate is not a property of all in vitro cell cultures.
6.3.6 The reduced detection of PrPSc is not due epitope masking
To confirm that the reduced detection of PrPSL in association with XS106 cells was
not due to the masking the epitope recognised by monoclonal antibody 8H4
(Appendix 1) the experiment was repeated using a different PrP-specific monoclonal
antibody, 7A12 (Appendix 1). The monoclonal antibody 7A12 recognises an epitope
contained within amino acids 122 - 143 of the PrP protein (Zanusso et al., 1998).
This epitope is distinct from the epitope recognised by 8H4 antibody which is
contained within amino acids 147-164 (Zanusso et al., 1998). Experiments
demonstrated that the levels of PrPSc detected following exposure of XS106 cells to
scrapie brain homogenate was likewise visibly reduced over the 96 hrs observation
period when the monoclonal antibody 7A12 was used to detect PrPSc (Fig. 6.8 a).
Staining of membranes with ethidium bromide confirmed that cell transfer to the
membranes had been successful (Fig. 6.8 b). Therefore, these data demonstrate that
the reduced detection of PrPSc is not due to the masking of the epitope recognised by
8H4 antibody. Furthermore, these data confirm that XS106 cells are capable of
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Figure 6.7- XS52 cells retain PrPSc (a). Duplicate cultures of XS52 cells were
exposed to either normal brain homogenate (NBr) or scrapie brain homogenate
(ME7) for 16 hrs. Cells were maintained in culture for the times indicated and then
transferred to PVDF membranes and membranes treated in the absence (-) or
presence (+) of proteinase K (PK). Membranes were probed with the PrP-specific
monoclonal antibody 8H4. Cell blot analysis showed abundant accumulations of
PrPSc in association with XS52 cells over the 96 hr observation period (a). No PrPSc
was detected in association with XS52 cells exposed to normal brain homogenate (a).
Ethidium bromide staining ofmembranes confirmed the transfer of cellular DNA (b).
This figure is representative of 5 separate studies.
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Figure 6.8- The degradation of PrPSc by XS106 cells is not due to the masking of the
epitope recognised by the monoclonal antibody 8H4 (a). Duplicate cultures of
XS106 cells were exposed to either normal brain homogenate (NBr) or scrapie brain
homogenate (ME7) for 16 hrs. Cells were maintained in culture for the times
indicated and then transferred to PVDF membranes and membranes treated in the
absence (-) or presence (+) of proteinase K (PK). Membranes were probed with the
PrP-specific monoclonal antibody 7A12. Cell blot analysis showed a progressive
decrease PK resistant PrPSc in association with XS106 cells over the 96 hr
observation period (a). No PrPSc was detected in association with XS106 cells
exposed to normal brain homogenate (a). Ethidium bromide staining of membranes
confirmed the transfer of cellular DNA (b). This figure is representative of two
separate studies.
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6.3.7 Exposure to the scrapie agent does not adversely affect the viability or
metabolic activity of XS106 cells
Following exposure to scrapie brain homogenate as described in Chapter 2 (section
2.8.2) the viability of XS106 cells was monitored by trypan blue exclusion (Fig. 6.9 a
and b). Uninfected cells and cells exposed to normal brain homogenate were
included as controls and experiments were performed in duplicate. Cells exposed to
scrapie brain homogenate remained viable and confluent through out the 96 hr
observation period (Fig. 6.9 a and b). Uninfected cells and cells exposed to normal
brain homogenate as controls also remained viable during the observation period
(Fig. 6.9 a and b).
The metabolic activity of XS106 cells following exposure to the scrapie agent over a
96 hr observation period was also monitored using the Alamar blue assay which
determines the chemical reduction of growth medium, as a measure of metabolic
activity (Chapter 2, section 2.6.3). Uninfected XS106 cells and cells exposed to
normal brain homogenate were included as a control and experiments were
performed in duplicate. Experiments demonstrated that the metabolic activity of
uninfected XS106 cells, cells exposed to normal brain homogenate, and cells
exposed to scrapie brain homogenate remained similar and constant over the 96 hr
observation period (Fig. 6.10 a and b). The metabolic activity of all cell cultures did
increase at 24 hrs following addition of fresh medium at the 16 hr time point but by
48 hrs had returned to the level observed before the addition of the medium.
Therefore, these data show that the addition of scrapie brain homogenate to XS106
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Figure 6.9- The viability of scrapie exposed XS106 cells as determined by trypan
blue exclusion. All experiments were performed in duplicate (a and b). XS106 cell
viability was determined following exposure to either scrapie brain homogenate
(red), normal brain homogenate (green) or uninfected cells (blue). Cells were




Figure 6.10- The metabolic activity of XS106 cells following exposure to scrapie as
determined by the Alamar blue assay. All experiments were performed in duplicate
(a and b). The metabolic activity of XS106 cells was determined following
exposure to either scrapie brain homogenate (red), normal brain homogenate (green)
or un-infected cells (blue). Cells were exposed to brain homogenate for 16 hrs and
maintained in culture for up to 96 hours.
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these data suggest that the reduction in detection of PrPSc after exposure of XS106
cells to scrapie brain homogenate was not simply due to a loss of viable cells.
6.3.8 XS106 cells reduce scrapie infectivity.
To determine whether the degradation of PrPSc by XS106 cells was concurrent to a
reduction in scrapie infectivity, lysates were prepared from XS106 cells exposed to
terminally scrapie-affected brain homogenate (Chapter 2; section 2.8.5) at the times
indicated. XS106 cells exposed to normal brain homogenate and non-infected
XS106 cells were included as negative controls. As a further control the XS52 cell
line was used in parallel studies to determine whether any degradation of scrapie
infectivity by XS106 cells was typical of any in vitro cultivated cell line exposed to
the scrapie agent. After exposure to the scrapie agent at the times indicated, cell
lysates were prepared and infectivity titres were determined by incubation period
assay by intra-cerebral injection of 2 x 105 cells into each of nine C57BL/Dk
indicator mice (Chapter 2; section 2.8.5). Infectivity titres are expressed as log i.e.
50% infectious dose (ID5o)/per 1 X 106 cells.
To determine the starting dose of inoculum cells were initially exposed to in this
chapter, an equivalent amount of scrapie-affected brain homogenate was injected i.c
into a group of indicator mice. All assay mice inoculated with this homogenate
alone developed clinical signs of scrapie at approximately 173 ± 4 days post-
inoculation (dpi), representing an approximate scrapie infectivity titre of 6.8 log i.c.
IDso/dose (Table 6. 2). As expected all assay mice which were exposed to normal
brain homogenate only or lysates from non-infected cells or cell lysates prepared
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Table 6.2- Scrapie infectivity in cell lysates (r? = 1 X 106) prepared from XS
cell lines
Sample3 Time post-exposure Incidence13 Mean incubation titrec
(hrs) period ± SEM
(days)
XS106 alone n/a 0/9 9 X > 266 n/a
XS52 alone n/a 0/8 8 X > 266 n/a
NB alone n/a 0/8 8 X > 266 n/a
ME7 alone n/a 6/6 173 ±4 6.8
XS106 + NB 16 0/9 9 X > 266 n/a
XS106 + ME7 16 8/9 190 ±3 1 X> 266 5.9
XS106 + ME7 24 8/8 188 ±2 6.0
XS106 + ME7 96 7/8 213 ±7 1 X> 266 4.7
XS52 + NB 16 0/7 7 X > 266 n/a
XS52 + ME7 16 7/7 185 ±7 6.2
XS52 + ME7 24 8/8 188 ± 1 5.3
XS52 + ME7 96 6/6 194 ±4 5.7
a; Abbreviation NB = normal brain homogenate; ME7 = terminally scrapie-
affected brain homogenate, XS106 = XS106 cells, XS52 = XS52 cells.
b; Incidence = number of animals affected/number of animals tested. The
notation "N X > 266" means the mice were free of the signs of scrapie up to
at least this time after inoculation.
c; Scrapie infectivity titres expressed as log i.e. 50% infectious dose units/1 X
106 cells.
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from cells exposed to normal brain homogenate remained free from the signs of the
disease up to 266 dpi (Table 6.2), suggesting that an infectivity titre if present would
be below 2.8 log i.e. ID5o/l X 106.
The majority of assay mice (8/9) inoculated with cell lysates prepared from XS106
cells exposed to scrapie brain homogenate collected at 16 hrs post exposure
developed clinical signs of scrapie at approximately 190 ± 3 dpi, representing an
approximate scrapie infectivity titre of 5.9 log i.e. ID50/I X 106 cells (Table 6.2).
Similarly, all assay mice inoculated with XS106 cell lysates collected at 24 hrs post¬
exposure developed clinical signs of scrapie at approximately 188 ± 2 dpi,
representing an approximate scrapie infectivity titre of 6.0 log i.e. ID50/I X 106 cells
(Table 6.2). No significant difference between the infectivity titres at 16 hrs and 24
hrs after exposure was observed (P = 0.586) as determined by statistical analysis of
disease incubation periods for each group of each indicator mice (Chapter 2; section
2.9). However, by 96 hrs after exposure the infectivity titre had declined to
approximately 4.7 log i.e. ID50/1 X 106 cells (Table 6.2) which was significantly less
than the level measured at both 16 and 24 hrs post-exposure as determined by
statistical analysis of disease incubation periods for each group of indicator mice (P
= 0.004 and P = 0.002 respectively). In contrast the level of scrapie infectivity
associated with XS52 cells at 16, 24 and 96 hrs post-exposure (range 5.7 - 6.2 log
i.e. ID50/I X 106 cells; Table 6.2) was not significantly different at each time point (P
= 0.596, 0.145 and 0.625 respectively). Furthermore, no significant difference was
observed between XS52 cell lysates at 16 and 24 post-exposure when compared to
XS106 cell lysates at 16 and 24 hrs post-exposure (P = 0.455 and 0.963
respectively). However, a significant difference between the level of scrapie
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infectivity associated with XS52 cells at 96 hrs post-exposure and the level of
infectivity associated with XS106 cells at 96 hrs post-exposure was observed (P =
0.002). Taken together these data suggest that the partial degradation of PrPSc by
XS106 cells is concurrent to a partial decline in the level of scrapie infectivity
associated with these cells. Furthermore, these data show that the progressive
decline in scrapie infectivity observed in cultures of XS106 cells exposed to scrapie
brain homogenate is not a property of all in vitro cell cultures.
6.3.9 LPS inhibits the degradation of PrPSc by XS106 cells
Previous research has suggested that stimulation of the innate immune system with
CpG oligonucleotides shortly after peripheral exposure of mice to the scrapie agent
increases survival time (Sethi et al., 2002). Therefore, experiments were performed
in this chapter to investigate the effect of another stimulate of the innate immune
system, LPS, on XS106 cells exposed to the scrapie agent.
LCs interacts with LPS via the toll-like receptors (TLRs) 2 and 4 (Kaisho and Akira,
2003; Takeuchi et al., 2003) in association with the surface receptor CD14 (Wright et
al., 1990). To confirm that XS106 cells expressed both these TLRs their mRNA
expression was determined by RT-PCR analysis. Data presented here shows that
XS106 cells express both TLR-2 and TLR-4 (Fig. 6.11). The expression of CD14
was not investigated in this study however, others have shown that XS cell lines
express CD 14 (Yamada and Katz, 1999). Taken together these data suggest that









Fig 6.11- XS106 cells express mRNA for TLR 2 (a) and TLR 4 (b). Expression was
determined by RT-PCR analysis. All products were resolved through gel
electrophoresis containing ethidium bromide. RT-PCR analysis confirmed the
presence of TLR 2 mRNA by the visualisation of a single band at 336 bp (a; lanes
land 2). The presence of TLR 4 mRNA was confirmed by the visualisation of a
single band at 406 bp (b; lanes 1 and 2). Lane M, 100 bp molecular marker. Lane C,
mRNA obtained from XS106 cells as a control.
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cells exposed to scrapie brain homogenate alone showed a progressive decrease in
PrPSc over the 96hr observation period (Fig 6.12 c). However, cells stimulated with
LPS prior to exposure to scrapie brain homogenate showed no decrease in PrPSc over
the same time period (Fig. 6.12 a). In contrast, no PrPSc was detected in association
with XS106 cells exposed to normal brain homogenate and LPS (Fig. 6.12 a) or cells
exposed to LPS alone as controls (Fig. 6.12 e) at any of the time points analysed.
Ethidium bromide staining confirmed the successful transfer of cells to the
membranes in each instances (Fig. 6.12 b, d and e).
As PrPc is converted to PrPSc during scrapie infection (Prusiner, 1991) FACS
analysis was used to determine whether LPS stimulation altered the surface
p . .
expression of PrP by XS106 cells. Experiments demonstrated that stimulation of
XS106 cells with LPS did not alter their surface expression of PrPc (Fig. 6.14 b).
Similarly, analysis of LPS stimulated cells exposed to normal brain homogenate
showed no significant difference in PrP expression in comparison to cells exposed
to normal brain homogenate alone (Fig. 6.14 c). However, LPS stimulated cells
# p
exposed to scrapie brain homogenate showed a significant increase in PrP
expression in comparison to cells exposed to scrapie brain homogenate only (Fig.
6.14 d; P = 0.028). This increase in PrPc expression by LPS stimulated cells
exposed to scrapie brain homogenate was not due to an increase in cell size or
proliferation as no visible difference was observed between scatter plots which
determine the size and complexity of cell populations (Fig 6.15 a and b).
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Figure 6.12- LPS stimulation blocks the degradation of PrPSc by XS106 cells. XS106
cells were stimulated with LPS one hour before exposure to scrapie brain
homogenate (a). Duplicate cultures of XS106 cells were exposed to either normal
brain homogenate (NBr) and LPS or scrapie brain homogenate (ME7) and LPS for
16 hrs. Cells were maintained in culture for the times indicated and then transferred
to PVDF membranes and membranes treated in the absence (-) or presence (+) of
proteinase K (PK). Membranes were probed with the PrP-specific monoclonal
antibody 8H4. Cell blot analysis showed abundant accumulations PrPSc in
association with XS106 cells over the 96 hr time period (a). In contrast XS106 cells
exposed ME7 only (c) showed a progressive decrease in PrPSc over the 96 hr
observation period. No PrPSc was detected in association with XS106 cells exposed
to normal brain homogenate and LPS (a) or LPS only (e). Ethidium bromide (Eth
Br) staining of membranes confirmed the presence of cellular DNA (b and d). This
figure is representative of two separate studies.
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Figure 6.14- The effect of LPS stimulation on PrPc expression by XS106 cells.
XS106 cells were gated as shown (a). Uninfected vs LPS stimulated cells (b); cells
exposed to normal brain homogenate (NB) vs cells stimulated with LPS and exposed
to NB (c) and cells exposed to scrapie brain homogenate (ME7) vs cells stimulated
with LPS and exposed to ME7 (d) were stained with the PrP-specific monoclonal
antibody 8H4 and then analysised by FACS. MFI; mean fluorescent intensity of




Figure 6.15- The size (FSC-height) and complexity (SSC-height) of XS106 cells
was unaltered following LPS stimulation. Scatter plots of XS106 cells exposed to
scrapie brain homogenate alone (a) or cells stimulated with LPS prior to scrapie
exposure (b) were produced by FACS analysis.
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Together these data show that LPS stimulation inhibits the degradation of PrPSc by
XS106 cells exposed to the scrapie agent. The inhibited degradation of PrPSc by LPS
stimulated XS106 cells might be due to the increased expression of PrPc by XS106
cells following LPS stimulation.
6.3.10 The surface expression of co-stimulatory and activation markers by
XS106 cells is unaltered following exposure to the scrapie agent.
XS106 cells were analysed by FACS analysis to determine whether exposure of the
cells to scrapie brain homogenate altered the expression of the following surface
antigens: PrP, CD40, CD80, CD86, Iak, CD205, CD54 and CDllc (Fig. 6.16 a-j).
XS106 cells were exposed to scrapie brain homogenate as described in Chapter 2
(section 2.8.2) and analysed 24 hrs post-exposure. XS106 cells exposed to normal
brain homogenate for the same time period were included as a reference control. All
experiments were performed in quadruplicate and statistical analysis performed.
Data demonstrates that exposure to the scrapie agent did not significantly change the
expression of PrP or any of the co-stimulatory or activation markers analysed when
compared to cells exposed to normal brain homogenate (Fig.6.16 a-j) (Table 6.3).
Therefore these data suggest that XS106 cells do not undergo maturation or
activation after in vitro exposure to the scrapie agent.
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CDIak NB MFI- 87
,CDIak ME7 MFI- 76
A
CD40 NB MFI-19
CD40 ME7 MFI- 18
CD205 NB MFI- 8
CD205 ME7 MFI- 6
10° 10' 10; 10' 10*
CD80 NB MFI-11
CD80 ME7 MFI- 11
CD54 NB MFI- 56
CD54 ME7 MFI- 56
CD86 NB MFI- 1
CD86 ME7 MFI- 1
CD11c NB MFI- 12
CD11c ME7 MFI- 16
10° 10' 10: 10J 10*
FL1 -Hei#*
Figure 6.16- Flow cytometry (FACS) analysis of the surface expression of PrP and
co-stimulatory and activation markers by XS106 cells following 16 hrs exposure to
scrapie brain homogenate (ME7). XS106 cells were gated as shown (a). Cells were
stained with a panel of monoclonal antibodies specific for; CD40 (b), CD80 (c),
CD86 (d), Iak (e), CD205 (f), CD54 (g), CDllc (h) and 8H4 (PrP; i). Cells were
exposed to either ME7 (black histograms) or normal brain (NB) (grey histograms).
MFI; mean fluorescent intensity of cells which stained positive for surface markers.
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Table 6.2- Effect of scrapie exposure on surface expression by XS106 cells.
XS106 cells were exposed to either scrapie brain homogenate (ME7) or
normal brain homogenate (NBr) for 16 hrs and surface antigen expression
analysised at 24 hrs post-inoculation by flow cytometry. Data represents the
mean fluorescent intensity (MFI) ± standard deviation (SD).
Mean Fluorescent Intensity ± SD
Surface Antigens NBr ME7
CD40 19 ±3 18 ± 1
CD80 11 ± 1 11 ± 1
CD86 1 ±0 1 ±0
lak 86 ± 15 75 ± 12
CD205 8 ± 2 6 ± 4
CD54 55 ± 10 56 ±5
CD11c 11 ±2 16 ±2
PrP 1 ±0 1 ±0
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6.4 Discussion
Studies by Huang et al demonstrated that dendritic cells were capable of acquiring
and transporting PrPSc across the gut lumen (Huang et al., 2002). Furthermore the
prion protein peptide PrPio6-i26 is a chemoattractant (Kaneider et al., 2003) and pro¬
inflammatory stimulus (Bacot et al., 2003) for monocyte-derived dendritic cells.
These studies suggest that LCs may also have the potential to acquire and respond to
the scrapie agent following inoculation via the skin. In order to further investigate
the interaction of LCs with the scrapie agent, the LC-like cell line XS106 was
utilised. Data presented here shows that XS106 cells rapidly associate with scrapie
brain homogenate following in vitro exposure. Experiments also suggest that XS106
cells partially degrade PrPSc and scrapie infectivity over a 96 hr observation period.
Surprisingly, exposure to the scrapie agent did not change the surface expression of
PrP or the following co-stimulatory and activation markers: CD40, CD80, CD86, Iak,
CD205, CD54 and CDllc. Together these data suggest that LCs might partially
degrade the scrapie agent within the epidermis but exposure to the agent would not
induce their maturation. Interestingly LPS stimulation inhibited PrPSc degradation by
XS106 cell suggesting that the ability of LCs to degrade PrPSc might be lost in the
presence of other antigens within the epidermis. This loss of function might be
related to the up-regulation of PrPc expression on XS106 cells following LPS
stimulation.
The XS106 cell line was originally established from the epidermis of newborn A/J
mice (Timares et al., 1998) and has previously been characterised as having a
"mature" LC phenotype due to high expression of la, CD80 and CD86 in comparison
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to other XS cell lines using the same experimental conditions (Timares et al., 1998;
Xu et al., 1995a; Xu et al., 1995b). Similarly in this study XS106 cells expressed
high levels of Iak, CD80, CD40 and CD86 in comparison to the XS52 cells. In this
study FACS analysis suggested that the expression of Iak, CD80 and CD86 by these
cells is relatively low compared to the levels reported by others (Schuhmachers et al.,
1995; Xu et al., 1995b). These differences in surface phenotype may be due to
differences in the concentrations of growth factors added to the culture medium.
XS106 cells are cultured in the presence of GM-CSF, which induces LC maturation
and up-regulation of the expression of Iak, CD80 and CD86 (Romani et al., 1989;
Shimada et al., 1987). These cells are also cultured in the presence of supernatant
derived from the culture medium of the stromal cell line NS47 (Xu et al., 1995a).
This supernatant contains colony-stimulating factor-1 which has been shown to
inhibit the maturation of XS cell lines (Takashima et al., 1995). Therefore, it is
possible that the relative amounts of these and other factors added to the media used
in this study differed from those used in other laboratories (Timares et al., 1998).
Such differences might have contributed to the differing surface phenotypes
observed between studies. Furthermore, differences in the source and types of
antibodies used in this study and others could contribute to the differences in
phenotype observed. However, the levels of expression of the maturation markers;
Iak, CD80, CD40 and CD86 by XS106 cells in comparison to XS52 cells used in this
study suggests that XS106 cells were of a "mature" phenotype.
To maintain TSE infection, host cells must express the cellular isomer of the host
prion protein, as mice deficient in PrP (Prnp~' mice) do not develop disease (Bueler
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et al., 1993; Manson et al., 1994a). Previous studies have suggested that LCs express
PrPc (Sugaya et al., 2002), although others have reported that the PrPc status of DCs
is variable (Luhr et al., 2002). Experiments in this chapter show that XS106 cells
express both PrPc mRNA and protein, thus suggesting that XS106 cells might be
permissible to replication of the scrapie agent. However studies in this thesis
demonstrate that the PrP status of bone-marrow derived cells, which include LCs, is
not critical for scrapie pathogenesis following inoculation via the skin (Chapter 4).
XS106 cells were analysed by immunofluorescent confocal analysis to determine
whether these cells were able to acquire PrPSc following in vitro exposure to scrapie-
affected brain homogenate. Previous studies have shown that mis-folded PrP at the
cell surface is internalised (Kiachopoulos et al., 2004) and undergoes retrograde
transport to the endoplasmic reticulum were it is it is targeted for degradation
(Beranger et al., 2002; Heller et al., 2003). Following exposure of XS106 cells to
either scrapie brain homogenate or normal brain homogenate in this study, deposits
of PrP which appeared intra-cellular could be detected within 10 mins of exposure
and were maintained for the 24 hour time period studied. These PrP deposits
appeared to be localised in the region of the endoplasmic reticulum and the Golgi.
Recent studies utilising neuroblastoma N2a cells infected with the scrapie agent have
shown that PrPSc is translocated to the nucleus (Mange et al., 2004). In this study
PrP appears to accumulate in the nucleus as shown by the close association of PrP
(green) with DNA (blue) (Fig. 6.4). However, it is recognised that conclusions on
the apparent localisation of PrP within XS106 cells would require further
confirmation as cytospin preparations as used this study can display an altered
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cellular morphology. To determine the precise cellular localisation of PrP,
immunofluorescent confocal analysis should be repeated on XS106 cells cultured
and immunolabelled on concave coverslips in order to maintain their cellular
morphology. Alternatively electron microscopy could also be used to determine the
precise cellular location of PrP. Furthermore, confocal studies alone were unable to
determine whether the PrP detected was PrPSc from the inoculum, or the up-regulated
expression ofPrPc by XS106 cells, or a combination of both.
Confocal analysis of uninfected cells displayed visibly less immunostaining for PrP
than that associated with cells exposed to either scrapie or normal brain homogenate.
The intensity of PrP staining in uninfected cells appeared to increase slightly over the
24 hr time period studied. The function of PrP is not known, however studies have
suggested that PrPc may be involved in cell survival under conditions of
physiological stress by functioning as an antioxidant (Martins et al., 2002).
Therefore, the increased PrP staining on uninfected XS106 cells might be related to
increased cellular stress due to prolonged in vitro culture.
Previous studies have shown that macrophages are capable of sequestering and
degrading scrapie infectivity in vitro (Beringue et al., 2000b; Carp and Callahan,
1981; Carp and Callahan, 1982). Studies have also shown that CDllc+ dendritic
cells in vitro are capable of degrading PrPSc (Luhr et al., 2002; Lupi, 2002). Thus
LCs may likewise be able to acquire and degrade the scrapie agent. To determine
whether the LC-like XS106 cell line was able to degrade PrPSc and scrapie infectivity
cell immunoblot analysis and incubation period assays were utilised, respectively.
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Experiments here demonstrate that XS106 cells were able to acquire and partially
degrade PrPSc and scrapie infectivity following in vitro exposure. Accumulations of
PrPSc and scrapie infectivity were also detected in association with the highly
immature LC-like cell line, XS52. However, the levels of PrPSc and scrapie
infectivity associated with this cell line remained relatively constant over the 96 hr
time period studied and did not appear to be degraded. These data demonstrate that
the reduced detection of PrPSc and scrapie infectivity was not simply due to the cell
culture conditions. The surface phenotype of XS52 cells has been shown to be Ialow,
CD86" and E-cadherin+ (Xu et al., 1995a). The surface phenotype of XS52 cells has
a close resemblances to freshly cultured LCs from the epidermis (Xu et ah, 1995a),
whereas XS106 cells have a mature surface phenotype. This suggests the ability of
XS106 cells to partially degrade PrPSc and scrapie infectivity may be related to its
maturation and activation status of the cells. These data demonstrate that XS106
cells are able to partially degrade the scrapie agent and suggest that LCs may be able
to perform the same function in vivo.
The time period over which observable degradation of the scrapie agent occurred (96
hrs) suggests that scrapie infected LCs in vivo may undergo apoptosis in this time
frame (Austyn et ah, 1988). In vivo LCs migrate to the draining lymph node within
24 hrs of encountering antigen. Following presentation of antigen to T-lymphocytes
LCs and are considered to undergo apoptosis within the draining lymph node within
3-6 days of arrival as no LCs can be detected within the efferent lymphatics (Austyn
et ah, 1988). Thus LCs in vivo might release any non-degraded residual PrPSc into
199
the surrounding microenvironment either in the epidermis or the draining lymph
node contributing to disease pathogenesis.
The viability and cellular metabolism of the cell cultures was monitored following
exposure to scrapie homogenate to determine whether the reduced levels of PrPSc
detected were due to impaired cellular metabolisms or cell death. No visible
difference in cell viability or metabolism was observed in scrapie exposed cells when
compared to uninfected cells or cells exposed to normal brain homogenate. Similar
studies have shown that scrapie infection does not affect the growth rate or cellular
metabolism of N2a neuroblastoma cells when compared to uninfected controls
(Bosque and Prusiner, 2000). Recent research suggests that cellular viability is only
compromised in scrapie infected cells if PrPSc accumulates in the cytosol (Ma and
Lindquist, 2001; Ma et al., 2002). In the studies presented here, PrPSc appeared to
accumulate within the Golgi and endoplasmic reticulum of XS106 cells and not
within the cytosol following exposure to scrapie brain homogenate.
LCs have been shown to become to activated and mature in response to different
exogenous stimuli including, inflammatory cytokines (Cumberbatch et ah, 2001;
Cumberbatch et ah, 1997b), CpG oligonucleotides (Ban et ah, 2000) and LPS (De
Smedt et ah, 1996). Studies by Sethi et al (Sethi et ah, 2002) have shown that
treatment of scrapie infected mice with CpG oligonucleotides extends the disease
incubation period. The effect of CpG treatment on scrapie disease pathogenesis was
suggested to be due to the stimulation of the innate immune system, possibly via
TLRs (Sethi et ah, 2002). Studies have demonstrated that LCs express TLR-2 and
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TLR-4, which both bind LPS (Kaisho and Akira, 2003) and data presented in this
chapter shows that XS106 cells also express both TLR-2 and TLR-4. To investigate
whether LPS-stimulation would increase the ability of XS106 cells to degrade PrPSc,
cells were stimulated with LPS prior to exposure to scrapie-affected brain
homogenate. Experiments demonstrated that LPS-stimulation blocked the
degradation of PrPSc by XS106 cells. These data appear to be in opposition to the
hypothesis that stimulation of the innate immune system via TLRs would increase
PrPSc degradation (Sethi et al., 2002). However, recent data shows that the CpG
nucleotide treatment regime carried out by Sethi et al (Sethi et ah, 2002) destroys
lymphoid follicles (Heikenwalder et ah, 2004), the main peripheral site of
replication for the scrapie agent (Mabbott et ah, 1998). Furthermore, although
exposure of dendritic cells to LPS can induces the up-regulation of TLRs 2, 4 and 9
(An et ah, 2002), it is unlikely that TLRs are involved in degradation of the scrapie
agent as previous studies by Prinz et al have shown that scrapie pathogenesis is
unaffected in Myd88mice (Adachi, 1998) which are defective in TLR signalling
(Prinz et ah, 2003a). In addition, although XS106 cells express mRNA for TLR-2
and TLR-4 recent data suggests that TLR-2 is only weakly expressed by LCs
(Takeuchi et ah, 2003). Therefore, it is conceivable that XS106 cells might not
become fully activated following LPS stimulation.
Data presented in this chapter has shown that exposure of XS106 cells to either
scrapie brain homogenate alone or LPS alone has no effect on the expression of
cellular PrP . However, exposure to scrapie brain homogenate and LPS results in a
p p #
significant up-regulation of PrP by these cells. If PrP is involved in cell survival
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during physiological stress (Brown et al., 1997a; Brown et ah, 1997b; Milhavet et ah,
2000; Wong et ah, 2001) it is conceivable that exposure to one of these stimuli alone
would have no effect on PrP expression, but both stimuli together might induce
physiological stress, resulting in an up-regulation of PrPc. As PrPc is converted to
PrPSc during TSE disease (Prusiner, 1982) the up-regulation of PrPc by host cells
might enhance scrapie pathogenesis. Thus the up-regulation of PrP by XS106 cells
following LPS stimulation and exposure to the scrapie agent might mediate the
replication of PrPSc, blocking PrPSc degradation by these cells. Previous studies in
mice have demonstrated that treatment with LPS prior to inoculation with the scrapie
agent increase the efficiency of scrapie infection (Kimberlin and Walker, 1990).
Taken together these data suggest that LPS-stimulated LCs in vivo might enhance
scrapie pathogenesis following transmission via the skin.
Macrophages have been previously suggested to play a dual role in scrapie
pathogenesis. They are considered to play a role in the degradation of scrapie
infectivity (Beringue et al., 2000b; Carp and Callahan, 1981; Carp and Callahan,
1982) but in some circumstances may also accumulate scrapie infectivity, especially
following exposure to high doses of inoculum (Prinz et al., 2002). Data presented in
this chapter suggest that LCs might have a similar role in TSE pathogenesis.
Experiments here demonstrated that that LCs can degrade PrPSc however data also
shows that these cells can retain PrPSc for example following LPS-stimulations.
The surface expression of Iak, CD40, CD80, CD86 and CD54 (ICAM-1) is up-
regulated on LCs following antigen encounter (Cumberbatch et al., 1992; Inaba et
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al., 1994; Schuler and Steinman, 1985). Studies by Bacot et al have shown that the
prion protein peptide PrPi06-i26 also induces up-regulation of the surface antigens,
HLA-DR, CD40, CD80 and CD83 by human monocyte-derived DC (Bacot et al.,
2003). The third question posed in this chapter was whether exposure ofXS106 cells
to the scrapie agent would induce a change in the surface expression of LC co-
stimulatory and activation markers when compared to cells exposed to normal brain
homogenate. However, the experiments presented here demonstrate that exposure to
the scrapie agent did not significantly change the expression of the surface markers;
CD40, CD80, CD86, Ia\ and CD54.
The surface expression of the C-type lectin CD205 and the aX intergrin CD1 lc was
also analysed following exposure of XS106 cells to the scrapie agent. It was
hypothesised that CD205 may be involved in the internalisation of the scrapie agent,
as this lectin binds carbohydrate residues and delivers them to the lysosome or late
endosome where they are degraded (Figdor et al., 2002; Jiang, 1995), the same
cellular compartment proposed for the degradation of PrPSc (Beranger et al., 2002;
Caughey et al., 1991; Heller et al., 2003). Similarly CDllc binds complement
component iC3b (Bilsland et al., 1994). Complement component C3 has been
previously shown to play a role in localising the scrapie agent to lymphoid follicles
(Klein et al., 2001; Mabbott et al., 2001). However, the surface expression ofCD205
or CDllc did not significantly change following exposure to the scrapie agent.
Expression of PrP by XS106 cells was also unaltered following exposure to the
scrapie agent.
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Scrapie infection does not illicit a humoral or cell-mediated immune response in vivo
(Fraser and Dickinson, 1978; Fraser and Farquhar, 1987; Porter et al., 1973). In this
study, the absence of changes in surface expression of co-stimulatory and activation
markers on XS106 cells suggest that the scrapie agent would be unlikely to activate
or induce the maturation of LCs in vivo. Other studies have demonstrated changes in
surface expression of some of the above markers following exposure of monocyte-
derived DCs to the prion protein fragment PrPi06-i26 (Bacot et ah, 2003). However, it
is possible that the absence of change in surface expression of the above markers in
this study might be due to differences in the source of the cells or the inoculum.
Furthermore, the prion protein fragment used in the Bacot study (Bacot et ah, 2003)
is likely to lack important additional constituents of PrPSc or the TSE agent which
may help to aid immune evasion.
In conclusion data presented in this chapter demonstrate that the LC-like cell line,
XS106 is capable of acquiring and partially degrading PrPSc and scrapie infectivity.
These data suggest that LCs in vivo may also be involved in the degradation of the
scrapie agent after inoculation via the skin. The absence of changes in surface
expression of co-stimulatory and activation markers suggest that LCs would not
become activated or undergo maturation after exposure to scrapie agent.
Furthermore, as the degradation of PrPSe by XS106 cells is blocked after LPS
stimulation this suggests the activation of LCs by other antigens or stimuli may
likewise block the ability of these cells to degrade the scrapie agent.
204
7






7.3.1 Effect of caspase-1 inhibition on the accumulation of the
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Following peripheral exposure, TSE agents usually accumulate in lymphoid tissues
before spreading to the brain. The mechanisms by which the scrapie agent is
transported to lymphoid tissues after skin scarification are not known. Langerhans
cells (LCs) reside in the epidermis and migrate to the draining lymph node (DLN)
after encountering antigen. To investigate the potential role of LCs in the active
transportation of the scrapie agent from the skin, mouse models were utilised in
which their migration was inhibited either due to CD40 ligand-deficiency (CD40L7"
mice), or following caspase-1 inhibition. Data shows that the early accumulation of
scrapie infectivity in the DLN and subsequent neuroinvasion was not impaired in
mice with impaired active LC migration. Thus, active LC migration is not involved
in the transport of the scrapie agent from the skin however these studies did not
address LC migration in the steady-state and thus this method of transportation can
not be excluded. Following intra-cerebral inoculation with the scrapie agent, wild-
type mice and CD40L"7" mice develop clinical disease with similar incubation
periods. However, after inoculation via skin scarification CD40L"7" mice develop
disease significantly earlier than wild-type mice. The shorter incubation period in
CD40L-/" mice was unexpected and suggests that a CD40L-dependent mechanism is
involved in impeding scrapie pathogenesis. These data suggest that LCs are not
involved in the active transportation of the scrapie agent from the skin to the draining
lymphoid tissues, however a CD40L-dependent mechanism may be involved




Previous data in this thesis (Chapters 4 and 5) has shown that mature PrP -
expressing follicular dendritic cells (FDCs) are critical for the propagation of scrapie
infectivity from the periphery to the CNS after skin scarification. However, it is not
known how scrapie infectivity is initially transported from the skin to FDCs within
germinal centres in which it replicates. FDCs could directly trap cell-free PrPSc, or
other agent associated molecules, in a complement-bound complex (Klein et al.,
2001; Mabbott et al., 2001), but it is also possible that migratory cells transport the
agent to lymphoid follicles.
Several cells have the potential to transport TSE agents including macrophages and
migratory bone-marrow derived dendritic cells (DCs). The evidence that
macrophages destroy infectivity and degrade PrPSc makes them an unlikely and
inefficient transport candidate (Beringue et al., 2000b; Carp and Callahan, 1981;
Carp and Callahan, 1982). Migratory bone-marrow derived DCs are a distinct
lineage from tissue-fixed, stromal derived, FDCs that are not considered to be of
haemopoietic origin (Endres et al., 1999; Kapasi et al., 1993; Kaspasi et al., 1998).
These DCs continually circulate throughout the host's tissues and tissue fluids where
they sample antigens and transport them to lymphoid tissues (Banchereau et al.,
2000). Unlike macrophages, DCs can retain some protein antigens in native, non-
degraded form (Wykes et al., 1998). Furthermore, a sub-population of these
migratory DCs has been shown to transport intestinally injected PrPSc to mesenteric
lymph nodes via the lymph (Huang et al., 2000) but direct demonstration of their
involvement in TSE pathogenesis is lacking.
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Langerhans cells (LCs) are a subset of DCs that reside in the epidermis and migrate
to the draining lymph node (DLN) following antigen encounter (Banchereau et al.,
2000). LCs are considered to provide a potential mechanism for the transmission of
some pathogens from the skin, such as dengue virus (Wu et al., 2000), HIV (Reece et
al., 1998), maedi-visna lentivirus (Ryan et al., 2000) and Venezuelan equine
encephalitis virus (MacDonald and Johnston, 2000). These characteristics suggest
that LCs are plausible candidates for the transportation of the scrapie agent from the
skin to the DLNs. Furthermore, studies in this thesis have shown that LC are capable
of sequestering PrPSc and scrapie infectivity (Chapter 6), further suggesting that LC
might be involved in transportation of the scrapie agent to the DLNs.
LCs require a number of stimuli to induce their mobilization out of the skin
(Banchereau et al., 2000). CD40 ligand (TnfsfS) and its receptor CD40 (Tnfrsf) are
members of the tumour necrosis superfamily (Banchereau et al., 1994). The CD40-
CD40L signalling pathway is just one component in a complex network of stimuli
that regulate the migration of antigen-bearing LCs out of the epidermis to the DLNs
(Moodycliffe et al., 2000). In mice deficient in CD40 ligand (CD40L"/_ mice), the
number and morphology of LCs in the epidermis is the same as wild-type mice but
they fail to migrate from the skin and substantially fewer accumulate in the DLN
(Moodycliffe et al., 2000). Likewise, caspase-1 plays an important role in the
regulation of LC migration. Caspase-1 is a cysteine protease which specifically
cleaves the IL-ip precursor to release the biologically active cytokine (Garcia Calvo
et al., 1998; Thornberry, 1991; Thornberry et al., 1992; Thornberry et al., 1994).
Specific inhibition of the cytokine IL-ip by a caspase-1 inhibitor impairs LC
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migration from the epidermis (Antonopoulos et al., 2001). If LCs are involved in the
transportation of the scrapie agent from the skin then delaying or preventing the
migration of LCs to the DLNs may result in a prolonged disease incubation period or
reduced disease susceptibility.
In order to investigate the potential role of LCs in the active transportation of the
scrapie agent from skin to draining lymphoid tissues, scrapie pathogenesis was
studied in models where the active migration of these cells from the epidermis was
impaired, either due to CD40L deficiency (Moodycliffe et al., 2000), or caspase-1
inhibition (Antonopoulos et al., 2001).
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7.3 Results
7.3.1 Effect of caspase-1 inhibition on the accumulation of the scrapie agent in
lymphoid tissues.
Previous studies have shown that topical treatment with a pharmacological inhibitor
caspase-1 potently inhibits LC migration from the skin (Antonopoulos et al., 2001).
Therefore experiments were conducted to investigate whether the early accumulation
of the scrapie agent in DLNs was affected after topical treatment with a caspase-1
inhibition Prior to inoculation with the scrapie agent by skin scarification (1.0%
scrapie brain homogenate), C57BL/Dk mice were treated at the site of inoculation
with Ac-YVAD-cmk, a cell-permeable, irreversible, non-competitive caspase-1
inhibitor (Garcia Calvo et ah, 1998; Thornberry, 1991; Thornberry et ah, 1994),
according to a previously established protocol (Antonopoulos et ah, 2001) . This
treatment effectively blocks both spontaneous and induced LC migration from the
epidermis (Antonopoulos et ah, 2001) (Fig. 7.1). As a control, application of Ac-
DEVD-cmk, a specific inhibitor of caspase-3 which has little effect on caspase-1
(Garcia Calvo et ah, 1998) was included. Caspase inhibitors were dissolved in
dimethyl sulfoxide (DMSO) to allow absorption through the skin. Other control
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Figure 7.1- Casapse-1 inhibitor II (Ac-YVAD-cmk) specifically and irreversibly
inhibits capase-1 activity by the expulsion of the carboxylate leaving group (COO")
to form a thiomethyl ketone with the active site of the enzyme, cysteine (-S).
After peripheral inoculation of immunocompetent mice with the ME7 scrapie strain,
high levels of infectivity and PrPSc accumulate in lymphoid tissues within the first
few weeks post-inoculation and are maintained throughout the course of infection
(Brown et al., 1999; Mabbott et al., 2000b)(Chapter 3; Figure 3.1). In the present
study inguinal lymph nodes (ILNs) draining the site of inoculation were taken from
mice from each treatment group 49 days after inoculation with the scrapie agent.
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The scrapie infectivity titres in pooled {n = 2) tissue homogenates were estimated by
bioassay in groups of up to 12 indicator mice. As expected, ILNs from untreated
mice contained high levels of scrapie infectivity (approximately 6.7 log i.e. 50%
infectious dose (ID50)/g). However, this study demonstrates that infectivity titres in
ILNs from Ac-YVAD-cmk pre-treated mice were similar to those from untreated
mice (approximately 6.4 log i.e. ID50/g) indicating that pharmacological blockade of
caspase-1 dependent LC migration from the skin did not affect the early
accumulation of scrapie infectivity in ILNs. No significant effect on the early
accumulation of scrapie infectivity in ILNs was observed in mice pre-treated with
Ac-DEVD-cmk or DMSO alone as controls, when compared to untreated control
mice (approximately 6.0 and 5.9 log i.c.IDso/g, respectively).
Similarly, immunoblot analysis of pooled ILNs (n = 2) taken from terminally
scrapie- affected untreated control C57BL/Dk mice detected abundant accumulations
of detergent insoluble proteinase K (PK) resistant PrPSc (Fig. 7.2 a lane 2). A typical
three-banded pattern was observed between the molecular mass values of 20-30 kDa,
representing the unglycosylated, monoglycosylated and diglycosylated isomers of
PrP (in order of increasing molecular mass). Abundant levels of PrPSc accumulation
were also observed in pooled ILNs samples from mice treated with Ac-YVAD-cmk,
Ac-DEVD-cmk or DMSO alone (Fig. 7.2 a lanes 4, 6 and 8). Likewise, immunoblot
analysis of spleen tissue taken from terminally scrapie-affected mice showed
abundant accumulation of PrPSc in tissues taken from each treatment and control
groups (Fig. 7.2 b lanes 2, 4, 6, and 8). These data demonstrate that pharmacological
212




PK - + - + -
clinical pos pos pos
dpi 321 326 317
pos
322
















Figure 7.2- PrPSc accumulation in lymph nodes (a) and spleen tissue (b) from
terminally scrapie-affected C57BL/Dk mice treated with either Caspase-1 inhibitor II
(Ac-YVAD-cmk), Caspase-3 inhibitor III (Ac-DEVD-cmk) or Dimethyl sulfoxide
(DMSO) prior to inoculation by skin scarification. Age-matched controls which
received no treatment prior to inoculation by skin scarification were also included
(None). Samples were treated in the absence (-) or presence (+) ofproteinase K (PK)
prior to electrophoresis. Abundant levels of PrPSc accumulation were detected in the
lymph nodes (a; n = 2) and spleens (b) of all terminally scrapie affected mice from
each treatment group, pos., mice that developed clinical signs of scrapie; dpi, days
post-inoculation at which tissues were collected for analysis.
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blockade of caspase-1 dependent LC migration does not effect the accumulation of
scrapie infectivity or PrPSc within lymphoid tissues.
7.3.2 Effect of caspase 1 inhibition on susceptibility to scrapie infection
After inoculation by skin scarification all untreated C57BL/Dk mice in this study
developed clinical scrapie with a mean disease incubation period of approximately
316 ± 2 days post-inoculation (Table 7.1). Pre-treatment with Ac-YVAD-cmk prior
to inoculation with the scrapie agent had no significant effect on the onset of clinical
symptoms or the disease incubation period (Table 7.1) when compared to control
mice, as all mice succumbed to scrapie approximately 320 days post-inoculation (P =
0.192) (Table 7.1). No significant effect on the disease incubation period was also
observed in mice pre-treated with Ac-DEVD-cmk or DMSO alone as a control when
compared to untreated control mice (P = 0.774 and P = 0.148, respectively) (Table
7.1). Thus, these data show that pharmacological blockade of caspase-1 dependent
LC migration does not affect susceptibility to scrapie infection when inoculated via
the skin. Histopathological analysis of brain tissue from each treatment or control
group displayed the characteristic spongiform pathology, gliosis and disease-specific
PrP accumulation typical of peripheral inoculation with the ME7 scrapie strain (Fig.
7.3). No significant difference in the pathological targeting of vacuolation in the
brain was observed between treatment and control groups (Fig. 7.4 a-d). Together
these data demonstrate that pharmacological blockade of caspase-1 dependent LC
migration does not affect neuroinvasion or the pathological targeting of vacuolation
in the brain. These data are consistent with the finding that impaired LC migration
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TABLE 7.1- Treatment of skin with the caspase-1 inhibitor II Ac-YVAD-cmk prior
to scapie inoculation by skin scarification does not affect disease susceptibility.
Pre-treatmenta Incidenceb Mean incubation
period (days) ± SEM
None 9/9 316 ± 2
DMSO 10/10 323 ±4
Ac-YVAD-cmk 14/14 323 ±4
Ac-DEVD-cmk 10/10 316 ± 3
a, Prior to scrapie inoculation mice were pre-treated at the shaved inoculation site
with Ac-YVAD-cmk (a caspase-1 inhibitor), or Ac-DEVD-cmk (a caspase-3
inhibitor) or vehicle alone (DMSO) as controls. Age-matched controls which
received no treatment were also included (None).
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Figure 7.4- Treatment with the caspase-1 inhibitor (Ac-YVAD-cmk) prior to
inoculation with scrapie strain ME7 by skin scarification does not effect pathological
targeting of vacuolation. Prior to inoculation with scrapie via skin scarification mice
were treated at the site of inoculation with either the caspase-1 inhibitor II, Ac-
YVAD-cmk (a), Dimethly sulfoxide (DMSO) (b), or the caspase-3 inhibitor III Ac-
DEVD-cmk (c). Age-matched controls which received no treatment prior to skin
scarification were also included (None) (d). Vacuolation in the brain was scored on a
scale of 0-5 in the following grey-matter (G1-G9) and white-matter (W1-W3) areas:
Gl, dorsal medulla; G2, cerebellar cortex; G3, superior colliculus; G4,
hypothalamus; G5, thalamus; G6, hippocampus; G7, septum; G8, retrosplenial and
adjacent motor cortex; G9, cingulate and adjacent motor cortex; Wl, inferior and
middle cerebellar peduncles; W2, Decoction of superior cerebellar peduncles; W3,
Cerebral peduncles. Each point represents mean vacuolation score ± S.E.M for
groups of 5-9 mice.
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due to caspase-1 inhibition did not affect the early accumulation of the scrapie agent
within lymphoid tissues (section 7.3.1).
7.3.3 Lymphoid tissues of CD40L"'" mice contain FDCs but lack germinal
centres.
Next scrapie pathogenesis in mice with a permanent block in LC migration out of the
skin due to a targeted deletion of the Tnfsf5 gene (CD40L"7" mice) was investigated
(Moodycliffe et al., 2000).
Tail snips were taken from all mice used in the CD40L"" study and the genotype of
each mouse strain was determined by PCR analysis of total DNA (Fig. 7.5).
Analysis of total DNA from wild-type mice confirmed the presence of the Tnfsf5
gene (CD40L) by the visualization of a single band at 250 bp (Fig.7.5 lanes 1-4). In
contrast analysis of DNA from CD40LV" mice confirmed the absence of the wild-
type allele and only the presence of a band specific for the neomycin resistance gene
at 500 bp (Fig. 7.5 lanes 5-8). These data confirmed the genotypes of all mice used
within this study were correct.
CD40L"7" mice are incapable of mounting T-cell dependent humoral immune
responses and as a consequence germinal centre development is impaired (Xu et al.,
1994). Therefore, FDC status was assessed in spleens from CD40L"" mice and
C57BL/6 wild-type mice. Germinal centres containing PNA-binding B lymphocytes
were detected in the spleens of all C57BL/6 wild-type mice, but not in spleens of
CD40L"'" mice (Fig. 7.6 a). Despite the impaired germinal centre formation in
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WT CD40L"'-
Figure 7.5- Confirmation of the presence or absence of the CD40L gene in wild-type
C57BL/6 (WT) and CD40L~~ mice by PCR analysis of total DNA from tail biopsies.
Analysis of total DNA from CD40L~~ mice (lanes 5-8) confirmed the presence of a
portion of the neomycin resistance gene (neo) by the visualisation of only a single
band at 500 bp. The presence of the CD40L allele in the WT mice (lanes 1-4) was
confirmed by the visualisation of only a single band at 250 bp. Results of four mice
from each genotype are shown which are representative of results from all mice used
in this study.
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Figure 7.6- Germinal centre architecture in spleens of C57BL/6 wild-type (WT)
mice and CD40Lmice, (a) Immunohistochemical analysis detected the presence
of PNA-positive germinal centre B lymphocytes in spleens from WT mice (red; left
hand panel) but not in tissue from CD40L " mice (right hand panel). Original
magnification, XI00. (b) Immunohistochemical analysis of FDC networks in spleen
tissue from WT (left hand panels) and CD40Lmice (right hand panels). Adjacent
frozen sections were stained with FDC-M2 (upper row; red) monoclonal antiserum to
detect FDCs, 8C12 monoclonal antiserum to detect CD35 (middle row; red), and
B220 monoclonal antiserum to detect B lymphocytes (lower row; red). Original
magnification, X200. All sections were counterstained with haematoxylin (blue).
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lymphoid tissues of CD40L"" mice, mature FDC networks surrounded by B-
lymphocytes (CD45R/B220 positive cells) were detected (Fig. 7.6b). Expression of
the markers FDC-M2 and CD35 by FDCs in spleens of CD40L/_ mice appeared
similar to that observed in lymphoid tissues from C57BL/6 wild type mice (Fig.
7.6b). Thus, these data show that lymphoid tissues of CD40L/_ mice contained
mature FDC networks and lymphocytes arranged in a manner indistinguishable from
those ofwild-type mice.
7.3.4 Effect of CD40L deficiency on accumulation of the scrapie agent in
lymphoid tissues.
Next the early delivery of the scrapie agent from the skin to the draining lymphoid
tissues in the absence ofmigratory LCs in CD40L-/" mice was studied. ILNs draining
the site of inoculation and spleens were taken from two wild-type mice and two
CD40L~~ mice 49 days after inoculation with the scrapie agent by skin scarification
(1.0% scrapie brain homogenate). The scrapie infectivity titres in pooled (// = 2)
tissue homogenates were estimated by bioassay in groups of up to 12 indicator mice.
As expected draining ILNs from wild-type mice contained high levels of scrapie
infectivity (approximately 5.8 log i.e. ID50/g). In the absence of efficient LC
migration from the skin the early accumulation of scrapie infectivity in the draining
1LN was not impaired, as high levels of infectivity were also detected in the of ILNs
from CD40L"'" mice taken 49 days post inoculation (approximately 5.9 log i.e.
IDVg).
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Only trace levels of infectivity (< 2.5 log i.e. ID5o/g) were detected in pooled spleen
samples from the same wild-type mice and CD40L7" mice taken 49 days post
inoculation. However, at the terminal stage of disease abundant detergent insoluble,
relatively proteinase K-resistant accumulations of PrPSc were detected in spleens
from wild-type mice (Fig. 7.7 lanes 2 and 4) and CD40L7" mice (Fig. 7.7 lanes 6 and
8). Taken together, these data demonstrate that after inoculation via the skin,
infectivity is propagated to the draining lymph node via the lymphatics in a LC-
independent manner, and subsequently distributed to the spleen, probably via the
bloodstream. As only trace levels of infectivity are measured in the spleen at a time
when high levels of infectivity are detected in the draining lymph node, these data
suggest that the initial transmission from the skin to local lymphoid tissues does not
occur via the bloodstream.
7.3.5 Susceptibility of CD40L"/" mice to scrapie infection.
When challenged i.e. with a moderate dose of the scrapie agent (1.0% scrapie-brain
homogenate from a terminally scrapie-affected mouse), wild-type mice and CD40L
mice developed clinical signs of scrapie with similar incubation periods of 159 to
165 days (Table 7.2). Histopathological analysis of brain tissue from terminally
affected wild-type and CD40L7" mice displayed the characteristic spongiform
pathology, disease-specific PrP accumulation and gliosis typical of i.e. inoculation
with the ME7 scrapie strain, although microglia activation appeared more
pronounced in the brains of CD40L"7" mice (Fig. 7.8). However, the severity and
distribution of pathological vacuolation in the brain was not significantly different
between mouse strains (Fig. 7.9 a). Thus these data suggest that the CD40L
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Figure 7.7- PrPSL accumulation in spleen tissue from terminally scrapie-affected
C57BL/6 wild-type (WT) (lanes 2 and 4) and CD40LV" mice (lanes 6 and 8)
inoculated with scrapie by skin scarification. Immunoblots show the accumulation
of detergent insoluble, relatively proteinase K (PK) resistant PrPSc. Treatment of
tissues in the presence (+) or absence (-) of PK prior to electrophoresis is indicated,
pos., mice that developed clinical signs of scrapie; dpi., days post-inoculation at
which the tissues were taken for analysis.
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TABLE 7.2- Susceptibility ofwild-type (C57BL/6) and CD40L"7" mice to scrapie
after inoculation via skin scarification or i.e. injection.
Skin scarification3 i.e. inoculation
1 % (wt/vol) 0.1% (wt/vol) 1 % (wt/vol)
Mouse Scrapie Incubation Scrapie Incubation Scrapie Incubation
Strain incidence periodb incidence period incidence period
C57BL/6 8/8 344 ± 5 8/9 355 ± 13, IX > 504c 5/5 165 ±1
CD40L" 9/10d 312 ±5 7/8e 331 ±6 6/6 159 ±1
a, Mice were inoculated with the ME7 scrapie strain by skin scarification of the
medial surface of the right thigh.
b, In days, mean ± S.E.M.
c, One mouse remained free from the signs of scrapie 504 days post-inoculation at
which point the experiment was terminated. No histopathological signs of scrapie
were detected in the brain.
d, One mouse died at 306 days post-inoculation. No histopathological signs of
scrapie were detected in the brain.
e, One mouse died at 359 days post-inoculation. No histopathological signs of
scrapie were detected in the brain.
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WT CD40L-'-
Figure 7.8- Histological analysis of brain tissue from terminally scrapie affected,
wild-type (WT) mice (left hand column) and CD40L_/" mice (right hand column)
inoculated intracerebrally with scrapie strain ME7. Large PrP accumulations
(brown) were detected in the hippocampi of all mice which developed clinical signs
of scrapie (top row). Immunostaining of adjacent sections for glial fibrillary acidic
protein (GEAP) (red) shows diffuse gliosis in the hippocampi of all terminally
scrapie affected mice (second row). Adjacent sections were also stained with
hematoxylin and eosin and all displayed extensive vacuolation (third row). Analysis
of LEA-binding microglia suggested their activation was more pronounced in the
brains ofCD40L"7"mice when compared to wild-type mice (bottom row). All sections
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Figure 7.9- Similar pathological targeting in the brains of terminally scrapie-affected
CD40L " mice and C57BL/6 wild-type mice. Mice were inoculated with the ME7
scrapie strain by i.e. injection (a) or via skin scarification (b). Vacuolation in the
brain was scored on a scale of 0-5 in the following grey-matter (G1-G9) and white-
matter (W1-W3) areas: Gl, dorsal medulla; G2, cerebellar cortex; G3, superior
colliculus; G4, hypothalamus; G5, thalamus; G6, hippocampus; G7, septum; G8,
retrosplenial and adjacent motor cortex; G9, cingulate and adjacent motor cortex;
Wl, inferior and middle cerebellar peduncles; W2, Decoction of superior cerebellar
peduncles; W3, Cerebral peduncles. Each point represents mean vacuolation score ±
S.E.M for groups of 5-9 mice. •, C57BL/6 wild-type mice, o, CD40L"'" mice.
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signalling pathway is not involved in the cerebral pathogenesis following inoculation
with the ME7 scrapie strain.
After inoculation with the scrapie agent by skin scarification, CD40L7" mice
developed clinical disease significantly earlier than wild-type mice (Table. 7.2). For
example, after inoculation with a moderate dose of the scrapie agent (1.0% brain
homogenate), all wild-type mice developed clinical signs of scrapie with a mean
incubation period of 344 ± 5 days (n = 8). In contrast, CD40L~~ mice developed
clinical scrapie 32 days earlier than the wild-type controls, with a mean incubation
period of 312 ± 5 days (P = 0.0003). Characteristic spongiform pathology and
disease-specific PrP accumulations and gliosis typical of an infection with the ME7
scrapie strain were detected in the brains of all peripherally inoculated wild-type and
CD40L"" mice (Fig. 7.10). Although the activation status of LEA-binding microglia
appeared more pronounced in the brains of CD40L"/_ mice when compared to wild-
type mice (Fig. 7.10), no significant difference in the severity or distribution of
vacuolation in the brain was observed between mouse strains (Fig. 7.9 b). Thus the
shortened incubation period in CD40L" " mice was unlikely to be attributed to an
exaggerated neuropathology in these mice when compared to wild-type mice.
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Figure 7.10- Histological analysis of brain tissue from terminally scrapie-affected
C57BL/6 wild-type mice (WT; left hand column) and CD40L7" mice (right hand
column) inoculated with scrapie by skin scarification. Large PrP accumulations
(brown) were detected in the hippocampi in all mice which developed clinical signs
of scrapie (upper row). Immunostaining of adjacent sections for glial fibrillary acidic
protein (GFAP) shows high levels of gliosis in the hippocampi of all terminally
scrapie affected mice (second row; red). Adjacent sections were also stained with
hematoxylin and eosin and all displayed extensive vacuolation (H&E; third row).
Analysis of LEA-binding microglia suggested their activation was more pronounced
in the brains of CD40L " mice when compared to wild-type mice (bottom row). All
sections were counterstained with hematoxylin (blue). Original magnification, XI00
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7.4 Discussion
In order to investigate the potential role of LCs in the transportation of the scrapie
agent from the skin to draining lymph nodes (DLNs), mouse models were utilised
where the migration of LCs from the skin was impaired (Antonopoulos et al., 2001;
Moodycliffe et ah, 2000). Pharmacological blockade of LC migration
(Antonopoulos et ah, 2001) by treatment with an irreversible inhibitor of caspase-1
prior to inoculation with the scrapie agent through the skin did not impair the early
accumulation of infectivity in draining lymphoid tissue or delay subsequent
neuroinvasion. The migration of LCs from the skin is also impaired in CD40L
mice (Moodycliffe et ah, 2000). The early accumulation of infectivity in draining
lymphoid tissues of these mice was likewise not impaired in the absence of LC
migration from the skin. Together, these data suggest that LCs are not involved in
the transport of the scrapie agent from the skin to lymphoid tissue. When wild-type
mice and CD40L" " mice were challenged with the scrapie agent directly into the
CNS, both strains of mice developed clinical signs of scrapie with similar incubation
periods and exhibited similar CNS pathology. In contrast, after inoculation via skin
scarification the disease incubation period was shorter in CD40L"7" mice when
compared to wild-type mice. The shortened disease incubation period in CD40L""
mice was unexpected and demonstrates that a CD40L-dependent process involved in
impeding scrapie neuroinvasion was disrupted due to CD40L deficiency.
Transport mechanisms of the scrapie agent from the site of exposure to the germinal
centres in which they replicate are not known. Migratory bone-marrow derived DCs
are a credible candidate transport mechanism as these cells sample antigens in the
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periphery and transport them to lymphoid tissues (Banchereau et al., 2000). DCs can
also retain some protein antigens in native, non-degraded form (Wykes et ah, 1998).
Recent research has demonstrated that bone-marrow derived DCs can acquire PrPSc
in vitro (Huang et ah, 2002; Luhr et ah, 2004; Luhr et ah, 2002) and that a sub-
population ofmigratory DCs has the potential to transport intestinally injected PrPSc
to mesenteric lymph nodes via the lymph (Huang et ah, 2002). Others have shown
that the prion protein fragment PrPi06-i26 is a chemoattractant and pro-inflammatory
for monocyte-derived dendritic cells (Bacot et ah, 2003; Kaneider et ah, 2003).
Furthermore, studies in this thesis have shown that LCs can acquire scrapie brain
homogenate in vitro (Chapter 6). Despite these observations direct demonstration of
the involvement of DCs in the initial delivery of TSE agents to lymphoid tissues is
lacking. Studies by Oldstone and colleagues (Oldstone et ah, 2002) have suggested
CDllc+ DCs are not involved in peripheral TSE pathogenesis. However, in their
study mice were inoculated with high doses of the RML scrapie strain which have
been shown consistently to bypass the need for replication in lymphoid tissues in
other RML scrapie models (Prinz et ah, 2002) and in the ME7 scrapie model (Fraser
et ah, 1996). Here the potential role of LCs in scrapie pathogenesis is investigated
after inoculation with doses of the agent that requires amplification in lymphoid
tissues prior to neuroinvasion (Taylor et ah, 1996a).
The cytokines interleukin-ip (IL-ip) and tumour necrosis factor (TNF)-a play key
roles in regulating the migration of LCs from the epidermis to DLNs (Cumberbatch
et ah, 1997b; Stoitzner et ah, 1999). LC migration from the epidermis is blocked
following specific inhibition of either of these cytokines (Cumberbatch et ah, 1997b).
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IL-ip is synthesized as an inactive 31 kDa precursor which is specifically cleaved to
release the active 17 kDa IL-ip molecule by the cysteine protease caspase-1
(Thornberry et al., 1992). In mice deficient in caspase-1 and therefore subsequently
deficient in IL-ip LC migration from the skin is impaired (Antonopoulos et al.,
2001). Furthermore, treatment of skin with Ac-YVAD-cmk, an irreversible inhibitor
of caspase-1 (Garcia Calvo et al., 1998; Thornberry et al., 1994), potently blocks
induced LC migration from the skin (Antonopoulos et al., 2001).
Treatment ofmice with Ac-YVAD-cmk blocks induced LC migration from the skin
by approximately 67% (Antonopoulos et al., 2001). Therefore the possibility exists
that the magnitude of impaired LC migration was insufficient to observe a
measurable effect on disease pathogenesis. However, this assumption relies on a
67% reduction in LC migration correlating to a direct 67% reduction in delivery of
the scrapie agent to the DLNs. Previous studies have shown that only a small
subpopulation of intestinal DCs (0.5-5%) are required to transport detectable levels
of PrPSc from the gut lumen to the DLNs (Huang et al., 2002; Huang et al., 2000).
Thus, it is likely that the majority of LC sub-populations, if involved in the
transportation of the scrapie agent, would be retained within the 67% of LCs unable
to migrate from the epidermis, after Ac-YVAD-cmk treatment. After peripheral
inoculation it is likely that a portion of the original inoculum is degraded by
macrophages (Beringue et al., 2000b; Carp and Callahan, 1981; Carp and Callahan,
1982) prior to its replication in association with FDCs. This effect is dose
dependent: with small doses being more easily destroyed than a higher dose where a
greater portion would be retained (Prinz et al., 2002). Therefore, if a 67% reduction
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in LC migration did correlate with a 67% reduction in initial delivery of the scrapie
agent to the DLNs then the fraction of original inoculum available for degradation
would be smaller and hence further reduce the inoculum titre, hence affecting disease
pathogenesis. With the above points in mind, it is believed that the effects of Ac-
YVAD-cmk treatment on LC migration would be sufficient to cause a measurable
effect on scrapie pathogenesis if LCs were involved. However, to further address
this issue a CD40L~/~mouse model was also utilised where there is a permanent block
in LC migration from the epidermis (Moodycliffe et al., 2000).
CD40-CD40L interactions have also been shown to play an important role in
regulating the migration of antigen-bearing LCs to the DLNs as their migration from
the epidermis is blocked in CD40L"" mice (Moodycliffe et al., 2000). This defect in
LC migration was associated with defective TNF-a production in the skin
(Moodycliffe et al., 2000). Data in this chapter show that blockade of LC migration
from the epidermis through treatment with Ac-YVAD-cmk prior to inoculation with
the scrapie agent did not effect the early accumulation of infectivity in draining ILNs
or delay subsequent neuroinvasion. High levels of scrapie infectivity were also
detected within the ILNs of wild-type and CD40L"/" mice 49 days post-inoculation.
A time point previously suggested in this thesis (Chapter 3, Fig 3.1) to be the point
when infectivity levels peak in the draining ILN. Thus, the early accumulation of the
scrapie agent in the draining lymphoid tissue was not impaired in mice with defective
LC migration. Therefore the initial transportation of the scrapie agent from the skin
to draining lymphoid tissue occurs through a LC-independent mechanism.
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Every effort was taken at the time of skin scarification to avoid causing damage to
the dermis or drawing blood to prevent the leakage of infectivity into the
bloodstream during inoculation. If scrapie infectivity had leached into the
bloodstream, a need for LCs in transportation to lymphoid tissues would obviously
have been by-passed. Analysis of spleen tissue 49 days post-inoculation failed to
detect infectivity in tissues collected from the same wild-type and CD40L7" mice.
These data therefore suggest that the initial transmission of the scrapie agent from the
skin to lymphoid tissues does not occur via the bloodstream which would have
resulted in a widespread dissemination of infectivity throughout the lymphoid
system. Spleen tissue collected for immunoblot analysis from terminally-affected
wild-type and CD40L"" mice detected large accumulations of PrPSc. Therefore, after
inoculation via the skin infectivity is first propagated to the draining lymph node via
the lymphatics in a LC-independent manner and subsequently distributed to the
spleen, probably via the bloodstream. These data are concurrent with data presented
in Chapter 3 and 5 of this thesis.
Mice deficient in CD40L are incapable of mounting T-cell dependent humoral
immune responses (Xu et al., 1994). Although mature FDC networks surrounded by
B-cells were detected in the spleens of CD40L"'" mice, germinal centres containing
PNA-binding B lymphocytes were absent. After inoculation by skin scarification
CD40L'" mice accumulated levels of PrPSc and infectivity in their lymphoid tissues
comparable to wild-type mice, despite an absence of germinal centres. Thus, the
absence of PNA-positive germinal centres in CD40L_/~ mice does not affect the
ability of their lymphoid tissues to accumulate PrPSc and infectivity after exposure to
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the ME7 scrapie strain. These data are consistent with previous studies utilizing
interleukin-6 deficient (IL-6~ y mice which also have diminished germinal centres but
mature FDC networks in the spleen (Mabbott et al., 2000b). After peripheral
inoculation with ME7 scrapie, spleens of IL-6"7" mice accumulated levels of PrPSc and
scrapie infectivity comparable to those in spleens of wild-type mice and maintained
these levels for the duration of the disease.
Congruent with the observation that the early accumulation of scrapie infectivity in
lymphoid tissues was not impaired in the absence of LC migration, further studies
demonstrated that scrapie susceptibility was not reduced in mice with blocked LC
migration. When challenged with the scrapie agent by skin scarification, CD40L7"
mice succumbed to clinical disease with a significantly shorter incubation period
than wild-type mice (Table. 7.2). The shortened incubation period in CD40L"7" mice
was unexpected as a similar affect on scrapie pathogenesis was not observed after
inhibition of LC migration by topical treatment with a caspase-1 inhibitor (Table.
7.1). CD40 signaling on neurons has been shown to play a physiological role in
promoting neuronal maintenance and survival (Tan et al., 2002). Thus the shortened
scrapie incubation period observed in peripherally-inoculated CD40L"7" mice might
have been due to an increased susceptibility of CD40L-deficient neurons to TSE-
induced neurodegeneration. Following inoculation of wild-type and CD40L"7" mice
with the scrapie agent directly into the CNS (i.e. inoculation), all mice developed
clinical disease with similar incubation periods. Furthermore, the pathological
targeting of the scrapie-induced vacuolation (Fig. 7.8b), disease-specific PrP
accumulation, or gliosis (Fig. 7.7) within the brain was not significantly different
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between mouse strains, although microglia activation appeared more pronounced in
CD40L"'" mice. Despite this apparent increase in microglia activation, the magnitude
and distribution of the disease-specific vacuolation in the 12 different brain regions
were similar between the CD40L"" and wild-type mice. These data demonstrate that
the CD40-CD40L signaling pathway does not play a critical role in the cerebral
pathogenesis of ME7 scrapie. Therefore, the shortened incubation period observed
in peripherally inoculated CD40L"" mice was most likely due to an absence of a
CD40L-dependent mechanism in the periphery. These data also suggest that a
CD40-CD40L dependent mechanism is involved in impeding scrapie pathogenesis.
This is in contrast to recent data by Burwinkel et al (Burwinkel et al., 2004) that
suggests that the CD40-CD40L signaling pathway is involved in the development
and progression of the disease in the CNS following inoculation with 139A scrapie
strain. In their study CD40L"/~ mice succumb to disease 40 days earlier than wild-
type control mice following i.e. inoculation. Congruent with the findings in our
study, no significant differences in the extent of disease-specific PrP accumulations
or GFAP-expressing astrocytes were detected in the brains of CD40L~~ and wild-type
mice. However their study detected more pronounced microglial activation and
disease associated vacuolation in CD40L7" mice than controls. This is in contrast to
this study were the magnitude and distribution of vacuolation in CD40L_/~ mice was
remarkably similar to wild-type mice following inoculation either directly into the
CNS or the skin (Fig. 7.9 a and 7.9 b). In wild-type mice the distribution and
magnitude of vacuolation within the brain is significantly different between 139A
and ME7 scrapie strains; for example the 139A scrapie strain induces stronger white
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matter vacuolation. Therefore taken together these two studies suggest that it is
possible the effects of CD40L on scrapie pathogenesis within the brain are strain-
dependent.
CD40-CD40L interactions have a diverse range of activities within the immune
system and further studies are necessary to determine the precise effect of the
blockade of this signalling pathway on peripheral scrapie pathogenesis. Apart from a
lack of PNA-binding germinal centres (Xu et al., 1994), there was little evidence of
disrupted lymphoid architecture in lymphoid tissues of CD40L" " mice. Thus the
reduced incubation period was unlikely to be due to affects on lymphoid architecture,
such as the repositioning of splenic FDCs in close association with peripheral nerves
as recently shown in mice deficient in the CXCR5 chemokine receptor (Prinz et ah,
2003b).
CD40-CD40L interactions provide important signals for optimal macrophage
activation and CD40L-deficiency increases susceptibility to certain intracellular
pathogens (Campbell et ah, 1996; Marriott et ah, 1999; Soong et ah, 1996). For
example, macrophages from Leishmania-infected CD40L"7" mice contain high
parasite burdens and are unable to effectively control the parasitemia (Soong et ah,
1996). As studies suggest that macrophages may sequester and destroy scrapie
infectivity (Beringue et ah, 2000b; Carp and Callahan, 1981; Carp and Callahan,
1982), it is reasonable to speculate that in the absence ofCD40-CD40L signalling in
CD40L~/~ mice the clearance of scrapie infectivity by cells such as macrophages is
likewise inhibited. For example, studies from Prinz and colleagues (Prinz et ah,
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2002) demonstrate that in the absence of TNF receptor 1-signaling, replication of the
scrapie agent can occur in macrophages.
Following uptake by DCs, antigens rapidly enter the lysosomal compartment where
they are broken down into peptides for presentation to lymphocytes in association
with MHC class II (Banchereau et al., 2000). A recent study suggests that DCs may
handle TSE agents in a similar manner, as bone-marrow-derived DCs are able to
process and degrade PrPSc following in vitro exposure (Luhr et al., 2004; Luhr et al.,
2002). Similarly, studies in this thesis have shown that LC-like cells are capable of
degrading PrPSe and scrapie infectivity. Thus, highly efficient antigen processing
LCs might be impeded in processing of the scrapie agent in CD40L-deficient mice.
Inhibition of CD40L-dependent clearance mechanisms might allow infectivity to
accumulate earlier in draining lymphoid tissue shortening the disease incubation
period. Treatments that modulate this CD40L-dependent protective mechanism
might provide an effective therapeutic strategy for early intervention in TSE
pathogenesis.
Data presented here suggest that LCs are not involved in the active transportation of
the scrapie agent from the skin to lymphoid tissues. However these data do suggest
that a CD40-CD40L dependent mechanism is involved in impeding scrapie
neuroinvasion. The precise mechanism by which scrapie infectivity is transported
from the skin to lymphoid tissues remains to be identified. Experiments in this
chapter only addressed the role of active LC migration in the transportation of
scrapie, it is possible that LCs may transport scrapie to the DLN in a steady-state.
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Furthermore, it is possible that scrapie infectivity is transported in a cell-free manner.
Soon after entering the host antigens are rapidly opsonised by complement
components. Recent research has shown that complement components play an
important role in the localization of the scrapie agent to lymphoid tissues (Ishii et al.,
1984; Klein et ah, 2001; Kovacs et ah, 2004; Lotscher et ah, 2003; Mabbott et ah,
2001) suggesting the scrapie agent might be delivered to lymphoid tissues as cell-
free complement-bound complexes. Understanding the earliest peripheral
mechanisms involved in the transportation or degradation of the scrapie agent will be
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8.1 Infection of the skin with TSE agents
Studies in this thesis have demonstrated that following transmission via the skin low
levels of scrapie infectivity persist in the skin for up to 7 days after inoculation
(Chapter 3). It is not known which cells within the skin the scrapie agent associates
with during this time period. Previous studies have shown that both keratinocytes
and Langerhans cells (LCs) within the epidermal layers of the skin express the host
cellular form of the prion protein PrPc (Pammer and Tschachler, 2002; Pammer et
al., 1998; Sugaya et al., 2002). This raised speculation that these cell types might be
the first cellular targets for TSE agent replication following exposure via the skin.
However, studies reported here have demonstrated that scrapie infectivity does not
replicate in the skin early in the disease incubation period (Chapter 3). During the
clinical phase of scrapie in sheep the animals develop a chronic itch of the skin
(McGowan, 1922; Scott, 1993), suggesting that it is possible that scrapie infectivity
might return to the skin later in the incubation period as the disease becomes more
systemic. For example, infectivity is detectable in the skin of greater kudu affected
with BSE (Cunningham et al., 2004). However, it is also conceivable that the itching
displayed by scrapie-affected sheep is due to the degeneration of sensory neurons
within the central nervous system (CNS). Taken together these data suggest that it is
unlikely that scrapie infectivity is transmitted via abraded skin during the early stage
of the disease, but this route of transmission might occur during the clinical phase.
Keratinocytes in the epidermis of the skin are continually shed from the skin and are
completely renewed within approximately 28 days (Williams, 1995). As the level of
scrapie infectivity present declines to trace levels by 7 days after inoculation, it is
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likely that much of the original infectivity is shed from the skin. It is also possible
that in a clinically affected animal the shedding of TSE-infected cells from the
epidermis could result in environmental contamination and subsequent spread of
infection. For example, studies have demonstrated that animals can acquire TSE
infection through exposure to other TSE-infected animals(Brotherston et al., 1968;
Haralambiev et ah, 1973; Miller et ah, 2004) or exposure to pastures previously
inhabited by TSE- affected animals(Greig, 1940; Miller et ah, 2004; Palsson, 1979).
As PrPSc is relatively resistant to degradation (Brown and Gajdusek, 1991;
Somerville et ah, 2002) it is possible that TSE-infected epithelial cells could
contaminate the natural environment. For example, a scrapie-affected sheep
scratching against a fence post might leave scrapie-infected epidermal cells on the
post, which then might be transferred to another animal scratching against the same
post.
Alternatively, the natural transmission of TSE agents via the skin might occur via
ectoparasites (Lupi, 2003). Infestation by ecoparasites is common occurrence in
sheep as well as other wild and domestic animals. Studies have demonstrated that
flies (Sarcophaga carnaria) (Post et ah, 1999) and mites (Lepidoglyphus destructor,
Acarus farris) (Wisniewski et ah, 1996) can acquire infectivity when exposed to
TSE-affected brains, suggesting that ectoparasites might function as reservoirs or
vectors for the transmission of TSE agents in the natural environment.
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8.2 Transport of TSE agents from the skin
8.2.1 Langerhans cells
Studies in this thesis have shown that scrapie infectivity first accumulates to high
levels in the draining lymph node (DLN) following transmission via the skin
(Chapter 3). However, it is not known how TSE agents are transported from the site
of inoculation to the DLN. Previous research has shown that a sub-population of
dendritic cells (DCs) are capable of transporting PrPSc from the gut lumen to the
mesenteric lymph nodes (Huang et al., 2002). LCs are a subset ofDCs that reside in
the epidermis and migrate to the DLN following antigen encounter (Banchereau et
ah, 2000). In this thesis it was hypothesised that LCs might actively transport the
scrapie agent from the skin to the DLN (Chapter 7). In these studies mouse models
were utilised in which active LC migration was inhibited either due to CD40 ligand-
deficiency (CD40L"/_ mice) (Moodycliffe et ah, 2000), or following caspase-1
inhibition (Antonopoulos et ah, 2001) (Chapter 7). These studies demonstrated that
the transport of the scrapie agent from the skin to the DLN was not impaired in the
absence of active LC migration (Chapter 7). However, recent studies have
demonstrated that LCs can also migrate from the epidermis in a steady-state without
becoming immunologically activated (Hemmi et ah, 2001; Yoshino et ah, 2003).
These studies suggested that steady-state migration might be a pathway employed
following encounter with self-antigen, where high levels of pro-inflammatory
cytokines are not produced. Thus, this would prevent the up-regulation of
immunostimulatory molecules, which could induce autoreactivity. As PrPSc is likely
to be considered a self-antigen due to its similarity to the host protein PrP (Stahl et
ah, 1993), it is possible that LCs might transport TSE agents via a steady-state
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migratory pathway. This hypothesis is supported by studies in this thesis which
demonstrate that LCs do not become immunologically activated following in vitro
exposure to the scrapie agent (Chapter 6).
Alternatively, LCs might have a similar role in TSE pathogenesis to that of
macrophages, which have been suggested to play a dual role in scrapie pathogenesis
(Beringue et al., 2000b; Carp and Callahan, 1981; Carp and Callahan, 1982; Prinz et
al., 2002). Macrophages are considered to degrade the TSE agent (Beringue et al.,
2000b; Carp and Callahan, 1981; Carp and Callahan, 1982), but in some
circumstances may also accumulate PrPSc, especially following exposure to high
doses of inoculum (Prinz et al., 2002). Experiments in this thesis demonstrate that
that LCs can partially degrade the scrapie agent, however data also shows that these
cells can retain PrPSc following LPS-stimulation (Chapter 6). Thus, the role of LCs
in TSE pathogenesis might be dictated by the microbiological and immune status of
the host. Previous studies in mice have demonstrated that treatment with LPS prior
to intra-peritoneal inoculation with the scrapie agent increased the efficiency of
scrapie infection (Kimberlin and Walker, 1990). The mechanism by which LPS
increased the efficiency of infection was not identified. It has been suggested that
LPS-stimulation might reduce the amount of infectivity taken up by phagocytic cells
(Kimberlin and Walker, 1990), possibly by reducing their responsiveness to a second
antigen (Steinman, 1991). These data suggest that transmission of TSE agents via
the skin in the naturally occurring disease in the field might be more efficient than




The skin is highly innervated containing predominately-unmyelinated C-fibre nerves
that are present within both the dermis and epidermis (Williams, 1995). The nerves
at the site of inoculation (medial surface of the thigh) in this study belong to the
obturator nerve, which arises from the second to fourth lumbar ventral rami of the
spinal column (Berry et al., 1995). Previous studies have shown that demylinated
nerves are more permissive to scrapie infection (Kimberlin et al., 1983a). It is
therefore conceivable that following skin scarification the TSE agent could be
directly transported from the skin by peripheral nerves to the spinal column and then
to the brain. However, studies by Taylor et al (Taylor et al., 1996a), and studies
reported in this thesis (Chapter 4), have demonstrated that highly immunodeficient
SCID mice are refractory to scrapie infection following transmission via the skin.
These data suggest that the scrapie agent is unable to reach the CNS directly via
peripheral nerves in the skin but requires an amplification phase within the lymphoid
tissues prior to neuroinvasion. The nerves in the skin at the site of inoculation might
contain TSE infectivity. However, it is possible that the amount of agent available
for uptake by nerves within the skin is insufficient to induce the clinical disease
within the lifespan of the host. Thus, an obligatory accumulation phase within
lymphoid tissues (Chapter 4 and 5) is required to generate the threshold levels of
infectivity required to induce clinical disease. Alternatively, the nerves within the
skin might not be permissive for infection and a systemic spread of infectivity is
required to access the nerves that are permissive to infection.
244
.2.3 Dermal dendritic cells
An alternative TSE transport mechanism might be via dermal dendritic cells (DDCs)
within the dermis of the skin (Chapter 1; Fig. 1.1.) which provide a LC-independent
antigen-presenting pathway (Kurimoto et ah, 1994; Streilein, 1989). To determine
the role of all DCs in TSE agent transport, a DC-deficient mouse model could be
utilised. CDllc is expressed by all murine DC subsets except LC and DDC which
only express this surface marker at low levels prior to maturation (Kimber et ah,
1999; Larregina et ah, 2001; Stoitzner et ah, 1999). In CD1 lc-DTR transgenic mice
the diphtheria toxin receptor (DTR) is expressed under the control of the CDllc
promoter (Brocker et ah, 1997). Murine cells unlike primate cells are insensitive to
diphtheria toxin. Therefore, injection of CD1 lc-DTR transgenic mice with diphtheria
toxin temporarily depletes those cells only expressing the DTR (i.e. DCs) (Jung et
ah, 2002). As skin derived DCs do not express high levels of CDllc this mouse
model would not be appropriate for studying the role of skin derived DCs in TSE
pathogenesis. However, alternative transgenic mouse models could be generated in
which DTR was expressed under the control of the Langerin promoter (Valladeau et
ah, 2002) or the CD205 promoter (Figdor et ah, 2002) to investigate a role for LCs,
or the CD Id promoter (Gerlini et ah, 2001) to investigate the role of DDCs in the
transport of TSE agents.
8.2.4 Cell-free
Alternatively, TSE agents might also be transported from the skin to the DLN via
cell free mechanisms. Soon after entering a host some antigens are rapidly bound by
complement components (Nielsen et ah, 2000; Song et ah, 2000). Studies have
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shown that after peripheral exposure to antigen immune complexes rapidly localize
within the subcapsular sinus of the DLN before localisation to FDCs which express
complement receptors CR1, CR2 and CR3 (Kamperdijk et al., 1987; Van De Berg et
al., 1995). It is therefore conceivable that the scrapie agent is bound by complement
upon entering the host and transported to FDCs via this cell-free mechanism. Studies
have already suggested that complement and cellular complement receptors may play
a role in the localization and retention of TSE agents by FDCs (Klein et ah, 2001;
Lotscher et ah, 2003; Mabbott et ah, 2001). These studies have demonstrated that
the absence of early complement components such as Clq and C3 the disease
incubation period is significantly extended (Klein et ah, 2001; Lotscher et ah, 2003;
Mabbott et ah, 2001). To investigate whether TSE agents are transported from the
skin to the DLN in a cell-free or a cell-associated manner the afferent lymphatics
draining the site of inoculation could be cannulated and cells and lymph draining the
site of inoculation collected. However, this would be technically difficult to perform
in mice due to the small size of lymphatic vessels. However, this technique has
already been performed in rat models intra-intestinally infected with the TSE agent
(Huang et ah, 2000).
8.3 Accumulation of TSE agents in lymphoid tissues
Following peripheral exposure, high levels of TSE infectivity and PrPSc usually
accumulate in lymphoid tissues prior to the dissemination of infection to the CNS
(Brown et ah, 1999; Eklund et ah, 1967; Farquhar et ah, 1994; Kimberlin and
Walker, 1979; Mabbott et ah, 2000b). At present the targeting of the LRS prior to
neuroinvasion has been demonstrated in vCJD patients (Hilton et ah, 1998), CWD in
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deer and elk (Sigurdson et al., 1999), sheep with natural scrapie (van Keulen et ah,
1996) and rodents experimentally inoculated with scrapie (McBride et ah, 1992).
Studies of experimental rodent models inoculated intra-peritoneally or orally with the
scrapie agent have shown that mature PrPc-expressing FDCs are critical for the
replication and accumulation of TSE agents within lymphoid tissues and its
subsequent neuroinvasion (Brown et ah, 1999; Klein et ah, 1998; Mabbott et ah,
2000a; Mabbott et ah, 2002; Mabbott et ah, 2000b; Mabbott et ah, 2003; Montrasio
et ah, 2000). PrPSc accumulation in association with FDCs has also been detected in
the lymphoid tissues of patients with vCJD (Hilton et ah, 1998), sheep with natural
scrapie (Andreoletti et ah, 2000; Heggebo et ah, 2002; Hermann et ah, 2003) and
deer with CWD (Sigurdson et ah, 2002). Similarly, studies in this thesis have
demonstrated that following exposure to the scrapie agent via scarified skin
infectivity accumulates first in the draining ILN to high levels prior to targeting the
non-draining ILN and the spleen (Chapter 3). Furthermore, PrPc-expressing FDCs
are critical for the accumulation of the scrapie agent within lymphoid tissues and
subsequent neuroinvasion following skin scarification (Chapter 4 and 5). However,
it is not known how TSE agents are transported from the DLN to other lymphoid
tissues. Studies have previously demonstrated that it is possible to transmit TSE
infectivity via blood (Houston et ah, 2000; Hunter, 2003; Hunter and Houston, 2002;
Llewelyn et ah, 2004; Pincock, 2004). Data presented in this thesis suggests that the
scrapie agent might be transported from the draining ILN to other lymphoid tissues
via the efferent lymphatic into the blood (Chapter 3, 5, 7), as similar levels of scrapie
infectivity are first detected within the non-draining ILN and spleen at the same time
point after inoculation.
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The importance of the spleen for the accumulation and replication of TSE agents
following peripheral challenge has been demonstrated by genetic asplenia and
splenectomy of rodents either prior to or shortly after TSE inoculation (Clarke and
Haig, 1971; Fraser and Dickinson, 1970; Fraser and Dickinson, 1978). In the
absence of the spleen around the time of inoculation the disease incubation period is
*
significantly prolonged (Clarke and Haig, 1971; Fraser and Dickinson, 1970; Fraser
and Dickinson, 1978). However, the presence of the spleen is not obligate for
establishing scrapie infection, as splenectomy does not affect disease susceptibility
(Clarke and Haig, 1971; Fraser and Dickinson, 1970; Fraser and Dickinson, 1978).
Furthermore, splenectomy of mice either before or after subcutaneous inoculation
with TSE agents has no affect on the disease incubation period (Fraser et al., 1992;
Kimberlin and Walker, 1989a). This suggests that other lymphoid tissues
accumulate TSE agents in the absence of the spleen. Similarly, data presented in this
thesis suggests that the spleen is not critical for the accumulation and subsequent
neuroinvasion of the scrapie agent following transmission via the skin (Chapters 3, 5
and 7). Treatments which temporarily dedifferentiate FDCs, block the early
accumulation of PrPSc and infectivity in lymphoid tissues and significantly delay
neuroinvasion when treated prior to peripheral inoculation with TSE agents (Mabbott
et al., 2000a; Mabbott et al., 2002; Mabbott et al., 2000b; Mabbott et al., 2003;
Montrasio et al., 2000; Prinz et al., 2002). However, these treatments have no effect
on TSE pathogenesis once infection is established within the peripheral nervous
system (Mabbott et al., 2000a; Mabbott et al., 2003; Montrasio et al., 2000). In this
study, temporary dedifferentiation of FDCs within the first two weeks after
inoculation with the scrapie agent via the skin delays neuroinvasion (Chapter 5).
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However, the lack of any observable effect of treatment on disease pathogenesis
when given 42 days after inoculation via the skin (Chapter 5) suggesting that
neuroinvasion had occurred by this time. Furthermore, these data suggest that
neuroinvasion might have occurred directly from the draining ILN, which contained
high levels of PrPSc at 42 days after inoculation, whereas the spleen and the non-
draining lymph node contained only limited levels (Chapter 5).
8.4 How do TSE agents reach follicular dendritic cells?
Once TSE agents reach lymphoid tissues after exposure by skin scarification it is not
known how they are transported within lymphoid tissues to FDC networks. If skin
derived DCs were responsible for the transportation of TSE agents from the skin to
the DLN, then these cell populations would most likely migrate to the paracortex
which is anatomically distinct from the outercortex where FDCs reside (von Andrian
and Mempel, 2003).
Studies have demonstrated that some migratory DCs containing processed antigen
are phagocytosed by resident DCs within lymph nodes (Inaba et al., 1998). Thus, it
is possible that the TSE agents might be transferred from skin derived DCs within
the paracortical region to other sub-populations of DCs, such as germinal centre
dendritic cells (GCDCs) found within the FDC containing outercortex, (Grouard et
al., 1996). As GCDCs express both complement and Fc-receptors (Grouard et al.,
1996), these cells would also have the potential to acquire complement bound TSE
agents.
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Studies have shown that a population of skin-derived DCs that express CXCR5
respond to B-lymphocyte chemoattractant (CXCL13) stimulation, allowing them to
directly migrate to germinal centres within lymph nodes (Saeki et al., 2000). As DCs
can directly transfer native antigen to B-lymphocytes (Batista et ah, 2001; Wykes et
ah, 1998), it is possible that skin-derived DCs could also transfer TSE agents directly
to B-lymphocytes within germinal centres (Saeki et ah, 2000; Wykes et ah, 1998; Yu
et ah, 2002). However, these cells would have to retain TSE agents in their native
form. Although, studies described in this thesis have demonstrated that LCs have the
potential to degrade both scrapie infectivity and PrPSc however this was not evident
until at least 48 hours post-exposure (Chapter 6). It is likely that this time would be
sufficient for LCs to migrate to the DLN and deliver TSE agents to B-lymphocytes in
native form (Austyn et ah, 1988). In order to determine whether LCs could transfer
the TSE agent directly to other cell populations LCs could be exposed to
fluorescently labelled PrPSc and co-cultured with other cell populations such as B-
lymphocytes and FDCs. The transfer of PrPSc could be determined by FACS
analysis of the recipient cell populations.
In addition, the scrapie agent could be disseminated into the microenvironment of the
DLN following apoptosis of skin derived DCs. Between 2-3 days after arrival at the
DLN, skin derived DCs undergo apoptosis following interactions with T-
lymphocytes (Ingulli et ah, 1997; Kawamura et ah, 1998), releasing apoptotic bodies
into the microenvironment of the DLN which are then cleared by phagocytic
cells(Jacobson and McCarthy, 2002). Therefore, skin derived DCs infected with
TSE agents might transfer them to the phagocytic cells via apoptotic bodies
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(Jacobson and McCarthy, 2002). Studies in this thesis have shown that the partial
degradation of the scrapie agent by LCs occurs over a 96 hour time period (Chapter
6). In vivo it is likely that LCs would have undergone apoptosis prior to degradation
of the agent. In order to investigate whether LCs infected with TSE agents undergo
apoptosis in vivo and release their contents, a reporter transgene could be inserted
into a LC cell line and the cells exposed to fluorescently labelled PrPSc. The PrPSc
containing LCs could then be injected into syngeneic mice and DLNs collected post-
inoculation. The presence of functional LCs could be determined by the expression
of the reporter gene which would be undetectable following apoptosis. The cellular
dissemination of PrPSc could be determined by FACS analysis or confocal
microscopy.
Exosomes are secreted intralumenal contents of multivesicular bodies which are
released by many cell types including DCs (Zitvogel et al., 1998) and B-lymphocytes
(Raposo et al., 1996). Recent research has demonstrated that exosomes released
from PrPSc neuroglial infected cell lines are capable of transferring PrPSc both in vitro
and in vivo (Fevrier et al., 2004). These data suggest that TSE agents might be
released from skin derived DCs via exosomes which could then fuse with the cell
surface of other local cell populations.
TSE agents might also be disseminated within the DLN by a cell-free mechanism.
Following peripheral exposure lymph-borne antigens initially drain to the
subcapsular sinus of the DLN. Antigens are then transported either directly into the
medullary sinuses and leave the DLN via the efferent lymph vessel, or they drain into
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a reticular conduit system gaining access to the follicles (von Andrian and Mempel,
2003). Lymph-borne molecules can only drain via the conduit system if they are
taken up by resident phagocytic cells or if they are of a molecular weight of less than
approximately 60-kDa (Nolte et al., 2003). Studies have shown that a 60-kDa PrP
molecule derived from TSE-affected brain is most likely a PrP dimer (Priola et ah,
1995). These data suggest that if PrPSc arrived at the DLN as cell free dimers or
aggregates greater than 60 kDa then their size would be to large to permit drainage
via the conduit system (Nolte et ah, 2003).
8.5 Neuroinvasion by TSE agents
Several studies have demonstrated that TSE agents gain access to the CNS via the
neural pathways and ganglia of the peripheral nervous system (Beekes and McBride,
2000; Beekes et ah, 1998; Glatzel and Aguzzi, 2000; Glatzel et ah, 2001; McBride
and Beekes, 1999; McBride et ah, 2001). For example, after oral inoculation of
hamsters with the 263K scrapie strain, neuroinvasion from the gut occurs via the
vagus and splanchnic nerves (Beekes and McBride, 2000; Beekes et ah, 1998;
McBride et ah, 2001). The route of neuroinvasion following inoculation via the skin
is not known. The vagus nerve does not constitute the major innervation nervous
pathway within the ILNs or the spleen (Felten and Felten, 1991; Mignini et ah, 2003)
tissues in which scrapie infectivity is first detected following inoculation via the skin.
However, studies have shown that after intra-peritoneal inoculation with TSE agents
sympathetic nerves within the spleen are important for subsequent neuroinvasion of
the agent (Glatzel et ah, 2001).
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Little is known of the innervations of ILNs in mice. A number of studies have
demonstrated that the cervical, mesenteric and popliteal lymph nodes of mice are
innervated by both sympathetic and sensory nerve fibres from the lumbar region of
the spinal column (Berry et al., 1995; Felten and Felten, 1991; Mignini et al., 2003).
These nerves innervate the paracortical, cortical and medullar regions of the lymph
node (Felten and Felten, 1991; Mignini et al., 2003). However, the presence of these
fibres within the germinal centres has not yet been identified (Mignini et al., 2003).
In comparison, approximately 98% of nerve fibres within the spleen are sympathetic
(Mignini et al., 2003) and are derived primarily from the superior mesenteric-coeliac
ganglion which connects to the thoracic region of the spinal column (Berry et al.,
1995; Mignini et al., 2003). Nerve fibres within the spleen can be detected in the
periarterial lymphatic sheath, marginal zone, sinuses and the parafollicular zone with
the occasional fibre supplying the follicles (Mignini et al., 2003).
At present it is not known how TSE agents are transported from FDCs to the nerves
within lymphoid tissues. However, artificial movement of FDCs closer to peripheral
nerves, by disruption of chemokine gradients responsible for the localisation of
FDCs in lymphoid tissues (Endres et al., 1999; Force et al., 1995; Futterer et al.,
1998), enhanced the neuroinvasion of the scrapie agent (Prinz et al., 2003b). This
suggests that TSE agent transport to peripheral nerves could occur directly from
FDCs. However, it is also possible that TSE agents might be transported to nerves
by mobile cells, such as the DCs (Aucouturier et al., 2001). As the lymphoid
follicles in the spleen appear to be more innervated than those of the ILN and the
nerves from the spleen enter the spinal column at a point closer to the brain than that
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observed for the ILNs (Cano et al., 2001; Felten and Felten, 1991; Mignini et al.,
2003), it would be reasonable to assume that neuroinvasion would occur faster from
the spleen than the ILNs following skin scarification. However, data presented in
this thesis suggests that neuroinvasion is most likely to occur first from the draining
ILN (Chapter 5). Although, this does not exclude the possibility that neuroinvasion
also occurs from the spleen at a later time point. Further studies are needed to
determine the precise neuroanatomical pathway by which TSE agents spread to the
CNS following inoculation via the skin.
8.6 Potential opportunities for therapeutic intervention
Once TSE agents spread to the CNS the neurodegeneration they cause is likely to be
irreversible. Therefore, the development of therapeutic strategies which block the
neuroinvasion of TSE agents are more likely to be effective at preventing clinical
disease or extending the disease incubation period than those which target the disease
within the CNS.
Blockade of the lymphotoxin-P receptor (LTpR) signalling pathway by treatment
with LTpR-Ig, results in the temporary dedifferentiation of FDCs within 3 days of
treatment for approximately 28 days (Mackay and Browning, 1998). Previous
studies have shown that treatment with LTpR-Ig before intra-peritoneal or oral
inoculation with the scrapie agent reduces disease susceptibility and extends survival
time (Mabbott et al., 2000a; Mabbott et al., 2003; Montrasio et al., 2000). Data in
this thesis has shown that treatment with LTpR-Ig likewise extends survival time
when given up to 14 days after exposure to the scrapie agent via scarified skin
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(Chapter 5). However, FDC dedifferentiation at 42 days after inoculation did not
affect neuroinvasion suggesting that the scrapie agent had spread from FDCs to
peripheral nerves between 14-42 days after inoculation (Chapter 5). These
observations indicate that the time period in which FDCs can be manipulated to
delay TSE pathogenesis following inoculation via the skin is short.
DCs are the most powerful professional antigen presenting cells within the body
(Banchereau et al., 2000; Banchereau et ah, 2001; Banchereau and Steinman, 1998).
Inaba and co-workers were the first to demonstrate that injection of DCs previously
exposed to antigen in vitro could generate an immune response in vivo (Inaba et ah,
1990). Since this initial study DCs have been considered for use as vectors for
immunotherapy against cancer (Paczesny et ah, 2003) and viral diseases (Ludewig,
2003). TSE infections do not appear to induce humoral (Chandler, 1959; Clarke and
Haig, 1966; Marsh et ah, 1970; Pattison et ah, 1964; Porter et ah, 1973) or cellular
(Kingsbury et ah, 1981) immune responses. Studies in this thesis have shown that
LCs can acquire PrPSc but do not alter their expression of the cellular markers
associated with an immune response, suggesting that LCs respond to PrPSc in a
toleragenic manner. Recent research has identified an epitope within the PrP
molecule which is displayed specifically by PrPSc (Paramithiotis et ah, 2003) thus, it
is possible that DCs could be primed in vitro to recognise this epitope and be injected
in vivo to generate an immune response specific to TSE agents. In conclusion, data
in this thesis has demonstrated how understanding the earliest stages of TSE diseases
might aid in the development of therapeutic strategies.
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8.7 Conclusion
Collectively data presented here demonstrates that scrapie infectivity administered
via the skin is transported to the DLN where it accumulates to high levels prior to
dissemination to other lymphoid tissues, most likely via the blood (Chapter 3). The
mechanism by which the scrapie agent is transported from the skin to the DLN is
unknown as the early accumulation of the agent within the DLN and its subsequent
neuroinvasion was not impaired in mice with blocked LC migration (Chapter 7).
Thus, LCs are unlikely to be involved in the active transportation of TSE agents from
the skin. Once the scrapie agent has reached lymphoid tissues, PrPc-expressing
FDCs are critical for the accumulation of scrapie infectivity within these tissues
(Chapter 4). In the temporary absence of FDCs disease susceptibility is reduced
and/or the survival time increased (Chapter 5). Subsequent neuroinvasion from
lymphoid tissues appeared to occur between 14 and 42 days post-inoculation
(Chapter 5). In vitro studies have demonstrated that LCs acquire and degrade the
scrapie agent in a non-activated state (Chapter 6). Furthermore, this ability is lost in
the presence of LPS, suggesting that LCs could be involved in either the degradation
or accumulation of the scrapie agent depending on the microbiological and
immunological status of the skin. Although studies presented here show that LCs are
unlikely to be involved in the transport of the scrapie agent, further studies are
required to determine how the scrapie agent is transported from the site of
inoculation to the DLN. Understanding the earliest stages of TSE pathogenesis after
inoculation via the skin will aid in the development of therapeutic strategies and help
to determine the risk of natural TSE transmission via the skin.
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APPENDIX 1: PrP Epitopes








7A12 122-143 GGLGGY.. .MIHFGN
Table 1.1- Antigenic amino acid sequences for anti-PrP antibodies. Complied from
(Farquhar et al., 1989), (Korth et al., 1997) and (Zanusso et al., 1998). Sequences
were derived by PEPSCAN analysis.
10 20 30 40 50 60
MANLGYWLLA LFVTMWTDVG LCKKRPKPGG WNTGGSRYPG QGSPGGNRYP PQGGTWGQPH
70 80 90 100 110 120
GGGWGQPHGG SWGQPHGGSW GQPHGGGWGQ GGGTHNQWNK PSKPKTNLKH VAGAAAAGAV
130 140 150 160 170 180
VGGLGGYMLG SAMSRPMIHF GNDWEDRYYR ENMYRYPNQV YYRPVDQYSN QNNFVHDCVN
190 200 210 220 230 240
ITIKQHTVTT TTKGENFTET DVKMMERWE QMCVTQYQKE SQAYYDGRRS SSTVLFSSPP
250
VILLISFLIF LIVG-C-Terminal
Figure 1.1- PrPc sequence and antibody recognition sites. The mouse PrP amino
acid sequence was obtained from Swissport accession number P04925
(http://ca.expasy.org. sprot/). Antibody recognition sites have been matched
according to information found in the following publications; (Farquhar et al., 1989;
Korth et al., 1997; Zanusso et al., 1998). The PrPc sequence is highlighted according
to specific antibody binding sites; blue- 1B3, pink-6H4, green- 8H4 and red-7A12.
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Summary Background: Transmissiblespongiformencephalopathies<TSEs)arechronic
infectious neurodegenerative diseases that are characterized by the accumulation in
affected tissues of PrPSc, an abnormal isoform of the host prion protein (PrPc). Following
peripheral exposure, PrPSc usually accumulates on follicular dendritic cells (FDCS) in
lymphoid tissues before neuroinvasion. Studies in mice have shown that TSE exposure
through scarified skin is an effective means of transmission. Following inoculation via the
skin, a functional immune system is critical for the transmission of scrapie to the brain as
severe combined immunodeficiency (SCID) mice are refractory to infection. Until now, it
was not known which components of the immune system are required for efficient scrapie
neuroinvasion following skin scarification. Objective: To determine which cells are
critical for the transmission of scrapie to the brain following inoculation via the skin.
Methods: A chimeric mouse model was used, which had a mismatch in PrPc expression
between FDCs and other bone marrow-derived cells within lymphoid tissues. These chi¬
meric micewere challengedwith scrapie by skin scarification toallowthe separate rolesof
FDCs and lymphocytes in peripheral scrapie pathogenesis to be determined. Results: We
show that mature FDCs are essential for the accumulation of scrapie within lymphoid
tissues and thesubsequent transmission of infection to the brain followingTSEexposure by
this route. Furthermore, we show that the accumulation of PrPSc and infectivity in the
spleen is independent of PrP expression by lymphocytes or other bone marrow-derived
cells. Conclusion: Following inoculation with scrapie by skin scarification, replication in
the spleen and subsequent neuroinvasion is critically dependent upon mature FDCs.












The transmissible spongiform encephalophathies
(TSEs or prion diseases) are a group of infectious,
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fatal, neurodegenerative diseases, which affect both
animals and humans. The precise nature of the TSE
agent is still subject todebate[1]. However, PrP50, an
abnormal, detergent-insoluble, relatively protei-
nase-resistant isoform of a host glycoprotein PrPc
[2], is considered to constitute a major or possibly
the sole component of the infectious agent [3], The
deposition of PrPSc within the brain of an infected
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host correlates in most TSE diseases with the devel¬
opment of neuropathological changes, such as vacuo-
lation, gliosis, and neuronal loss.
Many TSEs including natural sheep scrapie,
bovine spongiform encephalopathy (BSE), chronic
wasting disease in mule deer and elk, and variant
Creutzfeldt-Jakob disease (vCJD) in humans are
thought to be acquired by peripheral exposure.
For example, the consumption of BSE-contaminated
meat products by humans is most likely to be
responsible for the emergence of vCJD [4], Follow¬
ing peripheral inoculation with TSE agents, high
levels of infectivity and PrPSc usually accumulate
in lymphoid tissues prior to the dissemination of
infection to the central nervous system (CNS).
Within the lymphoid tissues of TSE-infected hosts
[5-10], PrPSc accumulation initially takes place in
germinal centres in association with follicular den¬
dritic cells (FDCs). Studies in rodents, inoculated
intra-peritoneally with scrapie, have shown that
mature FDCs are critical for scrapie accumulation
in lymphoid tissues. Furthermore, in the absence of
mature FDCs, the spread of disease to the CNS is
significantly impaired [7,8,11-14], From the lym¬
phoid tissues, infectivity is translocated to the CNS
via peripheral nerves [15].
Although oral acquisition (ingestion) is consid¬
ered to be the main route of natural exposure to TSE
agents, other potential routes of exposure have
been identified. Sporadic sCJD in humans has been
transmitted iatrogenically through transplantation
of sCJD-contaminated tissues or pituitary-derived
hormones [16]. BSE and natural scrapie have also
been shown to be transmissible experimentally by
blood transfusion between sheep [17,18] raising
speculation that vCJD in humans might also be
transmitted via blood transfusion from an infected
donor. Studies in mice have shown that skin scar¬
ification is an effective means of scrapie transmis¬
sion highlighting another possible route of exposure
[19], For example, some cases of natural sheep
scrapie might be transmitted through sites of skin
scarification or skin lesions during close contact
with other scrapie-infected animals [20], Scrapie
might also be established through skin or gum
lesions in the mouth [21], or be passed from mother
to offspring via the unhealed umbilical cord or
through sites of skin trauma at birth. Surgical instru¬
ments contaminated with sCJD infectivity have also
been shown to have the potential to transmit dis¬
ease [22], Animal models of TSE transmission
through scarified skin highlight important health
and safety issues, which include whether scientists
and health workers are at risk of acquiring infectiv¬
ity when handling infected tissues or instruments.
Biopharmaceutical and cosmetic products derived
from sheep and cattle tissues might harbour TSE
infectivity, with the potential to transmit disease
when applied to abraded skin [23,24], Understand¬
ing the immunobiology of scrapie transmission via
the skin will help in determining the possible sig¬
nificance of this route in natural TSE infections and
aid the development of therapeutic strategies.
Previous studies have shown that a functional
immune system is critical for the translocation of
scrapie to the CNS following skin scarification, as
severe combined immunodeficiency (SCID) mice are
refractory to scrapie infection by this route [19],
Studies in this laboratory using the ME7 scrapie
strain have shown that following inoculation by
intra-peritoneal injection, mature FDCs are critical
for efficient neuroinvasion [7,8,13,44,45], Flow-
ever, whether FDCs or other components of the
immune system are required for efficient scrapie
neuroinvasion following inoculation by skin scarifi¬
cation is not known. For example, as the skin is
highly innervated, it is plausible that lymphocytes
or Langerhans cells acquire scrapie within the skin
and transport it directly to peripheral nerves. To
maintain TSE infection, host cells must express the
cellular isomer of the host prion protein, as mice
deficient in PrPc (Prnp~'~ mice) do not develop
disease [25,26], Thus, in order to determine which
cells are critical for the efficient transmission of
scrapie to the CNS following inoculation via the skin,
we used a chimeric mouse model previously estab¬
lished in this laboratory, which had a mismatch in
PrPc status between FDCs and other bone marrow-
derived cells within lymphoid tissues [7], These
chimeric mice were challenged with scrapie by skin
scarification to allow the separate roles of FDCs and
lymphocytes in peripheral scrapie pathogenesis to
be determined.
2. Material and methods
2.1. Mice and bone marrow grafting
129/O/a mice were used as immunocompetent
wild-type controls. Bone marrow (BM) from the
femurs and tibias of immunocompetent adult
129/O/a (Prnpw+) mice or PrP-deficient 129/O/a
(Prnp~'~) mice [26] was prepared as a single-cell
suspension (3 x 107 to 4 x 107 viable cells per ml) in
Flank's balanced salt solution (Life Technologies,
Paisley, UK). Recipient SCID/Prnp+/+ mice [7] were
reconstituted with 0.1 ml BM by injection into the
tail vein. Recipient mice and age-matched
ungrafted controls were used in subsequent experi¬
ments 28 days after BM grafting. All mice were
housed in individually ventilated cages to ensure
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a high standard of microbiological hygiene. All pro¬
tocols using experimental rodents were approved by
the Institute's Protocols and Ethics Committee and
carried out according to the strict regulations of the
UK Home Office 'Animals (scientific procedures) Act
1986'.
2.2. Scrapie challenge
Mice were inoculated with the ME7 scrapie strain
by skin scarification of the medial surface of the left
thigh. Briefly, prior to scarification, approximately
1 cm2 area of hair covering the site of scarification
was trimmed using curved scissors and then
removed completely with an electric razor.
Twenty-four hours later a 23-gauge needle was used
to create a 5 mm long abrasion in the epidermal
layers of the skin at the scarification site. Then using
a 26-gauge needle, one droplet (~6pl) of ME7
scrapie inoculum from a 1% (w/v) terminal scrapie
mouse brain homogenate in physiological saline was
applied to the abrasion and worked into the site
using sweeping strokes. The scarification site was
then sealed with OpSite (Smith and Nephew Medical
Ltd., Hull, UK) and allowed to dry before the ani¬
mals returned to their final holding cages. Where
indicated separate groups of mice were inoculated
by intra-cerebral (i.e.) injection with 20 pi of the
same 1% scrapie mouse brain homogenate in phy¬
siological saline (a dose of approximately 1 x 104 5
i.e. 50% infectious dose [ID50] units) as a titre con¬
trol. Following challenge, animals were coded,
assessed weekly for signs of clinical disease, and
killed at a standard clinical end-point [27], Scrapie
diagnosis was confirmed by histopathological
assessment of TSE vacuolation in the brain. For
bioassay of scrapie infectivity, half spleens were
pooled from four animals from each group and
prepared as 10% (w/v) homogenates in physiological
saline and 20 pi injected i.e. into groups of 12 C57BL
indicator mice. The scrapie titer in each spleen was
determined from the mean incubation period in the
assay mice, by reference to established dose/incu¬
bation period response curves for scrapie-infected
spleen tissue [28],
2.3. Immunohistochemical analysis
To monitor FDC status, spleen halves were snap-
frozen and stored at the temperature of liquid
nitrogen. Serial frozen sections (thickness, 10 pm)
were cut on a cryostat and FDCs were visualized by
staining with the FDC-specific rat monoclonal anti¬
serum FDC-M2 (AMS Biotechnology, Abingdon, UK),
or 8C12 monoclonal antiserum to detect CD35 (BD
PharMingen, Oxford, UK). B-lymphocytes were also
detected using the rat monoclonal antiserum B220
to detect CD45R (Caltag, Towcester, UK). Immuno-
labelling was carried out using alkaline phosphatase
coupled to the avidin-biotin complex (Vector
Laboratories, Burlingame, CA, USA). Vector Red
(Vector Laboratories) was used as a substrate.
For the detection of PrP in brain tissue, tissues
were fixed in periodate-lysine-paraformaldehyde
and embedded in paraffin wax. Sections (thickness,
6 pm) were deparaffinized, and pretreated to
enhance PrP immunostaining by hydrated autoclav-
ing (15 min, 121 °C), and subsequent immersion in
formic acid (98%) for 5 min [5], Sections were then
stained with the PrP-specific monoclonal antiserum
6H4 (Prionics, Zurich, Switzerland) and immunola-
belling detected using hydrogen peroxidase coupled
to the avidin-biotin complex (Vector Laboratories)
with diaminobenzidine (DAB) as a substrate.
All sections were counterstained with hematox¬
ylin to distinguish cell nuclei.
2.4. Prnp genotype analysis of spleen tissue
Total DNA was extracted from spleen tissue frag¬
ments (approximately 5 mg) by proteinase K diges¬
tion and purified by phenol-chloroform extraction
by standard techniques. The Prnp genotypes of
spleen samples from BM-grafted animals were
determined by PCR analysis through the amplifica¬
tion of the Prnp gene, and a portion of the neomycin
resistance gene to detect the presence of the
Prnp~'~ genotype [26], The PCR mixture (total
volume 60.7 pi) contained; 5 pi of 10x PCR buffer,
5.0 pi of 50 mm MgCl2, 1.0 pi of 10 mm dNTP mix
(Life Technologies), 1 pi of chromosomal DNA,
0.5 pi (100pmol/pl) of specific primers, 0.2 pi of
Taq polymerase (Life Technologies) and 50 pi of
sterile Dnase- and Rnase-free water. PCR analysis
was performed using the following specfic primers:
Prnp Fwd-5'-ATG GCG AAC CTT GGC TAC TGG CTG-
3'; Prnp Rev-5'-TCA TCC CAG GAT CAG CAA GAT
GAG-3'. These primers anneal to the start and stop
codons of the Prnp gene open reading frame,
respectively and generate a fragment of
750 bp. The sequences of the oligonucleotide pri¬
mers for the neomycin resistance gene were: Neo
Fwd-5'-TTG AGC CTG GCG AAC AGT TC-3'; Neo Rev-
5'-GAT GGA TTG CAC GCA GGTTC-3'. These primers
anneal to the neomycin resistance gene present in
Prnp~'~ mice, which is located within exon 3 of the
Prnp gene [26], These primer pairs were designed to
generate a 550 bp fragment.
Following a hot start at 94 °C for 3 min, an
amplification cycle was carried out for 30 cycles
at the following temperatures: 94 °C for 50 s, 62 °C
for 50 s, 72 °C for 50 s on a thermal cycler (Genius
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PCR System, Techne, Cambridgeshire, UK). A final
extension period at 72 °C for 10 min was included at
the end of the 30 cycles. PCR products were
resolved by electrophoresis at 125 V through a
1.5% agarose gel containing 1 pg/ml ethidium bro¬
mide.
2.5. Immunoblot detection of PrPSc
Spleen fragments (approximately 20 mg) were
prepared as previously described by [29], Briefly,
before immunoblot analysis, tissue homogenates
were treated in the presence or absence of 80 pg
proteinase K (to confirm the presence of PrPSc) and
subsequently partially purified by treatment with 2%
(w/v) N-lauroylsarcosine (in 0.1 MTris-HCl pH 7.4),
allowing sedimentation only of the proteinase-K-
resistant, detergent-insoluble fraction of PrP
(PrPSc). Samples were subjected to electrophoresis
through sodium dodecyl sulphate 10-20% polyacry-
lamide gels (Bio-Rad, Hemel Hempstead, UK) and
transferred to polyvinylidine difluoride membranes
(Bio-Rad) by semi-dry blotting. PrP was detected
with the PrP-specific mouse monoclonal antiserum
8H4 [30] (a kind gift from Professor Man-Sun Sy,
Case Western Reserve University School of Medi¬
cine, Cleveland, OH, USA). Immunolabelling was
carried out using horseradish peroxidase-conju-
gated rat anti-mouse antiserum (Jackson ImmunoR-
esearch Laboratories Inc., West Grove, PA, USA),
and bound horseradish peroxidase activity detected
with Supersignal® West Dura Extended Duration
Substrate (Pierce, Chester, UK).
2.6. Statistical analysis
All data are presented as the mean ± S.E.M. and
error bars are indicated on figures where the S.E.M.
was 5% of the mean. The statistical significance of
differences in means of experimental groups was
calculated using ANOVA one-way analysis with Mini-
tab software. A P-value of 0.05 was considered to be
significantly different.
3. Results
3.1. Bone marrow reconstitution of
SCID/Prnp4/4 mice restores scrapie
susceptibility following inoculation by
skin scarification
To test the hypothesis that mature FDCs are
critical for the translocation of scrapie to the CNS
following skin scarification, a chimeric mouse
model was used, which had a mismatch in PrP status
between its FDCs and lymphocyte populations [7],
The mouse models were produced by grafting SCI D/
Prnp+/+ mice with either PrP expressing (Prnp+/+)
or PrP-deficient (Prnp~'~) BM from immunocompe¬
tent 129/Ola mice. As FDCs are not considered to be
derived from BM in adult mice [31,32], the lymphoid
tissues of SCID/Prrip+/4 mice grafted with Prnp~'~
BM (SCID/Prnp+/+ + Prnp~'~ BM) will have PrP
expressing FDCs and other stromal-derived cells
but will lack PrP expression on lymphocytes. In
contrast, SCID/Prnp+/+ mice grafted with Prnp+/+
BM (SCID/Prnp+/+ + Prnp+/+ BM) will contain both
PrP expressing FDCs and lymphocytes.
Twenty-eight days after BM grafting, wild-type
129/O/a mice, SCID/Prnp+/+ mice, SCID/Prnp+/+ +
Prnp+/+ BM mice and SCID/Prnp+/+ + Prnp~'~ BM
mice were inoculated with the ME7 scrapie strain by
skin scarification. All immunocompetent wild-type
129/O/a mice developed clinical signs of scrapie,
approximately 333 ± 13 days post-inoculation
(n = 12; Fig. 1). Characteristic disease-specific
PrP accumulation (Fig. 2a) and spongiform pathol¬
ogy (Fig. 2e) typical of a peripheral infection with
the ME7 scrapie strain was detected in the brains of
all wild-type mice, which developed clinical dis¬
ease. In contrast, previous studies have shown that
SCID mice are refractory to challenge with ME7
scrapie by skin scarification up to 586 days post-
inoculation [19], Unfortunately, despite careful
husbandry, all ungrafted immunodeficient SCID/
Prnp+/+ mice in this study succumbed to non-infec¬
tious, non-TSE diseases (eg: thymic tumours) up to
274 days post-inoculation (Fig. 1). Immunohisto-
chemical analysis of brain tissue from all scrapie-
inoculated SCID/Prnp4/+ mice failed to detect any
signs of disease-specific PrP accumulation (Fig. 2b)
or vacuolation (Fig. 2f) consistent with the demon¬
stration that these mice are refractory to scrapie
following peripheral inoculation. However, the sus¬
ceptibility of most SCID/Prnp4/+ mice to scrapie
infection was restored following grafting with
either Prnp4/+ or Prop _/~ BM (Fig. 1). Here, 6/11
SCID/Prnp+/+ mice grafted with Prnp+/+ BM devel¬
oped scrapie with a mean incubation period of 380 ±
12 days post-inoculation. Likewise 8/10 SCID/
Prnp+/+ mice grafted with Prnp~'~ BM developed
scrapie with a mean incubation period of 378 ± 4
days post-inoculation. Characteristic spongiform
pathology and disease-specific PrP accumulation
were detected in the brains of all grafted SCID/
Prnp+/+ mice, which succumbed to clinical disease
(Fig- 2).
No significant difference was observed between
the mean incubation periods of SCID/Prnp+/+ mice
grafted with either Prnp+/+ or Prnp~'~ BM. How¬
ever, a significant statistical difference was
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Fig. 1 Reconstitution of SCID/Prnp+/+ mice with immunocompetent BM restores susceptibility to scrapie when
inoculated by skin scarification. Wild-type (WT) mice (■); SCID/Prnp t/+ mice, SCID/Prnp,/+ mice reconstituted with
Prnp+/+ BM (□; SCID/Prnp+/+ + Prnp+/ f BM) and SCID/Prnp+/+ mice reconstituted with Prnp_/_ BM (□; SCID/Prnp+/+
+ Prnp'' BM) were inoculated with the ME7 scrapie strain by skin scarification (scarif.). Wild-type mice were also
inoculated by i.e. injection as a titre control (s; WT i.c). Each bar represents the mean incubation period ± S.E.M. (O)
Incubation periods for individual mice that succumbed to clinical scrapie. (•) Times at which SCID/Prnp+/+ mice
succumbed to non-TSE related disease.
observed between the mean incubation periods of
SCID/Prnp+/+ mice grafted with either Prnp+/+ BM
or Prnp ' BM when compared with wild-type mice
(P = 0.014 and 0.004, respectively, ANOVA one-way
analysis). Grafted SCID/Prnp+/+ mice developed
clinical scrapie approximately 47 days later than
the mean incubation period of immunocompetent
wild-type controls. However, no significant differ¬
ence in the pathological targeting of vacuolation in
the brain was observed between wild-type and
Clinical pos. neg pos. pos.
Fig. 2 Histological analysis of brain tissue from wild-type mice (a and e), SCID/Prnp+/+ mice (b and f), SCID/Prnp+/+
mice reconstituted with Prnp+/" BM (SCID/Prnp~ /+ + Prnp1''' BM; c and g), and SCID/Prnp+/^ mice reconstituted with
Prnp~'~ BM (SCID/Prnpf/+ + Prnp~'~ BM; d and h) inoculated with scrapie by skin scarification. Large PrP
accumulations (brown; upper row) and spongiform pathology (H and E; lower row) were detected in the hippocampi of
all mice, which developed the clinical signs of scrapie. In contrast, no evidence of PrP accumulation (b) or spongiform
pathology (f) was detected in the brains of any SCID/Prnpw+ mice that succumbed to non-TSE diseases up to 274 dpi.
All sections were counterstained with hematoxylin (blue); pos.: mice that developed clinical signs of scrapie; neg.:
mice that were free of the signs of scrapie. Original magnification 200x.
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Fig. 3 Confirmation of the Prnp genotype in the spleens of SCID/Prr>p+/+ mice reconstituted with either Prnp+l+ BM
(lanes 1—4) or Prnp~' BM (lanes 5—8). Analysis of total splenic DNA from SCID/Prnp+/' mice reconstituted with Prnp^/+
BM confirmed the presence only of the Prnp gene by the visualisation of a single band at 750 bp (lanes 1 —4). The visualisation
of two bands at 750 and 550 bp (lanes 5-8) confirmed the presence of both Prnp gene and a portion of the neomycin
resistance gene (Neomycin), respectively, within splenic DNA samples from SCID/Prnp+/+ mice reconstituted with Prnp
BM (SCID/Prnp'/+ + PrnpBM). LaneM, 200 bp molecular size markers. Controls included: C1, splenic DNA from a SCID/
Prnp+/+ + Prnp BM mouse; C2, splenic DNA from a wild-type/Prnp+/+ mouse; W, PCR-amplified water was used as a
negative control.
grafted SCID/Prnp+/+ mice suggesting that neuroin-
vasion had occurred via a common pathway in each
case.
Although the susceptibility of most SCID/Prnp+/+
mice to scrapie was restored following BM grafting,
5/11 SCID/Prnpw+ + Prnp+/+ BM mice and 2/10
SCID/Prnp+/+ + Prnp~'~ BM mice remained free
from the signs of scrapie 521 days post-inoculation,
at which point the experiment was terminated
(Fig. 1). Successful reconstitution and normal germ¬
inal centre architecture were confirmed in these
mice (data not shown); however, immunohisto-
chemical analysis of brain tissue from all surviving
mice failed to detect any spongiform change or
disease-specific PrP accumulation (data not shown).
Likewise, no PrPSc accumulation was detected in
the spleen by immunoblot analysis (data not shown)
suggesting these mice would not have developed
clinical scrapie at a later stage.
3.2. Confirmation of immune status and
germinal centre architecture
Spleens and serum were taken from all mice to
monitor immune status. Consistent with the
absence of B-lymphocytes in SCID mice [33,34],
serum from all ungrafted SCID/Prnp'7' mice con¬
tained barely detectable levels of immunoglobulin
(Ig) when compared with those of wild-type mice
(data not shown). However, ELISA analysis con¬
firmed that reconstitution of SCIDIPrnp'1' mice
with immunocompetent BM from either Prnp+,+
or Prnp mice restored serum Ig levels to those
observed in wild-type mice (data not shown). Thus
functional BM-derived B-lymphocytes had been suc¬
cessfully grafted into recipient SCID/Prnp+/" mice.
We next determined the Prnp genotype in the
spleens of grafted mice by PCR analysis of total
splenic DNA (Fig. 3). Analysis of DNA from SCID/
Prnp+/+ mice grafted with Prnp*/+ BM detected
the presence of only the Prnp gene by the visualisa¬
tion of a single band at 750 bp (Fig. 3, lanes 1-4). In
contrast, two bands were detected in splenic DNA
samples from SCID/Prnp"/+ mice grafted with
Prnp~'~ BM, demonstrating the presence of both
the Prnp gene (750 bp) and the neomycin resistance
gene (550 bp) (Fig. 3, lanes 5-8). Thus, these results
confirmed the presence of only Prnp*/+ cells within
the spleens of SCID/Prnp1"7"1" + Prnpf'' BMmice, and
the presence of both Prnp^'+ andPrnp~' cellswithin
the spleens of SCID/Prnp"/+ + Prnp BM mice.
The germinal centre architecture in the spleen
was analysed by immunohistochemistry. As
expected, FDC-M2 and CD35 expressing FDC net¬
works and B-lymphocytes (CD45R/B220) were
detected in the spleens of all immunocompetent
wild-type mice (Fig. 4). B-lymphocytes produce
important factors for the maintenance and matura¬
tion of FDCs. In the absence of B-lymphocytes FDCs
do not receive these important stimuli and do not
mature [33,34], Thus mice deficient in B-lympho-
cytes are indirectly deficient in FDCs. As Fig. 4
illustrates, both FDC networks and B-lymphocytes
were absent in spleens of ungrafted SCID/Prnp ''
mice, consistent with the immunodeficent pheno-
type of SCID mice [33,34], However, FDC networks
in the spleens of SCID mice can be restored follow¬
ing grafting with B-lymphocytes or immunocompe¬
tent BM as a source of lymphocytes [34]. Likewise,
mature FDC networks and B-lymphocytes were
restored in spleens of SCID/Prnp"/+ mice following
grafting with either Prnp''' or Prnp 1 BM(Fig. 4).
Thus, the restoration of germinal center architec¬
ture in the lymphoid tissues of SCID IPrnp'mice,
following BM grafting, coincided with the restored
susceptibility of these mice to scrapie.
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Fig. 4 Immunohistochemical analysis of the germinal centre architecture in spleen tissue from wild-type mice, SCID/
Prnp4/+ mice, SCID/Prnp+/+ mice reconstituted with Prnp474 bone marrow (SCID/Prnp4"74" + Prnp4/+ BM), and SCID/
Prnp"74 mice reconstituted with Prnp bone marrow (SCID/Prnp'/++ Prnp "7" BM). Adjacent frozen sections were
stained with FDC-M2 antiserum to detect FDCs (red; a-d), CD35-specific monoclonal antiserum 8C12 to detect
complement receptor 1 (red; e-h) and the CD45R-specific antiserum B220 to detect B-lymphocytes (red; i-l). All
sections were counterstained with hematoxylin (blue). As expected, FDC-M2 and CD35 expressing FDC networks and B-
lymphocytes (CD45R/B220) were detected in the spleens of all immunocompetent wild-type mice (a, e and i,
respectively). In the absence of B-lymphocytes, FDCs do not receive important stimuli and can not mature. Thus mice
deficient in B-lymphocytes are indirectly deficient in FDCs. As panels b, f, and j illustrate, both FDC networks and
B-lymphocytes were absent in spleens of ungrafted SCID/Prnp+/+ mice. However, mature FDC networks and
B-lymphocytes were restored in spleens of SCID/Prnph/+ mice following grafting with either Prnp+'+ (c, g, and k) or
Prnp BM (d, h, and I). Original magnification 400x (a-h), 200x (i-l).
3.3. Scrapie infectivity and PrPSc
accumulation in the spleen
Following peripheral inoculation with the ME7
scrapie strain, high levels of infectivity and the
disease-specific isoform of the prion protein, PrPSc,
accumulate in the spleen within 42 days post-inocu¬
lation and are maintained throughout the course of
infection [29], Spleen samples were taken from four
mice from each experimental group of mice 220
days post-inoculation with scrapie via skin scarifica¬
tion. The scrapie infectivity titre in spleen lysates
from each group was estimated by bioassay in
groups of 12 indicator mice. As expected, spleens
from scrapie-inoculated wild-type mice contained
high levels of infectivity (approximately 5.7 log i.e.
ID50/g). In contrast, scrapie infectivity was unde¬
tectable in spleen samples from ungrafted SCID/
Prnp 7 mice assayed 220 days post-inoculation
suggesting a scrapie infectivity titre, if present,
below 2.6 log i.e. ID50/g (at least 1000-fold less
than the level detected in spleens of wild-type mice
assayed at the same time post-inoculation). Scrapie
infectivity accumulation was restored in the spleens
of SCID/Prnp /+ mice following grafting with either
Prnp4"74 or Prnp~7~" BM to the same magnitude
observed in wild type mice at the same time point
(approximately 6.7 and 5.7 log i.e. ID50/g, for
SCID/Prnp+/+ mice grafted with either Prnp4/T or
Prnp"7 BM, respectively).
Similarly, immunoblot analysis of spleen tissue
from terminally affected wild-type mice detected
large accumulations of detergent-insoluble protei-
nase-K-resistant PrPSc (Fig. 5). A typical three-
banded pattern was observed between molecular
mass values of 20-30 kDa, representing the ungly-
cosylated, monoglycosylated, and diglycosylated
isomers of PrP (in order of increasing molecular
mass). However, no PrPSc accumulation was detect¬
able within the spleens of any ungrafted SCID/
Prnp4"74 mice assayed at various times after inocu¬
lation (Fig. 5a, lanes 4, 6 and 8). In comparison,
PrPSc accumulation was restored in the spleens of
terminally scrapie-affected SCID/Prnp'7+ mice
grafted with either Prnp4"7' or Prnp 7 BM to levels
similar to those observed in wild type mice (Fig. 5b).
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Fig. 5 Immunoblot analysis of spleen tissue from
terminally scrapie-affected wild-type mice (WT), SCID/
Prnp+/+ mice, SCID/Prnp+/+ mice reconstituted with
Prnp+/+ bone marrow (SCID/Prnp+/+ + Prnp'/+ BM),
and SCID/Prnp+/+ mice reconstituted with Prnp~'~ bone
marrow (SCID/Prnp+/+ + Prnp~'~ BM). Treatment of
tissue in the absence (-) or presence (+) of proteinase K
(PK) prior to electrophoresis is indicated. After PK
treatment, a typical three-band pattern was observed
between molecular mass values of 20 and 30 kDa,
representing unglycosylated, monoglycosylated, and digly-
cosylated isomers of PrP (in order of increasing molecular
mass). PrP was detected using the PrP-specific monoclonal
antiserum 8H4. (a) High levels of PrPSc were detected in
the spleens of terminally scrapie-affected WT mice, but
none was detected in tissues from SCID/Prnp+/+ mice at
any time point, (b) However, high levels of PrPSc were
detected in spleens of SCID/Prnp+/+ mice grafted with
either Prnp+/+ (SCID/Prnp+/+ + Prnp+/+ BM) or Prnp~'~
BM (SCID/Prop'/4 + Prnp~'~ RM). I ane B is blank; pos.:
mice that developed clinical signs of scrapie; neg.: mice
that were free of the signs of scrapie; dpi: day post-
inoculation on which the tissues were analysed.
4. Discussion
Previous studies have shown that skin scarifica¬
tion is an effective means of scrapie transmission in
immunocompetent mice. However, immunodefi-
cient SCID mice are refractory to scrapie when
inoculated by this route, illustrating that a func¬
tional immune system is critical for the transmission
of scrapie to the CNS following inoculation via the
skin [19]. In this study, we have demonstrated that
reconstitution of SCID mice with immunocompetent
BM restores scrapie replication within lymphoid
tissues following skin scarification. This effect coin¬
cided with the induction of FDC network maturation
within the spleens of grafted SCID mice and subse¬
quent ability to accumulate high levels of scrapie
infectivity and PrPSc. Furthermore, we have shown
that following inoculation via the skin, scrapie accu¬
mulation in lymphoid tissues and subsequent trans¬
location to the CNS is dependent on mature FDCs
but independent of the PrP status of lymphoytes and
other BM-derived cells. Taken together, these find¬
ings are consistent with previous studies, which
demonstrate that following intra-peritoneal inocu¬
lation with the ME7 scrapie strain, a functional
immune system and more critically PrP-expressing
FDCs, are required for transport of the agent from
the periphery to the CNS [7,8,13],
SCID mice suffer from a congenital syndrome,
which is characterised by the loss of both B- and T-
lymphocyte immunity [33], Secondary to this
defect, they also lack functional FDCs as stimulation
from lymphocytes is required for the maturation
and maintenance of FDCs [34], Unfortunately,
despite careful husbandry due to their dysfunctional
immune system, all scrapie-challenged SCID/Prnp+/
+ mice in this study succumbed to non-TSE related
disease up to 274 days post-inoculation. These dis¬
eases were non-infectious (e.g. thymic tumours)
and were not a reflection of the microbiological
status of the husbandry conditions, which were
maintained to a high standard of hygiene. Previous
data from this laboratory [19] have shown that in
contrast to wild-type mice, SCID mice did not suc¬
cumb to clinical scrapie following exposure to a
similar dose of scrapie via skin scarification (mean
survival period = 442 ± 21 days post-inoculation,
n = 23, range = 259-586 days). Following intra¬
peritoneal inoculation with ME7, scrapie PrPSc is
detected in the brain considerably before the onset
of clinical signs [29], In the current study, we
measured the levels of disease-specific PrP accu¬
mulations in the spleens and brains of all scrapie-
inoculated SCID mice. No disease-specific PrP accu¬
mulation was detected within the brains or spleens
of any of the scrapie-inoculated SCID mice, support¬
ing the assumption that they would not have sub¬
sequently developed clinical disease consistent
with data from previous studies using this TSE strain
[19], Scrapie infectivity was also undetectable in
the spleens of scrapie-inoculated SCID mice,
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assayed 220 days post-inoculation. These data are
consistent with the hypothesis that following inocu¬
lation by skin scarification, scrapie infectivity is
unlikely to reach the CNS by direct transport via
nerves within the skin or via the bloodstream.
Engraftment of SCID/Prnp+/+ mice with immu¬
nocompetent BM-restored functional lymphocyte
populations within the spleen. Furthermore, these
lymphocytes were functional as they produced
immunoglobulins and were able to stimulate FDC
maturation and network formation [33,34], The
development of germinal centre architecture, com¬
parable to immunocompetent animals, coincided
with restored scrapie susceptibility and the accu¬
mulation of infectivity and PrPSc in lymphoid tissues
of these mice. Thus, these data demonstrate that
following inoculation through scarified skin, scrapie
accumulates in lymphoid tissues prior to neuroinva-
sion, as observed with other peripheral routes of
exposure [7,9,35,36], Our studies also demonstrate
that PrPc expression on FDCs alone in lymphoid
tissues is sufficient to establish scrapie infection.
In the presence of PrPc-expressing FDCs, the PrPc
status of bone marrow-derived cells had no signifi¬
cant effect on the accumulation of infectivity and
PrPSc in the spleen or on disease incubation period.
Further experiments are necessary to determine
whether following inoculation via the skin, PrPc-
expressing lymphocytes are permissive to scrapie
replication in the absence of PrPc expression by
FDCs. Flowever, these results are consistent with
the demonstration that PrPc expression on FDCs, not
lymphocytes, is critical for the peripheral accumu¬
lation and transport of scrapie [7,12,37], Thus, we
consider that lymphocytes would likewise be unli¬
kely to play a key role following inoculation via the
skin. Although not directly involved in the replica¬
tion of ME7 scrapie strain, lymphocytes play an
important indirect role in pathogenesis by main¬
taining the maturation of FDC networks within lym¬
phoid tissues [33,34],
Interestingly, grafted SCID/PrnpF/+ mice did dis¬
play significantly longer incubation periods in com¬
parison to immunocompetent wild-type mice.
Similar results have also been observed in grafted
SCID mice inoculated with scrapie strain C506M3 by
intra-peritoneal injection [38], The reason for the
delay in the onset of the neurological disease in BM-
grafted SCID/Prnp+/+ mice is not known, but it
might be that at the time of scrapie inoculation
the restoration of geminal centre functionality in
these mice was incomplete. Incomplete reconstitu-
tion of SCID/Prnp+/+ mice might be a consequence
of the high natural killer cell activity within SCID
mice, which may impair the development of donor
BM cells [39], This effect could have reduced the
number of potential peripheral target cells, such as
FDCs, available for agent replication at the time of
inoculation. In the temporary absence of FDCs at
the time of inoculation, both scrapie replication in
the spleen and subsequent neuroinvasion are sig¬
nificantly delayed [13]. To achieve efficient recon-
stitution, it has been suggested that mice are sub-
lethally -/-irradiated prior to cell transfer, to encou¬
rage full maturation of grafted bone marrow cells
[40], This procedure was not undertaken in this
study as SCID mice have an increased sensitivity
to irradiation due a general defect in DNA repair
mechanisms, which is believed to be closely linked
to the scid mutation [41], It was our concern that y-
irradiation may have adverse affects on the archi¬
tecture of the skin, blood-brain barrier, or nerve-
brain barrier of SCID mice; any of which may have
facilitated neuroinvasion by an atypical mechanism.
Although neuroinvasion was delayed in the recon¬
stituted SCID/Prnp+/+ mice, no significant differ¬
ence was observed in the severity or distribution of
vacuolation or disease-specific PrP accumulation
within the brains of wild-type and grafted SCID
mice, suggesting that neuroinvasion had occurred
in these mice via a common pathway.
Although the grafting of SCID/Prnp+/+ mice with
immunocompetent BM-restored scrapie susceptibil¬
ity in most cases, 5/11 SCID/Prnp+/+ + Prnp+/+ BM
mice and 2/10 SCID/Prnp+/+ + Prnp~'~ BM mice
remained free from the signs of scrapie 521 days
post-inoculation, at which point the experiment
was terminated. ELISA and PCR genotyping analysis
suggested that reconstitution had been successful in
these surviving mice (data not shown), yet they
were refractory to peripheral inoculation. Studies
suggest that following BM grafting of SCID mice, it
takes approximately 4-6 weeks for full restoration
of BM-derived cell populations and germinal centre
architecture [40], As this time period may vary
between individual animals, it is conceivable that
in this study, the surviving grafted SCID/Prnp"^"1"
mice may not have achieved a mature, fully func¬
tional immune status, prior to inoculation. This may
have prevented scrapie replication establishing due
to a lack of functional peripheral target cells such as
FDCs [13], In the absence of mature FDCs at the time
of inoculation, it is likely that a significant amount
of the inoculum is destroyed by macrophages
[42,43]. This delay is again consistent with the
hypothesis that scrapie infectivity is unlikely to
reach the CNS from the skin by the direct capture
of infectivity by nerves within the skin or by direct
transport via the bloodstream.
Flow scrapie is transported from the skin to FDCs
within draining lymphoid tissues is not known.
Migratory BM-derived Langerhans cells are a plau-
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sible candidate mechanism as they acquire antigens
in the skin and transport them to lymphoid tissues.
Data presented here demonstrate that following
inoculation via the skin, the accumulation of scrapie
in the spleen and disease incubation period are not
affected by the PrPc status of bone marrow-derived
cells. Thus, if scrapie is transported from the skin to
lymphoid tissues in a cell-dependent manner, these
data suggest that PrPcexpression by such cells is not
critical.
Data presented here demonstrate that scrapie
replication in the spleen following inoculation by
skin scarification occurs only in the presence of
mature FDCs and is independent of the PrP status
of surrounding splenic lymphocytes and other bone
marrow-derived cells. Furthermore, our results
indicate that mature, functional FDCs are required
for subsequent neuroinvasion. These data are con¬
sistent with previous research using the ME7 scrapie
strain, which suggests that FDCs are critical for
efficient scrapie neuroinvasion following intra-peri-
toneal exposure [7,8,13]. Once TSEs spread to the
CNS, the neurodegeneration they cause is consid¬
ered irreversible. The identification of an important
role for FDCs in the pathogenesis of disease follow¬
ing skin scarification provides an opportunity for
therapeutic intervention prior to neuroinvasion as
are already being investigated following other per¬
ipheral routes of exposure [13,14,44,45],
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Transmissible spongiform encephalopathies (TSEs) are a group of sub¬
acute infectious neurodegenerative diseases that are characterized by the
accumulation in affected tissues of PrPSc, an abnormal isoform of the host
prion protein (PrPc). Following peripheral exposure, TSE infectivity and
PrPSc usually accumulate in lymphoid tissues prior to neuroinvasion.
Studies in mice have shown that exposure through scarified skin is an
effective means of TSE transmission. Following inoculation via the skin, a
functional immune system is critical for the transmission of TSEs to the
brain, but until now, it has not been known which components of the
immune system are required for efficient neuroinvasion. Temporary dedif¬
ferentiation of follicular dendritic cells (FDCs) by treatment with an
inhibitor of the lymphotoxin-/? receptor signalling pathway (LT/iR-Ig)
3 days before or 14 days after inoculation via the skin, blocked the early
accumulation of PrPSc and TSE infectivity within the draining lymph
node. Furthermore, in the temporary absence of FDCs before inoculation,
disease susceptibility was reduced and survival time significantly extended.
Treatment with LT/JR-Ig 14 days after TSE inoculation also significantly
extended the disease incubation period. Flowever, treatment 42 days after
inoculation did not affect disease susceptibility or survival time, sug¬
gesting that the infection may have already have spread to the nervous
system. Together these data show that FDCs are essential for the accumu¬
lation of PrPSc and infectivity within lymphoid tissues and subsequent
neuroinvasion following TSE exposure via the skin.
Keywords: follicular dendritic cell; lymphotoxin; scrapie; skin, transmis¬
sible spongiform encephalopathy
Introduction
The transmissible spongiform encephalopathies (TSEs), or
prion diseases, are subacute neurodegenerative diseases
that affect humans and both wild and domestic animals.
Most TSEs, including natural sheep scrapie, bovine
spongiform encephalopathy (BSE), chronic wasting dis¬
ease in mule deer and elk, and kuru and variant Creutz-
feldt-Jakob disease (vCJD) in humans, are acquired by
peripheral exposure. Although the main route of trans¬
mission of BSE to cattle and other species is considered
to be oral (ingestion), other routes of TSE transmission
have been identified. Accidental iatrogenic transmissions
of sporadic (s)CJD to patients have occurred through the
transplantation of sCJD-contaminated tissues or via pitu¬
itary-derived hormones.1 Recent evidence also indicates
that vCJD in humans has been transmitted via blood
transfusion.2'3 Studies in mice have shown that skin scari¬
fication is an effective means of scrapie transmission,
highlighting another potential route of accidental trans¬
mission.4 Therefore, it is possible that some cases of nat¬
ural sheep scrapie might be transmitted through skin
lesions either in the mouth5 or during close contact,6 or
be passed from mother to offspring through sites of skin
trauma at birth. Surgical instruments contaminated with
sCJD infectivity have also been shown to have the poten¬
tial to transmit disease.7 Together, these examples high¬
light important health and safety issues concerning risks
to patients, health workers and scientists of acquiring dis¬
ease. Biopharmaceutical and cosmetic products derived
from sheep and cattle tissues might also have the poten¬
tial to transmit disease when applied to skin lesions.8'9
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Understanding the immunobiology of scrapie transmis¬
sion via the skin will aid the determination of risk and
the development of therapeutic strategies.
The host prion protein (PrPc) is critical for TSE agent
replication and accumulates as an abnormal, detergent-
insoluble, relatively proteinase-resistant isoform, PrP^, in
diseased tissues.10 PrP^, or an intermediate between PrPc
and PrPSc, is considered to constitute a major, or possibly
the sole, component of the infectious agent.11 Once TSEs
infect the central nervous system (CNS), the accumulation
of PrPSc is accompanied by neurodegeneration and, ulti¬
mately, the death of the host. Following peripheral inocula¬
tion, TSE agents usually accumulate in lymphoid tissues
prior to the dissemination of infection to the CNS. Within
the lymphoid tissues of TSE-infected hosts,12-16 PrPSc accu¬
mulation initially takes place in germinal centres in associ¬
ation with follicular dendritic cells (FDCs). Studies in
rodents inoculated intraperitoneal^ with scrapie have shown
that mature FDCs are critical for scrapie accumulation in
lymphoid tissues, and in their absence neuroinvasion is sig¬
nificantly impaired.12'13'17 From the lymphoid tissues, infec-
tivity spreads to the CNS via peripheral nerves.18,19
Previous studies have shown that a functional immune
system is critical for scrapie neuroinvasion following
inoculation by skin scarification, as mice with severe
combined immunodeficiency (SCID) do not accumulate
PrP c and infectivity in their spleens, or develop clinical
disease when inoculated with scrapie by this route.4,20
SCID mice are indirectly deficient in FDCs as they require
important stimuli from lymphocytes for their matur¬
ation.21 The induction of FDC development in SCID mice
by bone marrow grafting restores the accumulation of
scrapie in the spleen after inoculation via the skin.20
However, whether FDCs or other components of the
immune system are required for scrapie neuroinvasion
following inoculation via the skin is not known. In
an experimental system, migratory bone marrow-derived
dendritic cells have been shown to have the potential to
deliver scrapie infectivity directly to the nervous system.22
As skin is highly innervated, we considered that neuroin¬
vasion might occur via an FDC-independent pathway.
For example, lymphocytes or Langerhans' cells might
acquire scrapie within the skin and transport it directly to
local peripheral nerves. Therefore, in this study experi¬
ments were performed to investigate whether FDCs are
required for scrapie neuroinvasion after inoculation via
the skin.
Materials and methods
Treatment with lymphotoxin fi-receptor (LTfiR)
immunoglobulin
C57BL/Dk mice (8-12 weeks old) were given a single
intraperitoneal (i.p.) injection of a fusion protein contain¬
ing the soluble LT/JR domain linked to the Fc portion of
human immunoglobulin G1 (IgGl) (LT/?R-Ig)23 or with
100 fig of polyclonal human IgG (hu-Ig) (Sandoglobu-
lin®) as a control.
Scrapie inoculation
Mice were inoculated with the ME7 strain of scrapie by
skin scarification of the medial surface of the right thigh.
Briefly, prior to scarification « 1 cm2 of hair covering the
scarification site was trimmed using curved scissors and
then removed completely with an electric razor. Twenty-
four hours later, a 23-gauge needle was used to create a
5-mm long abrasion in the epidermal layers of the skin at
the scarification site. Care was taken to avoid damage to
the dermis or to draw blood during scarification. Then,
using a 26-gauge needle, one droplet (« 6 p\) of ME7
scrapie inoculum, from a 1% or 0-1% (w/v) terminal
scrapie mouse brain homogenate in physiological saline,
was applied to the abrasion and worked into the site
using sweeping strokes. The scarification site was then
sealed with OpSite (Smith & Nephew Medical Ltd, Hull,
UK) and allowed to dry before the animals were returned
to their final holding cages. Following challenge, the ani¬
mals were coded, assessed weekly for signs of clinical dis¬
ease and killed at a standard clinical end-point.24 Scrapie
diagnosis was confirmed by histopathological assessment
of TSE vacuolation in the brain.
At the time-points indicated, some mice were killed
and their spleens and inguinal lymph nodes (ILNs) were
taken for further analysis. For bioassay of scrapie infectiv¬
ity, two half spleens were pooled from each treatment
group and prepared as 10% (w/v) homogenates in phy¬
siological saline. Likewise, the ILNs draining the inocula¬
tion site were pooled from two mice and prepared as a
10% (w/v) homogenate. Groups of 12 C57BL/Dk indica-
HQtor mice were injected intracerebrally (i.e.) with 20 fil of
each homogenate. The scrapie titre in each sample was
determined from the mean incubation period in the assay
mice, by reference to established dose/incubation period
response curves for ME7 scrapie-infected spleen tissue, as
previously described.25
Immunohistochemical analysis
To monitor the effects of treatment on FDC status, ILNs
and half spleens were taken from two mice in each group
and snap-frozen at the temperature of liquid nitrogen.
Serial frozen sections (thickness, 10 ^m) were cut on a
cryostat and FDCs were visualized by staining with either
the FDC-specific rat monoclonal antiserum, FDC-M2
(AMS Biotechnology, Oxon, UK), or 8C12 monoclonal
antiserum to detect CD35 (BD Biosciences PharMingen,
Oxford, UK). Immunolabelling was carried out by
using alkaline phosphatase coupled to the avidin-biotin
2 © 2005 Blackwell Publishing Ltd, Immunology, 114, 1-10
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complex (Vector Laboratories, Burlingame, CA, USA).
Vector Red (Vector Laboratories) was used as a substrate.
For tire detection of PrP in the brain, tissues were
fixed in periodate-lysine-paraformaldehyde and embed¬
ded in paraffin wax. Sections (6-/mi thickness) were
deparaffinized and pretreated to enhance PrP immuno-
staining by hydrated autoclaving (15 min, 121°, hydra¬
tion) and subsequent immersion in formic acid (98%)
for 5 min.26 Sections were then stained with the PrP-
specific monoclonal antiserum, 6H4 (Prionics, Zurich,
Switzerland), and immunolabelling was detected by using
hydrogen peroxidase coupled to the avidin-biotin com¬
plex (Vector Laboratories), with diaminobenzidine (DAB)
as a substrate. Glial fibrillar)' acid protein (GFAP) was
detected on adjacent brain sections by using rabbit
GFAP-specific antiserum (DAKO Ltd, Ely, UK), and
immunolabelling was carried out by using alkaline phos¬
phatase coupled to the avidin-biotin complex with
Vector Red as a substrate.
All sections were counterstained with haematoxylin to
distinguish cell nuclei.
Paraffin-embedded tissue (PET) immunoblot detection
of PrPSc
PrPSl was detected in PET sections of spleen and ILNs,
as previously described.27 Briefly, tissues were fixed in
periodate-lysine-paraformaldehyde and embedded in par¬
affin wax. Serial sections (6-/mr thickness) were mounted
on poly(vinylidine ditluoride) membrane (Bio-Rad,
Hemel Hempstead, UK) and fixed by incubation at 55°
overnight. Membranes were then deparaffinized and
digested with proteinase K (20 /jg/ml) for 16 hr at 55°
(to confirm the presence of PrP c), washed in TBS/Tween
[10 mM Tris-HCl pH 7-8, 100 mM NaCl, 0-5% (v/v)
Fween] and denatured in 3 m guanidine isothiocyanate
(10 mM Tris-HCl, pH 7-8) for 10 min. Membranes were
blocked in 2% casein, and PrP was detected with the
PrP-specific rabbit polyclonal antiserum, 1B3,28 followed
by alkaline phosphatase-conjugated goat anti-rabbit
immunoglobulin (Jackson ImmunoResearch Laboratories
Inc., West Grove, PA). Bound alkaline phosphatase
activity was detected by using SigmaFast™ nitroblue
tetrazolium/5-bromo-4-chloroindol-2-yl phosphate (NBT/
BCIP) solution (Sigma, Poole, UK). Immunostained
membranes were assessed using an Olympus dissecting
microscope.
Statistical analysis
Where indicated, incubation periods are presented as
mean (days) ± standard error (SE). Significant differ¬
ences between incubation periods in different groups
were determined by using one-way analysis of variance
(anova).
Figure 1. Effect of treatment with lymphotoxin ((-receptor immuno¬
globulin (LT/SR-Ig) on follicular dendritic cell (FDC) status in the
inguinal lymph nodes of uninfected mice. Tissues were taken 3 days
after injection with polyclonal human immunoglobulin G (hu-lg)
(control) or LT/iR-Ig, and adjacent frozen sections were stained with
the FDC-specific monoclonal antiserum FDC-M2 (top row; red) and
8C12 antiserum to detect CD35 (bottom row; red). Expression of
FDC-M2 and CD35 were undetectable in inguinal lymph nodes after
treatment with I.T/lR-lg. All sections were counterstained with
haematoxylin (blue). Original magnification X 200.
Results
Effect of LT/JR-Ig treatment on FDC status in ILNs
The maintenance of FDCs in a differentiated state
requires continual stimulation through the LT/JR, as
mature cells rapidly dedifferentiate when this signalling
pathway is blocked.29 Here, temporary blockade of the
LT/JR signalling pathway was achieved by a single i.p.
injection of 100 /rg of LT/?R-Ig.23 Within 3 days of treat¬
ment with LT/?R-lg, expression of the FDC markers
FDC-M2 and CD35 (complement receptor 1) was unde¬
tectable in ILNs (Fig. 1) and in spleen (data not shown).
The effects of treatment with LT/JR-Ig on FDC status are
temporary, lasting «28 days.29'30 Treatment with 100 jtg
of hu-lg, as a control, had no adverse effect on FDC sta¬
tus in ll.Ns (Fig. 1) or in the spleen (data not shown).
Effect of LT/IR-Ig treatment on the early
accumulation of PrPSc within ILNs and the spleen
Following peripheral inoculation of mice with the ME7
strain of scrapie, high levels of PrP^ and infectivity accu¬
mulate in lymphoid tissues within the first few weeks post-
inoculation, and these levels are maintained throughout the
course of infection.12'13,31 In the present study, mice were
treated with LT/JR-Ig or hu-lg (as a control), 14 or 42 days
after inoculation with scrapie by skin scarification, and
spleens and both ILNs were taken from two mice of each
treatment group 3 days later (days 17 and 45, respectively).
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PrPSc accumulations within these tissues were detected by
PET immunoblot analysis. PrP c was detected within two
or three lymphoid follicles of the draining (right) ILNs of
hu-Ig-treated control mice, 17 days after inoculation with
scrapie (Table 1, treatment on day 14). The cellular dis¬
tribution of the PrPSc was consistent with its accumu¬
lation on FDCs.13 No PrPSc was detected in tire non-
draining (left) ILNs or spleen 17 days after inoculation
(Table 1, treatment on day 14). By 45 days after inocu¬
lation with scrapie, PrPSL was present in a greater
number of lymphoid follicles in the draining ILNs of
control-treated mice (Table 1, treatment on day 42;
Fig. 2a). Furthermore, PrPSt was also detectable in a
single lymphoid follicle in the left ILN (Table 1) and
in spleen (Table 1, treatment on day 42; Fig. 2c) at
this time-point. These data demonstrate that following
inoculation via the skin, PrPs^ accumulates first upon
FDCs in the draining ILN and subsequently spreads to
other non-draining lymph nodes and spleen between
17 and 42 days after inoculation.
When mice were treated with LT/IR-Ig, the number of
follicles containing PrP c in the draining ILN and spleen
were visibly reduced or completely absent 3 days after
treatment (Table 1; Fig. 2b, 2d, respectively). Therefore,
Table 1. The effect oi treatment with lymphotoxin /i-receptor
immunoglobulin (LT/JR-Ig) on the early accumulation of PrPSc in
the inguinal lymph nodes and spleens of scrapie-inoculated mice*f
hu-Ig LT/JR-Ig
Day of
treatment Right ILNJ Left ILN§ Spleen Right ILN Left ILN Spleen
14 ++ - - +/-
42 +++ + + +/- +/-
"Mice were given a single intraperitoneal (i.p.) injection (100 /rg) of
LT/?R-Ig or polyclonal human immunoglobulin G (hu-Ig), as a con¬
trol, on the days indicated after inoculation with scrapie via skin
scarification of the right thigh.
fTissues were taken 3 days after treatment, and the number of
PrP^-containing lymphoid follicles in inguinal lymph nodes (ILNs)
and spleen from two mice was scored as follows: +++, > 4 positive
follicles; ++, 2-3 positive follicles; +, 1 positive follicle; +/-, 1 posit¬
ive follicle in only one of the samples; no PrPs' detected.
(Inguinal lymph node draining the site of inoculation.
§Non-draining inguinal lymph node.
the temporary dedifferentiation of FDCs correlated with a
rapid reduction in the number of PrPSc-positive lymphoid



























Figure 2. Effect of treatment with lymphotoxin /i-receptor immunoglobulin (LT/?R-Ig) on the early accumulation of PrPSc in the draining ingu¬
inal lymph node and in the spleen. Mice were given a single intraperitoneal (i.p.) injection of LT/iR-Ig or polyclonal human immunoglobulin G
(hu-lg) (control) 42 days after inoculation with scrapie via skin scarification on the right thigh. Tissues from two mice from each group were
collected 3 days after treatment, and PrPSc accumulations were determined by paraffin-embedded tissue (PET) immunoblotting. Abundant PrPSt
accumulations were detected in the lymphoid follicles of polyclonal human immunoglobulin G (hu-Ig)-treated animals (a and c, dark staining,
arrowheads). In contrast, PrPSc accumulations were undetectable in tissues from LT/?R-Ig-treated mice (b and d). Terminally scrapie affected
brain tissue (e) and uninfected normal brain tissue (f) were included as controls to confirm the specificity of PrP c detection.
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Effect of LT/iR-Ig treatment on the early
accumulation of infectivity within ILNs and the
spleen
The draining ILNs and spleens were taken from two mice
of each control and LT/IR-Ig-treatment group 70 days
after scrapie inoculation by skin scarification. The scrapie
infectivity titre in pooled (n = 2) tissue homogenates was
estimated by bioassay in groups of indicator mice. As
expected, ILNs from each group of hu-Ig-treated control
mice contained high infectivity titres [6-3-6-7 log i.e. 50%
I^Hinfective dose (lD50)/g; Table 2], In the draining ILNs of
mice treated with LT/fR-Ig 3 days before scrapie inocula¬
tion, infectivity was undetectable, suggesting a scrapie
infectivity titre, if present, of <3-5 log i.e. ID50/g (at least
1000-fold less than the level detected in ILNs of control-
treated mice assayed at the same time postinoculation;
Table 2). Thus, temporary FDC dedifferentiation before
inoculation with scrapie via the skin blocks the early
accumulation of infectivity in the draining ILN. The
mean incubation periods obtained following injection of
pooled lysates of ILNs from mice treated with LT/IR-Ig
14 or 42 days after inoculation, were significantly longer
than those obtained following injection of lysates from
control mice (P < 0 01 and P < 0-001, n = 9, anova,
respectively; Table 2). Therefore, ILNs from mice treated
with LT/!R-Ig 14 or 42 days after inoculation, contained
detectable but significantly lower levels of infectivity than
those measured in ILNs from control-treated mice
(Table 2).
Similarly, spleens taken from each group of control-
treated mice 70 days after inoculation contained high lev¬
els of scrapie infectivity (6-0-71 log i.e. ID50/g; Table 3).
However, after treatment with LTjSR-Ig 3 days before
or 14 days after inoculation with scrapie, infectivity was
undetectable in the spleen, suggesting a scrapie infectivity
titre, if present, of < 3-5 log i.e. ID50/g (at least 1000-fold
less than the level detected in spleens of control-treated
Table 2. Effect of treatment with lymphotoxin ^-receptor immunoglobulin (LT/?R-Ig) on the accumulation of scrapie infectivity in the draining
inguinal lymph node 70 days after inoculation with scrapie via the skinf
hu-Ig LT/?R-Ig
Day of Mean incubation Mean incubation
treatment Incidence! period (days) ± SE Titre§ Incidence period (days) ± SE Titre
-3 7/7 196 ± 5 6-6 0/9 9x > 300 < 3-5
+ 14 7/7 193 ± 6 6-7 8/9 217 ± 3* 5-5
+42 8/8 203 ± 4 6-3 6/8 249 ± 4** 41
fMice were given a single intraperitoneal (i.p.) injection (100 /ig) of LT/?R-Ig or polyclonal human immunoglobulin G (hu-Ig) as a control on
the days indicated before or alter inoculation with scrapie via skin scarification of the right thigh. Inginal lymph nodes draining the site of
^inoculation were pooled from two mice and infectivity levels were determined by intracerebral (i.e.) injection of lysates into groups of C57BL/Dk
indicator mice.
|Incidence = number of animals affected/number of animals tested. The notation ln x > 300' means that mice were free of the signs of scrapie
up to at least this time-point after inoculation.
^Scrapie infectivity titles ^Apicostd as lug i.e. 50% infectious dose (lL>50J/g.
*P < 0 01, when compared to the mean incubation period for hu-Ig control tissues.
**P < 0 001, when compared to the mean incubation period for hu-Ig control tissues.
Table 3. Effect of treatment with lymphotoxin /^-receptor immunoglobulin (LT/?R-Ig) on the accumulation of scrapie infectivity in the spleen
70 days after inoculation with scrapie via the skinj
hu-Ig LT/?R-Ig
Day of Mean incubation Mean incubation
treatment IncidenceJ period (days) ± SE Titre§ Incidence period (days) ± SE Titre
-3 9/9 187 ± 3 7 1 0/9 9x > 300 <3 5
+ 14 8/8 188 + 4 7 0 0/8 9x > 300 <3*3
+42 9/9 202 ± 9 6 0 6/9 243 ± 5*, 3x > 300 = 4 1
fMice were given a single i.p. injection (100 /zg) of LT/?R-Ig or polyclonal human immunoglobulin G (hu-Ig) as a control on the days indicated
alter inoculation with scrapie via skin scarification of the right thigh. Spleens were pooled Irom two mice and inlectivity levels were determined
|by intracerebral (i.e.) injection of lysates into groups of C57BL/Dk indicator mice.
JSee Table 2, footnote!.
§See Table 2, footnote^.
*P < 0 02, when compared to the mean incubation period for hu-Ig control tissues.
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mice assayed at the same time postinoculation; Table 3).
However, comparisons of mean incubation periods
obtained following injection of spleen lysates from mice
treated 42 days after inoculation, suggested that spleens
from LT/IR-Ig-treated mice contained detectable, but sig¬
nificantly lower, levels of infectivity (at least 100-fold less;
P < 0-02, ti = 9, anova) than those measured in spleens
from control-treated mice (Table 3).
PrPSc accumulation within ILNs and the spleen
at the terminal stage of disease
As expected, abundant PrP^ was detected by immunoblot
analysis in ILNs and spleens from all hu-Ig-treated con¬
trol animals that developed clinical signs of scrapie (data
not shown). The effects of LT/IR-Ig treatment on FDC
status are temporary, and mature networks reappear
~ 28 days later.29'30 Therefore, the detection of abundant
PrP3^ in ILNs and spleens of LT/IR-Ig-treated animals
that developed clinical signs of scrapie (data not shown)
is consistent with the replication of residual infectivity on
recovered FDC networks in these tissues.
Effect of LT/IR-Ig treatment on scrapie susceptibility
Mice were given a single i.p. injection of LT/IR-Ig or
hu-Ig (as a control) at one of the following three time-
points relative to scrapie inoculation by skin scarification:
3 days before scrapie inoculation (so that mature FDCs
would be absent in lymphoid tissues at the time of chal¬
lenge); 14 days after inoculation (i.e. soon after the onset
of scrapie accumulation in the draining ILN; Table 1); or
42 days after inoculation, when abundant PrPSc (Table 1;
and Fig. 2a) and infectivity (J. Mohan et al. unpublished)
are detectable in the draining ILN.
All control mice treated with hn-Tg 3 Hays before scra¬
pie inoculation succumbed to disease with a mean incu¬
bation period of 320 ± 8 days (n = 6; Table 4). In
contrast, LT/IR-Ig-treatment 3 days prior to scrapie
inoculation reduced disease susceptibility and significantly
extended the survival time (Table 4). Four of seven
LT/IR-Ig-treated mice remained free of the signs of scra¬
pie for up to at least 480 days postinoculation. However,
three of seven LT/IR-Ig-treated mice did succumb to scra¬
pie after individual incubation periods of 350, 381 and
402 days. These incubation periods were beyond the
range seen in the hu-Ig-treated control mice (309—
327 days), and the mean incubation period (378 ±
15 days, n = 6) was significantly longer than the mean
incubation period for control mice (P < 0 001, anova).
Characteristic spongiform pathology, disease-specific PrP
accumulation and reactive astrocytes expressing high lev¬
els of GFAP were detected in the brains of all control and
LT/IR-Ig-treated mice that developed clinical scrapie
(Fig. 3). In contrast, spongiform pathology, disease-speci-
Table 4. Effect of treatment with lymphotoxin /?-receptor immuno¬














-3 6/6 320 ± 3 3/7 378 ± 15*,
4X > 480
+ 14 8/8 316 ± 3 8/8 351 ± 4""
+42 7/7 328 ± 6 8/8 343 ± 8***
fMice were given a single intraperitoneal (i.p.) injection (100 /rg) of
LT/JR-lg or human immunoglobulin G (hu-Ig) as a control on the
days indicated before or after inoculation with scrapie via skin scari¬
fication of the right thigh.
(See Table 2, footnotef.
*P < 0 001, when compared to hu-Ig controls.
"P < 0 000005, when compared to hu-Ig controls.
***p — 0158, when compared to hu-Ig controls.
fic PrP accumulation or reactive astrocytes were not
detected in the brains of the surviving LT/IR-lg-treated
mice (Fig. 3), indicating that infection had not spread to
the nervous system in these surviving mice.
All mice treated with LT/IR-Ig 14 days after inoculation
developed clinical disease with a significantly extended
incubation period when compared to control-treated mice
(P < 0-000005, n = 8, anova; Table 4). However, treat¬
ment with LT/IR-Ig 42 days after scrapie inoculation had
no significant effect on the survival time when com¬
pared to control-treated mice (P = 0-158, n = 8, anova;
Table 4).
Discussion
In order to determine the involvement of FDCs in scrapie
pathogenesis following inoculation via the skin, these cells
were temporarily dedifferentiated through the blockade of
the LT/IR signalling pathway, either before, or shortly
after, scrapie inoculation. Data presented here show that
treatment with LT/IR-Ig blocked the early accumulation of
scrapie in the draining ILN and spleen. These effects coin¬
cided with the temporary dedifferentiation of FDCs in
lymphoid tissues. When given 3 days before scrapie inocu¬
lation, LT/iR-Ig reduced disease susceptibility and exten¬
ded the survival time when compared to control-treated
mice. No pathological signs of scrapie were detected in the
brains of mice surviving treatment with LT/JR-lg, confirm¬
ing that neuroinvasion does not occur by the direct uptake
of infectivity by peripheral nerves in the skin. Thus, FDCs
are critical for the transmission of scrapie from the skin to
the CNS. Whereas treatment with LT/IR-Ig 14 days after
scrapie inoculation also significantly extended the urvival
6 © 2005 Blackwell Publishing Ltd, Immunology, 114, 1-10
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Figure 3. Immunohistological analysis of brain tissue from mice treated with polyclonal human immunoglobulin G (hu-Ig) (control) or with
lymphotoxin /S-receptor immunoglobulin (LT/SR-Ig) 3 days before scrapie inoculation by skin scarification. Large disease-specific PrP accumula¬
tions (upper row; brown), and reactive astrocytes expressing high levels of glial fibrillary acid protein (GFAP) (middle row; red) and spongiform
pathology (haematoxylin & eosin, lower row) were detected in the hippocampi of all mice showing clinical signs of scrapie. In contrast, in the
brains of LT/?R-Ig-treated mice that remained free of the clinical signs of disease, no evidence of PrP accumulation, reactive astrocytes or spongi¬
form pathology was detected 480 days after inoculation. All sections were counterstained with haematoxylin (blue). Original magnification X200.
dpi, days postinoculation on which the tissues were analysed; pos., mice that developed clinical signs of scrapie; neg., mice that were free of the
clinical signs of scrapie.
time, treatment 42 days after scrapie inoculation did not,
suggesting that infectivity had already spread to the per¬
ipheral nervous system by this time.
Lymphocytes provide essential cytokine signals for FDC
development and maturation,21'32'33 as immunodefkient
mice that lack expression of lymphotoxin (LT)oc34 or
UTfj lack mature FDC networks. Lymphocytes express
these cytokines as a membrane-bound heterotrimer
(LTcq/T), which signals through LT/IR on FDCs or their
precursors.36 FDCs likewise do not develop in LT/IR-
deficient mice.37 FDC networks require continual LT/IR
stimulation as they rapidly collapse from their mature
state when LT/IR signalling is specifically blocked by
treatment with LT/iR-Ig (Fig. I).23'29 A single treatment
with LT/iR-Ig temporarily dedifferentiates FDCs for
«28 days." FDCs trap and retain antigens on their
surfaces through interactions between complement com¬
ponents and cellular complement receptors.38'39 Further¬
more, complement components Clq and C3, and cellular
complement receptors are considered to play an import¬
ant role in the localization of scrapie infectivity to
FDCs.40'41 In the present work, treatment with LT/iR-Ig
resulted in the temporary loss of expression of the FDC-
associated molecules complement receptor 1 (CD35) and
FDC-M2 in ILNs and the spleen. The epitope recognized
by the FDC-M2-specific monoclonal antiserum has been
identified as complement component C4.42 Therefore, the
temporary loss of FDC-M2-specific immunostaining after
treatment with LT/iR-Ig suggests that any remaining
immature FDCs, if present, would be unable to trap and
retain complement-opsonized antigens. These data suggest
that these cells would also have lost their ability to cap¬
ture scrapie during the period of dedifferentiation.
Within 17 days after scrapie inoculation by skin scarifi¬
cation, PrP -containing FDC networks were detected in
the draining ILN of control mice, but not in the non-
draining lymph node or spleen. By 45 days after inocula¬
tion, the number of FDC networks containing PrP c had
visibly increased in the draining ILN and were also
detectable in a few networks in the non-draining ILN and
spleen. The detection of low levels of PrPSc in the non-
draining ILN and spleen at the later time-point suggests
that following accumulation in the draining lymph node,
PrPSc is disseminated to other lymphoid tissues via the
bloodstream. In contrast, mice treated with LT/IR-Ig
at 42 days post-TSE inoculation had visibly reduced or
undetectable accumulations of PrPSc within 3 days of
treatment. The reduced detection of PrP^ coincided with
the loss of FDCs following treatment with LT/IR-Ig. The
rapid reduction in PrPSc after treatment with LT/?R-Ig is
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probably a result of the release of PrPSL from dedifferenti¬
ating FDCs and its uptake and clearance by phagocytic
cells, such as macrophages.43-45
Following scrapie inoculation via skin scarification, high
levels of infectivity begin to peak in the draining 1LN
around 50 days postinoculation and subsequently plateau
(Mohan et ul. unpublished). In this study, ILNs and spleens
from control mice contained high levels of scrapie infectiv¬
ity at 70 days postinoculation. However, when mice were
treated with I.T/IR-Ig 3 days before inoculation, scrapie
infectivity was undetectable within the ILNs and spleen at
70 days postinoculation, ss 40 days after the expected reap¬
pearance of mature FDCs. Furthermore, in the temporary
absence of FDCs at tire time of inoculation, disease suscep¬
tibility was reduced and survival time in those treated mice
that did develop clinical disease was significantly extended.
Thus, these data suggest that scrapie infectivity from the
inoculum is unable to replicate in the draining lymphoid
tissue in the temporary absence of FDCs at the time of
inoculation. The reduced disease susceptibility of LT/iR-Ig-
treated mice and absence of infectivity in lymphoid tissues
at 70 days postinoculation suggests that tire original inocu¬
lum is cleared by macrophages.43-4^ However, three LT/JR-
Ig-treated mice did develop clinical disease, albeit with
incubation periods beyond the range observed in control,
treated mice. Therefore, in some LT/?R-Ig-treated mice, a
fraction of the inoculum was able to persist until the FDCs
reappeared.
The levels of infectivity responsible for natural TSE trans¬
missions are unknown but are probably much lower than
the moderate dose used in this study. SCID mice, which
have a permanent absence of FDCs, do not develop clinical
scrapie when inoculated via tire skin with the same dose of
scrapie used in the current study.4'-0 Therefore, the dose
of scrapie infectivity administered in previous4'20 and in the
current work is not taken up directly by peripheral nerves,
bypassing a need for replication in lymphoid tissues. The
lack of detection of disease-specific PrP accumulations in
the brains of surviving LT/IR-lg-treated mice demonstrates
that, in our study, neuroinvasion following inoculation via
the skin does not occur by direct uptake via nerves in the
skin. These data also suggest that infection will have
reached the CNS in the LT/?R-Ig-treated mice that did
develop clinical disease following replication on regener¬
ated FDCs, and not by direct uptake by peripheral nerves.
However, these data do not exclude the possibility, follow¬
ing inoculation with a higher dose of scrapie than the one
used here, that ncuroinvasion might occur via an FDC-
independent pathway, such as uptake by peripheral nerves.
Treatment with LT/IR-Ig 14 days after scrapie inocula¬
tion by skin scarification likewise significantly extended
the survival time, but had no effect on disease susceptibil¬
ity to the dose of scrapie used. PrP5' had already begun
to accumulate upon FDC networks in the draining ILNs
prior to treatment with LT/IR-Ig at 14 days postinocula¬
tion. This suggests that the level of infectivity which had
accumulated prior to treatment with LT/LR-Ig was suffi¬
cient to avoid substantial clearance by phagocytic cells
during the period of FDC dedifferentiation. The extended
incubation period in these LT/?R-Ig treated mice is prob¬
ably related to the time required for the FDC networks to
restore and initiate replication of the retained scrapie
infectivity. This would delay the subsequent transfer of
infectivity to peripheral nerves. Our data are also consis¬
tent with tire hypothesis that the action of macrophages
on TSE infectivity is concentration-dependent: the low
concentrations derived from the original inoculum may
he easily destroyed, whereas higher concentrations, such
as those present in the ILN 14 days after inoculation, are
less easily cleared and a fraction is retained.
Treatment with LT/JR-Ig has no effect on disease path¬
ogenesis once infection is established within the periph¬
eral or central nervous systems.3 '46 The lack of any
observable effect of LT/?R-Ig treatment on disease patho¬
genesis, when given 42 days after scrapie inoculation, sug¬
gests that neuroinvasion had already occurred prior to
treatment. Neuroinvasion may have occurred directly
from the draining ILN, which had a heavy deposition of
PrP50 at the time of treatment, whereas only limited
amounts of PrP52 were detected in the spleen (Table 1).
Removal of the spleen before i.p. scrapie inoculation sig¬
nificantly extends the survival time, suggesting that the
spleen plays an important role in neuroinvasion via this
route.47 In contrast, removal of the spleen before subcuta¬
neous scrapie inoculation has no effect on pathogenesis.48
Data from these studies and the current study indicate
that the major route of neuroinvasion following inocula¬
tion via the skin is not via the spleen.
Treatment with LT/IR-Ig inhibits or prevents the devel¬
opment of experimental autoimmune encephalomyelitis
by impairing T-lymphocyte responses and migration.49
LIGHT is a transmembrane protein produced by activated
T lymphocytes that also binds to LT/IR.50 However, the
effects of treatment with LTjSR-Ig on scrapie pathogenesis
are unlikely to be a result of impaired LT/LR- or LIGHT-
mediated T-lymphocyte responses or migration, as patho¬
genesis is unaffected in T-lymphocyte-deficient mice."'1-54
Signalling via LT/fR has been shown to be important for
the presence of migratory dendritic cells in the spleen.55
Therefore, it is plausible that blockade of the LT/IR-
signalling pathway might have affected cell trafficking or
the transport of scrapie infectivity to the draining ILN.
However, as treatment with LT/?R-Ig 14 days after inocu¬
lation significantly extended the survival time, the effects
of treatment on scrapie pathogenesis are unlikely to be
the result of effects on cell trafficking, as dendritic cells
migrate to draining lymphoid tissues within the first few
hours of antigen encounter.56 Migratory Langerhans' cells
might also transport TSEs from the epidermis to the
draining lymph node. However, as LTa- or LT/I-defici-
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ency does not affect the distribution of Langerhans' cells
in the skin, or their ability to take up antigen and migrate
to the draining lymph node,57 the effects of LT/?R-Ig
treatment on scrapie pathogenesis are also unlikely to be
caused by impaired transportation by Langerhans1 cells.
Collectively, these observations suggest that it is highly
unlikely that the major effects of LT/iR-Ig treatment on
scrapie pathogenesis are independent of its effects on
FDC maturation.
Our data demonstrate that mature FDCs are critical
for the accumulation of scrapie in the draining lymph
node following inoculation by skin scarification. Further¬
more, in the temporary absence of FDCs, disease suscep¬
tibility is reduced. Treatments that inactivate FDCs may
have therapeutic potential against peripherally acquired
TSEs. However, such treatments have no effect on patho¬
genesis once disease has spread from the FDCs to periph¬
eral nerves.58 While little is known about the precise
timing of these events, comparisons of the effects of
LT/IR-Ig treatment on scrapie pathogenesis following
inoculation by different peripheral routes indicate that
this period varies considerably according to the route of
exposure. Neuroinvasion will probably occur rapidly
from the gastrointestinal tract because treatment with
LT/IR-Ig, 14 days after oral inoculation, is ineffective.30
In the current study, our data suggest that neuroinvasion
occurs between 14 and 42 days after inoculation via the
skin. However, treatment with LT/SR-Ig remains effective,
even when administered up to 42 days after i.p. scrapie
inoculation.17'46 Thus, if manipulation of FDCs were to
be used therapeutically against TSEs, the time interval
available for intervention would depend critically on the
route of TSE exposure.
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